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Abstract 
  
Positron emission tomography (PET) is an imaging technique that uses a 
radioactive small molecule to monitor biological processes. As the radioactive molecule 
moves throughout the body, it emits positrons that allow it to be tracked using a PET 
scan. Key information can be learned during this scan, including how the molecule 
engages the target of interest, ability to cross the blood-brain barrier, how quickly it is 
cleared from the body, etc. As PET imaging becomes more prevalent, the need for 
more diverse tracers increases. This thesis describes several new methods for forming 
C–18F and C–11C bonds that have and will continue to be utilized for the synthesis of 
new PET imaging tracers.  
 Chapter 1 describes the importance of fluorinated arenes and their importance in 
PET imaging. Current methods for radiolabeling these substrates are discussed. 
Challenges for developing PET methodologies and labeling molecules with other 
radioactive isotopes are discussed. 
 Chapter 2 focuses on the development of copper-mediated [18F]radiofluorination 
methodologies using aryl boron acids and arylstannanes derivatives as precursors. Both 
methods have wide substrate scopes and were fully automated to provide clinical doses 
of [18F]MPP-F. 
 Chapter 3 details the development of a copper-mediated [11C]radiocyanation 
method that is applicable to various aryl boron and arylstannanes derivatives. This 
methodology was utilized to produce [11C]perampanel and [11C]LY2795050 on a clinical 
scale. [11C]LY2795050 was used for a non-human primate imaging study and is 
currently undergoing clinical trials. 
 
xx 
 
Chapter 4 focuses on the development of a copper-mediated directed C(sp2)–H 
[18F]radiofluorination method. Chapters 2 and 3 used pre-functionalized precursors, 
which can hinder application to more complicated substrates. The development of a C–
H activation method that uses a removable directing group could be highly 
advantageous for molecules in clinical trials.   
Chapter 5 details three incomplete projects: (1) [18F]radiofluorination of aryl 
iodides, (2) directed fluorination of other removable directing groups, and (3) improved 
[18F]radiofluorination of [18F]4F-MHPG. Preliminary results and future directions are 
discussed. 
This dissertation describes new methodologies that have been developed and 
how they have been applied in our lab and others. New methodologies to form C–18F 
and C–11C bonds will become more pertinent as the field of PET continues to grow and 
new targets are identified. We believe the methods discussed herein will serve an 
important role for helping the PET community diagnose and monitor diseases earlier 
and more effectively than alternative imaging techniques.  
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Chapter 1 
 
Introduction 
 
 
1.1. Significance of Aryl Fluorides 
Since the appearance of the first fluorine-containing drug on the market, approved 
by the FDA in 1955, there has been an increase in the number of fluorinated molecules 
approved.1–3 In 2005, as many as 30–40% of agrochemicals and 20% of pharmaceuticals 
on the market contained fluorine including half of the top 10 drugs sold.4 Introducing a 
fluorine atom onto a drug candidate can impart many new properties of interest, such as 
lipophilicity, pKa, and metabolism, while minimally effecting changes in molecular size.5 
For instance, Figure 1.1 shows an example of a fluorinated lead compound compared to 
the proto-compound where the addition of two fluorine atoms (1) decrease the basicity of 
the amine, improving bioavailability, and (2) block a site of metabolism.6 These two minor 
modifications lead to an increased binding affinity by an order of magnitude in addition to 
an increased bioavailability.6,7 Due to the rarity of organofluorine in nature, there are 
limited metabolic pathways for C–F functionalities allowing the drug to circulate in the 
body for longer periods.4,8 
 
Figure 1.1. Effect of Fluorinate Addition on Antipsychotic Drug Candidates 
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To incorporate a fluorine atom onto a molecule there are two approaches (1) start 
with fluorine in a building block or (2) introduce fluorine during the synthesis.4 Although 
new methods to introduce fluorine in a late-stage approach are being developed, this 
problem remains challenging due to fluorine being the most electronegative element.6 
Fluoride can form strong interactions with hydrogen bonds in water, alcohols, and amines 
and in addition, in the presence of hydrogen bond donors, fluoride is only weakly 
nucleophilic.9 Furthermore, in anhydrous conditions, fluoride is more nucleophilic but also 
demonstrates strong basic character which can lead to undesired reactions.9 An 
alternative to nucleophilic fluoride would be to use electrophilic fluorine, which can come 
in many forms. F2 is highly reactive and presents poor selectivity in fluorination reactions, 
but N–F fluorine sources have been used under more mild and selective conditions; 
however, they are generally more expensive than nucleophilic sources. 
A common method to install an aryl fluoride is to use the halogen exchange (Halex) 
process. The Halex process (SNAr fluorination) has several notable limitations including 
using metal fluoride sources that have poor solubility, requiring forcing reaction conditions 
(>100 °C), or requiring additives such as phase transfer reagents. For SNAr reactions to 
be productive, electron-withdrawing arenes are needed to help stabilize intermediates 
formed during the transition state (Scheme 1.1).  
 
Scheme 1.1. SNAr Fluorination 
 
 
1.2. Transition Metal-Mediated and -Catalyzed Aromatic Fluorination 
Many of the challenges associated with SNAr fluorination could be overcome using 
a transition metal to mediate and/or catalyze the fluorination reaction.10 Over the past 
several years, several transition metal-catalyzed or -mediated methods have been 
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developed for C‒F bond formation. Stoichiometric reactions with Pd have shown that the 
reductive elimination step is challenging.11 In 2009, a Pd-catalyzed method was reported 
using a nucleophilic fluorine source with aryl triflates.12 This methodology was later 
expanded to include aryl iodides and bromides.13 Since this initial report, other metal-
mediated and -catalyzed methods have been developed.9,10,14,15 
 
1.2.1. Cu-Mediated and -Catalyzed Nucleophilic Fluorination 
As an alternative to Pd, Cu is a relatively inexpensive option that has been shown 
to form aryl–F bonds. In 2011, Ribas and coworkers reported the first example of C–F 
bond forming reductive elimination from a well-defined aryl-Cu(III) complex.16 Following 
the initial report, a C–H fluorination method was reported using KF via a Cu(III) route.17 
In 2012, Hartwig and coworkers reported a copper-mediated fluorination of aryl iodides 
using a large excess of a Cu(I) complex and AgF (Scheme 1.2, reaction 1).18 The reaction 
was effective for electron-rich and -poor arenes as well as sterically hindered substrates, 
but the formation of a hydrodeiodinated side product rendered the purification 
challenging.18 The methodology performed best for aryl iodides, but aryl bromides could 
be used to obtain low yields of product (<20%).18 An alternative method was published in 
2013 by Liu and coworkers that used 2-phenyl pyridine derivatives and catalytic copper 
to fluorinate aryl bromides with an excess of AgF (Scheme 1.2, reaction 2).19 This method 
was limited to 2-pyridine substrates or similar motifs and could not be extended to 
additional directing groups.  
 
Scheme 1.2. Cu-Mediated Fluorination of Aryl–X Bonds 
 
 
Copper catalysis has also been developed for an SNAr-type nucleophilic 
fluorination of diaryliodonium salts. Nucleophilic fluorination of diaryliodonium salts has 
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been known since the early 1980s using KF as the fluoride source.20 The products can 
be formed in good yield, but typically as a mixture with the corresponding aryl iodide and 
reduced arene side products. A limitation of this methodology is the need to prepare the 
diaryliodonium substrates. Unsymmetrical diaryliodonium salts are preferred for 
enhanced selectivity, however they prove to be a synthetic challenge when targeting 
functionalized aryl fluorides. In 2013, a copper catalyzed method was utilized with 
unsymmetrical (mesityl)iodoniums salts and KF 21, which concluded the fluorination of the 
less sterically hindered arenes was preferred, allowing for use of a bulky mesityl group as 
a separable byproduct formation (Scheme 1.3).  
 
Scheme 1.3. Cu-Catalyzed Fluorination of (Mesityl)(aryl)iodonium Salts21 
 
 
Employing excess copper and KF were shown to fluorinate aryl trifluoroborate salts 
with good yields (Scheme 1.4).22 This was the first example showing organoborane 
derivatives undergo transmetallation and reductive elimination with nucleophilic fluoride 
and copper to give the desired C–F bond. The reaction could tolerate electron-poor 
substrates, while electron-rich substrates gave trace product.  
 
Scheme 1.4. Cu-Mediated Fluorination of Aryl Trifluoroborate Salts22 
 
 
1.3. PET Chemistry 
There is a wealth of modern imaging techniques that have been transformative for 
how maladies are detected, diagnosed, and treated. A PET scan is an in vivo imaging 
technique that uses a radioactive, positron-emitting molecule (known as a tracer) to 
monitor biological processes.23 Unlike a magnetic resonance imaging (MRI) or 
computerized tomography (CT) scan that provide structure information, a PET scan can 
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provide functional information about how the tracer is interacting with a desired target. 
The tracer is monitored in real-time giving a picture of the biochemical and physiological 
processes that are occurring. This can be a valuable diagnostic tool to help determine the 
nature of particular internal species, including whether a mass means a returned tumor 
or cell death. PET scans can be used to diagnose tumors, validate lead compounds that 
can cross blood-brain barrier and engage with the desired target, as well as monitor side 
pathways and metabolic processes.  
The radioactive agent is equipped with a radionuclide that has a half-life intrinsic 
to the isotope used (Table 1.1). New tracers are generally developed as [11C]radiotracer. 
This is due to the ubiquitous presence of carbon in natural products and drug compounds, 
which provide a multitude of possible incorporation sites. Exchanging a 12C atom for a 
position-emitting 11C atom should ensure that the molecule of interest behaves the same 
chemically and biologically.23,24 Due to the short half-life (20 min), syntheses have to be 
efficient and short, but multiple scans can be performed in the same day. Carbon-11 is 
typically generated as [11C]CO2 but can quickly be converted to [11C]CH4 and is generally 
used as a methylating reagent in the form of [11C]MeI or [11C]MeOTf.23 The other common 
form of [11C]radiotracers is a [11C]carbonyl group. This can be incorporated by a few 
methods, [11C]CO2, [11C]CO, or [11C]CN followed by hydrolysis. [11C]Cyanide offers an 
advantage because it can be readily generated from [11C]CO2.23,24 Chapter 3 describes 
an improved copper-mediated [11C]radiocyanation method utilizing aryl borane 
derivatives and arylstannanes.25 
Fluorine-18 is the most commonly used radionuclide due to its’ relatively long half-
life (110 min) and favorable imaging properties.23 Fluorine-18 is generated and available 
as electrophilic fluorine or nucleophilic fluoride. Nucleophilic fluoride is commonly 
accessible and provides high specific activity (ratio of 19F/18F) but is generated as an 
aqueous solution, diminishing the nucleophilicity of the fluoride. Electrophilic fluorine is 
generated as [18F]F2 with [19F]F2 as a carrier gas causing the specific activity (ratio of 19F 
to 18F) to be low. High specific activity is critical for imaging certain biological targets with 
low concentrations, such as neurotransmitter receptors in the brain.24 [18F]F2 is very 
reactive and requires specialized systems that are not common. Electrophilic fluorination 
methods have been developed with 19F that would be desirable as an 18F analogue. There 
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have been recent methodologies developed to form these electrophilic fluorine sources 
for the PET scale.26,27 
In addition to 11C and 18F, other short-lived isotopes are used, such as 13N and 15O. 
Due to the short half-lives, these radionuclides are usually generated in a simple form 
and used for limitation imaging applications. On the other hand, iodine has a few long-
lived radioactive isotopes with iodine-124 being commonly used for PET imaging.  
 
Table 1.1. Commonly Used Isotopes 
Radionuclide Half-life, t1/2 (min) 
18F 110 
11C 20 
13N 10 
15O 2 
124I 4.2 d 
 
In regards to the radiotracers, [18F]FDG ([18F]fluorodeoxygluocose) is the most 
commonly used radiotracer (Figure 1.2). It has favorable properties that allow it to image 
many varieties of diseases and can be easily synthesized via an SN2 mechanism. FDG 
is processed in the body similarly to glucose, making it an unselective radiotracer due to 
large background noise as a function of unspecific absorption. To image a wider variety 
of biochemical and physiological processes, more scaffolds need to be accessed (Figure 
1.2). For each tracer, the radionuclide needs to be incorporated in the last steps of the 
synthesis prior to a deprotection (if needed) because of the short half-lives of the 
radionuclides. New methods need to be designed so that a vast number of novel 
radiotracers can be synthesized and tested. 
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Figure 1.2. Known Radiotracers 
 
 
1.3.1. Challenges for methodology development for PET chemistry 
A major limitation of PET imaging is the number and diversity of fluorine-18 
imaging agents that can be synthesized. Currently, one of the major obstacles to 
accessing more imaging agents lies in the source of fluorine-18, which is most commonly 
nucleophilic fluoride formed in water through cyclotron irradiation (18O(p,n)18F). The low 
concentration of fluorine-18 that is generated under these conditions (pmol quantities) in 
combination with the limited scope of fluorination methods that employ nucleophilic 
fluoride have both prevented the development of a unified radiofluorination method. As 
PET imaging becomes more common, there are many interesting potential imaging 
agents that cannot currently be accessed. The development of new nucleophilic 
fluorination methods that employ common intermediates would open-up more synthetic 
pathways to be assessed, and should ultimately allow the for identification of the most 
effective synthetic routes. The operational simplicity of a new method is another key 
consideration in the development process. Reaction conditions must be operationally 
simple, such that a non-expert chemist can reproduce these reactions on demand in a 
production setting. In addition, air sensitive methods are difficult to develop given that 
reactions employ a fluoride source that has been azeotropically dried from water and that 
reaction hot cells used in commercial radiochemistry are under ambient conditions. As 
such, for reproducibility all reagents should be bench stable. In order for a new method 
to be successful, it needs to provide access to more scaffolds and also be simple to 
implement in the existing radiopharmaceutical infrastructure.  
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For drug molecules, the fluorine atom is typically introduced as a building block in 
the original synthesis. For PET imaging, the radionuclide must be introduced in the last 
steps of the synthesis and generally some pre-functionalized (usually an aryl halide) has 
to be carried through the synthesis in place of the aryl fluoride. In recent years, there have 
been several late-stage fluorination methodologies developed that address this limitation, 
but there is still more to be done. The new methodologies have to have short reaction 
times because of the half-life of [18F]fluorine. C–H activation would serve as an alternative 
approach to requiring a pre-functionalized motif to be carried through a synthesis. Chapter 
4 describes a copper-mediated C–H activation method for [18F]radiofluorination of 8-
aminoquinoline directed arenes.28 Chapter 5 includes some preliminary results of 
translating an aryl iodide fluorination method to aryl–18F. 
In the case of nucleophilic fluoride, [18F]fluoride is generated in an aqueous 
solution and has to be azeotropically dried. Trace amounts of water can affect the 
nucleophilicity of the fluoride and can affect the metal-mediated methods negatively. New 
methodologies developed need to have mild water and air tolerance.  
 
1.3.2. Current Methodologies to Form a C(sp2)–18F Bond 
There have been several in-depth reviews that cover the methodologies developed 
to install an aryl–18F bond.9,23,24,29–33 One of the most reliable methods is SNAr using aryl 
halides or trimethylammonium salts as the leaving group (Figure 1.3). SNAr requires the 
R group to be electron-withdrawing, limiting the scaffolds that could be applied. To label 
an electron-rich molecule via SNAr, several post-fluorine modifications must occur, 
increasing the time of the synthesis, decreasing the yield, and chances of reproducibility.  
A commonly used alternative to SNAr is employing diaryliodonium salts as 
precursors (Figure 1.3).34–36 Symmetrical iodonium salts are easier to make for simple 
molecules, but are synthetically challenging for more complex molecules.37–39 
Additionally, the side products of the symmetrical iodonium salts can be challenging to 
separate (protodeiodinated and aryl iodide arenes). There are several limitations for 
diaryliodonium salts including sensitivity to both steric- and electronic-effects.40 Some of 
these limitations can be addressed by using a 2-thienyl diaryliodonium precursor.41 The 
incorporation of the 2-thienyl group as the sacrificial arene helps address selectivity.  
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In 2014, a more activated iodonium(III) precursor was designed.42 The spirocyclic 
hypervalent iodine(III) precursors were designed with an auxiliary on the iodine to avoid 
the limitations of the previous diaryliodonium methods, including the ortho-substitution. 
Both 2-thienyl and spirocyclic iodonium salts have been used for clinical applications.43–
47 A limitation of these methods is the requirement of high temperatures where 29most 
reactions require >150 °C leading to a limited scope due to the instability of some 
sensitive functional groups.  
 
Figure 1.3. Common Metal-Free Precursors  
 
New methodologies have been introduced that have not been widely implemented. 
A recently developed reagent, PhenoFluor, has been shown to do [18F]deoxyfluorination 
of phenols in a two-step method.48 Triarylsulfonium salts react in a similar manner to 
diaryliodonium salts and have similar limations.49 A derivative of this methodology uses 
dibenzothiophene sulfonium salts that undergo a ring-closing reaction to form a good 
leaving group for the incoming [18F]fluoride to attack the arene.50 Other 
[18F]radiofluorination methodologies include electrochemical fluorination of benzene,51 
phosphane-catalysed fluorination of iodanes,52 anilines via isolated N-arylsydnone 
intermediates,53 and a metal-free oxidative fluorination of phenols with tBu as a leaving 
group.54 
As with 19F fluorination methods, a way to overcome the challenges above are 
developing metal-mediated and -catalyzed methods to help increase the rate and yields 
of [18F]radiofluorination. In 2011, Ritter and coworkers developed a Pd-mediated 
methodology to perform [18F]radiofluorination.55 The key to this transformation is 
disguising nucleophilic fluorine to react as an electrophilic fluorine source by creating a 
Pd–18F complex that can react with the Pd–Ar complex to give the desired product 
(Scheme 1.5).55 The next generation methodology improved upon the initial methodology 
by using aqueous [18F]fluoride instead of a Pd–18F complex and used aryl-Ni complexes.56 
Although these methodologies have been shown to be compatible to produce radiotracers 
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for non-human primate imaging studies,57–59 they have not been widely implemented for 
several reasons. The most likely reason is due to the non-trivial synthesis of the Pd 
complexes, as PET radiotracers are typically synthesized by non-experts. Additionally 
this methodology has a lower efficiency of fluorination with ortho-substituted precursors.29 
Another Pd methodology that has been developed is a carrier-added Pd mediated 
[18F]radiofluorination of aryl triflates60 inspired by a newly developed fluorination 
methodology.12 Carrier-added is a limitation because it generates a low specific activity 
due to the excess of 19F in the reaction. In 2017, Ritter and coworkers developed a Ru-
mediated [18F]deoxyfluorination methodology that implemented phenols as starting 
materials.61 This methodology was applied used to radiolabel [18F]Bavarostat to image in 
rodent and non-human primates.62 
 
Scheme 1.5. Ritter and Coworker’s Pd-Mediated [18F]Radiofluorination 
 
Copper-catalyzed and -mediated methods are a relatively less expensive and less 
toxic alternative to the Pd and Ni transformations developed. In 2014, a copper-mediated 
method addressed some of the issues related with the diaryliodonium salts.63 
Unsymmetrical (mesityl)(aryl)iodonium salts were used a lower temperatures (<100 °C) 
with high yields and better selectivity. Similar to previous reports, ortho-substituted 
precursors are a limitation of this methodology. Recently, a C(sp2)–H activation method 
was developed that formed an iodonium salt in situ before performing the 
[18F]radiofluorination.64 This methodology addresses the limitation of some unstable 
iodonium salts, but introduces more limitations with the relatively harsh reaction 
conditions. Chapter 2 describes a mild copper-mediated nucleophilic [18F]radiofluorination 
method of aryl boronic acids and arylstannanes as an alternative to using iodonium 
salts.65,66 
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Chapter 2 
 
Cu-Mediated [18F]Fluorination of Organometallic Reagents1–3 
 
 
2.1. Electrophilic Fluorination of Organometallic Reagents 
Transition metal-mediated and/or -catalyzed methods have been developed to 
fluorinate organometallic reagents with electrophilic fluorine sources. Pd and Ag methods 
have been developed for both arylboronic acids and arylstannanes.4–7 These methods 
were shown to fluorinate a diverse array of starting materials and had some late stage 
fluorination properties that made their translation amendable to PET chemistry.8 
Changing from Pd and Ag to a more earth abundant metal, such as Cu, is desirable for 
PET chemistry because the metals have to be removed from the product at the end of 
synthesis.9 According to ICH guidelines, Cu has a larger allowable dose relative to Pd 
and Ag, making purification easier. Fluorination of arylboron derivatives was achieved 
with Cu in good yields.9 This method uses a specialized Cu catalyst that is not 
commercially available. This method was further extended to include arylstannanes and 
aryltrifluoroborane substrates.10  
In PET chemistry, electrophilic fluorination is not widely utilized due to the 
specialized equipment that is required.11 Furthermore, electrophilic radiofluorination 
methods result in products with dramatically lower specific activity (ratio of 18F/19F), which 
greatly reduces imaging sensitivity.12 Electrophilic methods for PET require the use of 
[18F]F2 whereas the 19F reactions that have been recently developed use F+ sources like 
Selectfluor or NFSI. To overcome this limitation there has been work to create [18F]NFSI13 
and [18F]Selectfluor14 from [18F]F2. While this transformation turns [18F]F2 into a more 
useful F+ reagent, [18F]F2 still requires the customized equipment and has a low specific 
activity that makes imaging challenging. For electrophilic fluorination, arylstannanes are 
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the state-of-the-art substrate (Scheme 2.1).11,15–19 Arylboron reagents have also been 
shown to form the fluorinated product with electrophilic 18F sources.20 Additionally, 
arylstannanes have already been validated as precursors to radiopharmaceuticals for 
human clinical trials,21–24 thereby mitigating concerns about toxicity and the feasibility of 
Sn removal.  
 
Scheme 2.1. Radiofluorination of Arylstannanes 
 
 
2.2. Nucleophilic Fluorination of Organometallic Reagents 
While nucleophilic fluorine sources are generally inexpensive and the preferred 
source of 18F, there are few examples that use organometallic reagents (Scheme 2.1). 
Early work by Ritter’s group developed Pd and Ni complexes that were formed from 
organometallic reagents and used [18F]fluoride to form the desired product.8,25 This 
seminal work transformed nucleophilic fluoride into an electrophilic fluorine source without 
the limitations mentioned in the previous section, but the Pd and Ni complexes are not 
commercial and not trivial to make, leading to limited implementation of this 
procedure.26,27 A translation of an electrophilic method to a nucleophilic method using Cu 
and [18F]KF was the basis for the following method development.28 
 
 
17 
 
2.3. Initial Results and Optimization for Aryl-B(OH)2 PrecursorsA 
The copper-mediated fluorination of aryl trifluoroborates with [19F]KF was the 
inspiration for the initial studies using [18F]KF.28 Our radiochemistry studies focused on 
implementing conditions similar to those used for [19F]fluorination (4 equiv Cu(OTf)2, 4 
equiv KF in MeCN at 60 °C for 20 h), where it was found that both potassium 
trifluoroborate salts and boronate esters undergo Cu-mediated radiofluorination. 
Trifluoroborate substrates contain exogenous 19F that could exchange with the 18F and 
dilute the specific activity of the product. To avoid this, boronate esters and boronic acids 
were investigated. Concomitant with the initial studies, Gouverneur reported a closely 
related radiofluorination of pinacol boronate esters;26 however, in our hands, this method 
proved less reproducible and generally afforded low RCCs. Boronic acids were chosen 
as substrates due to their ready availability and stability. When [18F]fluoride is generated 
from the cyclotron (18O(p,n)18F), it is produced as a solution in water. For the 
trifluoroborate chemistry, it was found that the yield was decreased in the presence of 
water.28 To generate an anhydrous [18F]fluoride source, the solution is azeotropically 
dried with MeCN. It has been found that adding various bases to the QMA (quaternary 
ammonium) eluent increases the efficiency of [18F]KF produced over [18F]HF which 
evaporates.3 As the methodology progresses from manual reactions to automated 
reactions, the amount of base in the reaction increases which can have detrimental 
effects on [18F]radiofluorination chemistry. 
During the optimization, we found that the presence of K2CO3 (which is typically 
used in the preparation of [18F]KF) resulted in low RCCs of the fluorinated products (Table 
2.1, entry 1).29 Investigating other bases that could be used as eluents lead to pyridinium 
p-toluenesulfonate (PPTS) and a mixture of KOTf/K2CO3 (Table 2.1, entries 2–3). During 
the production of [18F]KF, it was noted that when PPTS was used,3 only 50-60% of 18F 
was retained, likely due to volatile H18F forming, but with the mixture of KOTf/K2CO3 (73:1 
molar ratio) 80% of the 18F was preserved. As expected, no product was detected without 
pyridine or Cu (Table 2.1 entries 4 and 5, respectively). Other copper sources including 
                                            
A Dr. Andrew Mossine performed most of the optimizations for the arylboronic acid radiofluorination 
reactions 
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the copper(I) source used for the previously developed iodonium chemistry did not give 
any product (Table 2.1 entry 6).30  
 
Table 2.1. Optimization of Radiofluorination of 1-B(OH)2 
 
entry QMA eluent [Cu] [18F]1 (% RCC) 
1 K2CO3 Cu(OTf)2 nd 
2 PPTS Cu(OTf)2 48 
3 KOTf/K2CO3 Cu(OTf)2 61 
4a KOTf/K2CO3 Cu(OTf)2 3 
5 KOTf/K2CO3 -- nd 
6 KOTf/K2CO3 (MeCN)4CuOTf nd 
Conditions: 1-B(OH)2 (4 µmol, 1 equiv), Cu(OTf)2 (20 µmol, 5 equiv), pyridine (0.5 mmol, 
125 equiv), and [18F]KF in DMF (4 mM) at 110 ⁰C for 20 min. RCC was determined by 
radio-TLC (n ≥ 2). Nd = not detected. ano pyridine 
 
Using MeCN as the solvent instead of DMF did not give any product and using a 
mixture of DMF/MeCN gave decreased RCCs with increasing MeCN (Table 2.2, entry 2). 
This is particularly interesting because DMF was not an effective solvent under the 19F 
conditions (1 equiv aryl trifluorobornate, 4 equiv of Cu(OTf)2, 4 equiv of KF in MeCN at 
60 °C for 20 h).28 Furthermore, it was found that pyridine was critical for the success of 
the [18F]radiofluorination. The role of pyridine is being investigated, but it is likely serving 
as a base source and/or as a ligand on the copper species. Other pyridine derivatives 
gave increased or similar RCCs with electron-rich 4-phenyl or 4-methoxypyridine, but 
other electron-deficient pyridine derivatives or other bases gave trace product (Table 2.2, 
entry 3). Investigation into the stoichiometry of Cu and pyridine showed that pyridine ≥75 
equiv and Cu ≤5 equiv, relative to the arylboronic acid, were optimal (Table 2.2, entries 
4-6). Temperature studies showed that ≥100 °C was sufficient (Table 2.2, entry 7). Unlike 
the aryl trifluoroborate chemistry,28 this transformation was found to be tolerant of water 
(Table 2.2, entry 8). For most substrates attempted, the arylboronate ester gave a higher 
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RCC than the aryl boronic acid (Table 2.2, entry 9). The main byproduct observed in all 
cases is the protodeboronated product.  
 
Table 2.2. Stoichiometry of Reagents 
 
entry Cu(OTf)2 (equiv) pyridine (equiv) conditions [18F]1 (% RCC) 
1 5 125 -- 61 
2 5 125 10% MeCN 49 
3 5 125 4-Ph-pyridine 58 
4 5 75 -- 64 
5 10 125 -- 53 
6 2.5 125 -- 69 
7 5 125 100 °C 58 
8 10 125 8 equiv H2O 45 
9 5 125 Ar-Bpin 70 
Entry 1 conditions: [18F]1 (4 µmol, 1 equiv), Cu(OTf)2 (20 µmol, 5 equiv), pyridine (0.5 
mmol, 125 equiv), and [18F]KF in DMF (4 mM) at 110 ⁰C for 20 min. RCC was determined 
by radio-TLC (n ≥ 2). 
 
2.4. Substrate Scope for Ar-B(OH)2  
The substrate scope of aryl boronic acid [18F]radiofluorination was explored. As 
summarized in Figure 2.1, this method is compatible with a range of functional groups. 
The reaction proceeds in moderate to high RCC with arylboronic acids bearing electron-
withdrawing ([18F]2–[18F]7), electroneutral ([18F]8–[18F]11), and electron-donating 
([18F]12–[18F]15) substituents. Electron-rich [18F]15 was formed in 36% RCC, 
significantly higher than the yield obtained in the corresponding copper-mediated 
(mesityl)(aryl)iodonium chemistry (14% RCC).30 Meta ([18F]3, [18F]13, and [18F]15) and 
ortho-substituents ([18F]4 and [18F]10) were tolerated, although with lower RCC, likely 
due to slower transmetalation of the more sterically hindered aryl boronic acids. This 
method is also compatible with heteroaromatic ([18F]16) and vinylic ([18F]17) boronic 
acids. While the yield of [18F]16 was lower than that for many of the other substrates (18% 
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RCC), this substrate and [18F]12 demonstrate that this radiofluorination reaction proceeds 
without the need for protection of protic functional groups.  
 
Figure 2.1. Substrate Scope of Ar-B(OH)2  
 
Conditions: arylboronic acid (4 µmol, 1 equiv), Cu(OTf)2 (20 µmol, 5 equiv), pyridine (0.5 
mmol, 125 equiv), and [18F]KF in DMF (4 mM) at 110 ⁰C for 20 min. RCC was determined 
by radio-TLC (n ≥ 2). 
 
As mentioned above, the RCCs with aryl pinacol boronate esters are generally 
similar or higher than the boronic acid alternatives (Figure 2.2). The radiofluorination of 
aryltrifluoroborate substrates formed the desired product [18F]6, but in a low RCC (Figure 
2.2). 
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Figure 2.2. Substrate Scope with Various Boronate Derivatives  
 
Conditions: arylboronate derivatives (4 µmol, 1 equiv), Cu(OTf)2 (20 µmol, 5 equiv), 
pyridine (0.5 mmol, 125 equiv), and [18F]KF in DMF (4 mM) at 110 ⁰C for 20 min. RCC 
was determined by radio-TLC (n ≥ 2). 
 
 [18F]F-PEB ([18F]18) was used as an example of a biologically relevant molecule. 
This is an important radiotracer for quantifying metabotropic glutamate 5 receptors,31–35 
and it has been historically challenging to synthesize. As shown in Scheme 2.2, this 
method gave [18F]F-PEB in a moderate RCC of 8%. While this is relatively low, it would 
be more than enough for an animal or patient study, due to the low amounts of radiotracer 
needed for a PET scan. The synthesis of [18F]F-PEB was automated to give the product 
in 4% RCC and a specific activity of 750 Ci/mmol. Notably, automated yields are always 
lower than manual results because the automation accounts for any loss during 18F 
formation and purification starting from the amount produced from target irradiation.  
 
Scheme 2.2. Synthesis of [18F]F-PEB 
 
Conditions: 18-B(OH)2 (4 µmol, 1 equiv), Cu(OTf)2 (20 µmol, 5 equiv), pyridine (0.5 mmol, 
125 equiv), and [18F]KF in DMF (4 mM) at 110 ⁰C for 20 min. RCC was determined by 
radio-TLC (n ≥ 2). 
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2.5. Initial Results and Optimization for Aryl-SnR3 Precursors with KF 
While the first-generation method involving arylboron [18F]radiofluorination was 
quite effective, it still has some significant limitations. First, the arylboron 
[18F]radiofluorination worked well with electron-deficient substrates, but afforded lower 
RCCs with electron-rich substrates. Electron-deficient substrates can be made through 
alternative methods but forming C–18F bonds on electron-rich aromatic rings remains a 
challenge. Secondly, there was a large amount of protodeboronated product formed. This 
product can be difficult to separate, as it elutes at a similar retention time as the desired 
fluorinated product. Furthermore, this side product could competitively interact with the 
target during imaging, thus effectively lowering the specific activity by competing with the 
radioligand of interest for the target protein. Minimizing this side product formation was a 
key goal. We hypothesized that one way to minimize the protodeboronated species would 
be to use an arylstannane. Arylstannanes are known to undergo faster transmetalation 
than arylboron derivatives, which should lead to less side product formation.36  
The initial investigations focused on the Cu(OTf)2-mediated fluorination of 19-
SnBu3 with KF under conditions analogous to those demonstrated for aryl trifluoroborate 
substrates.28 After 18 h at 60 °C with 4 equiv KF in MeCN, the fluorinated product 19 was 
obtained in 42% yield as determined by 19F NMR spectroscopy (Table 2.3, entry 1). While 
this yield is lower than that reported with 19-BF3K under closely analogous conditions 
(70%, 20 h), the addition of 18-crown-6 as a phase transfer catalyst could be used to 
boost the yield with 19-SnBu3 to 55% (entry 2). Furthermore, as predicted, the fluorination 
of 19-SnBu3 is significantly faster than that of 19-BF3K. For example, 19-SnBu3 affords 
51% yield after just 15 min under these conditions. In contrast, the analogous reaction of 
19-BF3K requires more than 2 h to afford 50% yield. The faster rate with 19-SnBu3 is 
highly desirable for PET applications. The stoichiometry of fluoride was next investigated. 
Notably, this is another key consideration for translation, because [18F]fluoride is typically 
the limiting reagent during radiofluorination. With KF as the limiting reagent, the reaction 
still proceeded albeit in reduced yield (Table 2.3, entry 6). 
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Table 2.3. Cu-Mediated Nucleophilic Fluorination of 19-SnBu3 in Acetonitrile  
 
entry time (h) 18-crown-6 (equiv) yield 20 (%) 
1 18 -- 42 
2 18 4 55 
3 2 -- 42 
4 2 4 53 
5 0.25 4 51 
6b 0.25 4 15 
General conditions: 19-SnBu3 (0.025 mmol, 1 equiv), Cu(OTf)2 (4 equiv), KF (4 equiv), 
and 18-crown-6 (4 equiv) in MeCN (0.083 M) at 60 °C. Yield determined by 19F NMR 
spectroscopic analysis of the crude reaction mixture using 1,2-difluorobenzene as an 
internal standard. bKF (0.5 equiv) used. Yield based on KF.  
 
This method was next applied to a small set of arylstannanes (Figure 2.3). The 
objectives here were twofold: (1) to establish the effectiveness of the 15 min nucleophilic 
fluorination protocol for electronically diverse arylstannanes and (2) to examine the impact 
of the alkyl substituents on tin on the reaction. As shown in Figure 2.3, stannanes bearing 
electron donating (p-MeO), electron-neutral (p-Ph), and electron-withdrawing (p-Ac) 
substituents react to form fluorinated products in moderate to good yields in just 15 min 
at 60 °C. The p-MeO derivative is particularly noteworthy, as the corresponding 
aryltrifluoroborate is poorly reactive, affording <5% yield under any of the fluorination 
conditions examined.28 Substitution of the alkyl group on the stannane had a significant 
impact on the yield over this short reaction time, with the Me-substituted stannanes 
affording comparable or higher yield than the Bu derivatives in all cases. This likely 
reflects the faster transmetalation from the less hindered tin center.37 
 
Figure 2.3. Mini Substrate Scope in Acetonitrile  
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Conditions: arylstannane (0.025 mmol, 1 equiv), Cu(OTf)2 (4 equiv), KF (4 equiv) and 18-
crown-6 (4 equiv) in MeCN (0.083 M) at 60 °C for 15 min. Yield determined by 19F NMR 
spectroscopic analysis of the crude reaction mixture using 1,2-difluorobenzene as an 
internal standard. 
 
 During this method development, a paper reporting a similar transformation was 
published by Jennifer Murphy.38 This paper showed that pre-stirring the copper and 
fluoride source provided higher yields (Scheme 2.3). In their SI, the same reaction with 2 
equiv of Cu(OTf)2 and 2 equiv of KF afforded a 46% yield with no pre-stir and a 58% yield 
with a 10 or 20 min pre-stir. These results mirror the results below in Table 2.4 where pre-
stirring increases the yield for some substrates, although not universally. For the 4-F 
substrate, the addition of 18-crown-6 replaced the need for pre-stirring (Table 2.4, entries 
1, 2, 5, and 6). This trend was not observed for the 4-BnO substrate (Table 2.4, entries 
3, 4, 7, and 8). The pre-stirring and addition of 18-crown-6 likely improves the 
reproducibility of this reaction as the standard conditions varied greatly (26-52% without 
18-crown-6 versus 48-63% with 18-crown-6). 
 
Scheme 2.3. Effects of Pre-Stir from Murphy’s Report38 
 
Conditions: Cu(OTf)2 (4 equiv), KF (4 equiv) and 18-crown-6 (4 equiv) were pre-stirred in 
MeCN (0.2 mL) at rt for the selected time. Arylstannane (0.025 mmol, 1 equiv) in MeCN 
(0.1 mL, 0.083 M) were added to the mixture, heated to 60 °C for the selected time. Yield 
determined by 19F NMR spectroscopic analysis of the crude reaction mixture with an 
internal standard. 
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Table 2.4. Pre-stirring Effects on Optimized Conditions 
 
entry R time1 time2 18-crown-6 (equiv) yield (%) 
1 F 0 2 h 4 55 
2 F 1 h 1 h 4 50 
3 BnO 0 h 2 h 4 15 
4 BnO 1 h 1 h 4 43 
5 F 0 2 h -- 45 
6 F 1 h 1 h -- 52 
7 BnO 0 h 2 h -- 12 
8 BnO 1 h 1 h -- 52 
Conditions: Cu(OTf)2 (4 equiv), KF (4 equiv) and 18-crown-6 (4 equiv) were pre-stirred in 
MeCN (0.2 mL) at rt for the selected time. Arylstannane (0.025 mmol, 1 equiv) in MeCN 
(0.1 mL, 0.083 M) were added to the mixture, heated to 60 °C for the selected time. Yield 
determined by 19F NMR spectroscopic analysis of the crude reaction mixture using 1,2-
difluorobenzene as an internal standard. 
 
2.6. Initial Results and Optimization for Aryl-SnR3 Precursors with [18F]KFB 
Translation of this nucleophilic fluorination method to achieve the 18F-fluorination 
of 8-SnBu3 was the next objective. As is common in the radiofluorination field,12,39 
significant reoptimization was required, as the best 19F fluorination conditions afforded no 
detectable 18F-labeled product (Table 2.5, entry 1). This is likely a consequence of the 
dramatic change in fluoride stoichiometry (from 0.3 M with KF to approximately 0.1 nM 
with [18F]KF).40 Even with the addition of pyridine and switching to DMF as the solvent, 
no product was detected until the temperature was increased to 110 °C (Table 2.5, entries 
2-4). Less pyridine was found to give a similar result (Table 2.5, entry 5). This is 
particularly noteworthy because for automated reactions, all chemical impurities have to 
be removed. The only other Cu source that worked other than (py)4Cu(OTf)2 was 
(MeCN)4Cu(OTf) (Table 2.5, entries 6-7). Increasing the temperature to 140 °C increased 
the RCC for most substrates (Table 2.5, entry 8). At least 2 equiv of Cu(OTf)2 was found 
                                            
BThe work in this section was performed with the assistance of Dr. Allen Brooks. 
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to best (Table 2.5, entry 9). Increasing the Cu equiv did not increase the RCC. Changing 
the solvent from DMF to DMA was found to give a large increase in RCC for most 
substrates (Table 2.5, entry 10). The reaction was tolerant of trace amounts of water 
(Table 2.5, entry 11). As observed with 19F, this reaction was rapid, affording [18F]8 in 
65% RCC within just 5 min (entry 12).  
 
Table 2.5. Cu-Mediated Nucleophilic Fluorination of 8-SnBu3 with [18F]KF 
 
entry changes in conditions [18F]8 (% RCC) 
1 pyridine (0 equiv), MeCN, 60 °C nd 
2 pyridine (50 equiv), MeCN, 60 °C nd 
3 pyridine (50 equiv), 60 °C nd 
4 pyridine (50 equiv) 22 
5 -- 20 
6 (py)4Cu(OTf)2 (2 equiv) 14 
7 (MeCN)4Cu(OTf) (2 equiv) 2 
8 140 °C 42 
9 Cu(OTf)2 (1 equiv), 140 °C 29 
10 DMA, 140 °C 55 
11 H2O (0.5% v/v) 32 
12 DMA, 140 °C, 5 min 65 
Conditions: 8-SnBu3 (0.01 mmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and 
[18F]KF in DMF (0.01 M) at 110 °C for 30 min. RCC determined by radio-TLC (n ≥ 2). nd 
= no product detected by radio-TLC or HPLC. 
 
2.7. Additional Optimization for Aryl-SnR3 Precursors with KF 
With the optimized [18F]radiofluorination conditions determined, an array of 
arylstannane derivatives were examined with KF (Table 2.6). The previous report28 and 
all attempts after gave no product in DMF or DMA without pyridine. The DMA conditions 
(condition C) gave similar yields as the above MeCN and MeCN with 18-crown-6 
conditions (Table 2.6 entries 1-3). The anisole substrate gave no product with the 
trifluoroboroate substrate (Table 2.6, entry 4) and gave low yields in MeCN (Table 2.6, 
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entries 1-2). Now in the DMA conditions, moderate yield is observed with anisole (Table 
2.6, entry 3).  
 
Table 2.6. Comparison of Substrates in Various Fluorination Methods 
 
entry conditions [M] R = F R = MeO R = Ph 
1 A SnBu3 42 11 29 
2 B SnBu3 53 16 30 
3 C SnBu3 33 40 38 
4 D BF3K 70 n/a 48a 
Conditions: Yield determined by 19F NMR spectroscopic analysis of the crude reaction 
mixture using 1,2-difluorobenzene as an internal standard. (A) arylstannane (0.04 mmol, 
1 equiv), Cu(OTf)2 (4 equiv), and KF (4 equiv) in MeCN (0.083 M) at 60 °C for 2 h. (B) 
Condition A with 18-crown-6 (4 equiv). (C) arylstannane (0.01 mmol, 1 equiv), Cu(OTf)2 
(2 equiv), pyridine (15 equiv), and KF (4 equiv) in DMA (0.01 M) at 110 °C for 2 h. (D) 
aryltrifluoroborate (0.025 mmol, 1 equiv), Cu(OTf)2 (4 equiv), and KF (4 equiv) in MeCN 
(0.083 M) at 60 °C for 20 h. Conditions and results are from the literature.28 aIsolated 
yield: aryltrifluoroborate (0.5 mmol) 
 
 Given that the 14-SnBu3 provided the desired fluorinated product in moderate yield 
in the DMA conditions (Table 2.6, entry 3), a comparison with boron derivatives was 
performed (Table 2.7). The Ar–Bpin and Ar–BF3K derivatives both gave moderate yields 
of the desired fluorinated product 14.  
 
Table 2.7. Methoxy Substrates in DMA Conditions 
 
entry [M] yield 15 (%) 
1 SnBu3 40 
2 BF3K 28 
3 Bpin 44 
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Conditions: substrate (0.01 mmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and 
KF (4 equiv) in DMA (0.01 M) at 110 °C for 2 h. Yield determined by 19F NMR 
spectroscopic analysis of the crude reaction mixture using 1,2-difluorobenzene as an 
internal standard. 
 
2.8. Substrate Scope for Ar-SnR3 with [18F]KF 
The optimal conditions were applied to a series of aryl-, heteroaryl-, and 
vinylstannane precursors. As summarized in Figure 2.4, this method is compatible with 
aromatic substrates bearing electron-neutral ([18F]8), electron-withdrawing ([18F]1, 
[18F]27), and electron-donating substituents ([18F]14-[18F]15, [18F]20−[18F]24) as well as 
heteroaromatic ([18F]25) and vinylstannane ([18F]26) derivatives. Substrates such as 27-
SnBu3 include a functional handle that can be used for further elaboration. Ortho-
substitution was well-tolerated, with the o-MeO substrate 21-SnBu3 affording a yield 
comparable to that of the p-MeO substrate 14-SnBu3 (RCC = 57% versus 48%, 
respectively). The electron-rich substrates ([18F]14-[18F]15, [18F]20−[18F]24) are 
noteworthy, as they are challenging to radiofluorinate using traditional SNAr reactions.41  
 
Figure 2.4. Substrate Scope for Arylstannane Precursors 
 
Conditions: aryltributyltin substrate (0.01 mmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 
equiv), and [18F]KF in DMA (0.01 M) at 140 °C for 30 min. RCC determined by radio-TLC 
(n ≥ 2). aAr-SnMe3 used as substrate b100 °C; c18-crown-6 (0.5 equiv); d30 equiv of 
pyridine.  
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When this method was compared to other metal-mediated nucleophilic 
radiofluorination methods, overall the RCCs were comparable and, in many cases, 
significantly higher. Notably, the ortho-methoxy and 1,2,3-trimethoxy products were 
produced with a much higher RCC than the other metal-mediated methods. 
 
Table 2.8. Comparison of Substrates by Other metal-Mediated Methods 
 
References: condition A (Cu-mediated with arylstannanes),2 condition B (Cu-mediated 
with diaryliodonium salts),30 condition C (Cu-mediated with arylboronic acids),1 condition 
D (Cu-catalyzed with arylboron pinacol esters, note: decay-corrected “RCY”),26 and 
condition E (Ni-mediated method).25 
 
 A few arylboron derivatives were tested under the optimal conditions. For the 4–
Ac substrate, a lower temperature was found to be optimal and the arylboronic acid gave 
a similar result to the arylstannane, which was a slight improvement on the original report 
(Table 2.9, entries 1-2).1 The anisole starting material in the form of the arylboronic acid 
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or the arylpinacol borane was analyzed to see if there was a difference in RCC. With this 
substrate, an improvement is seen by increasing the temperature and again an 
improvement in RCC over prior methods (Table 2.9, entries 3-4).  
 
Table 2.9. Comparison of Arylboron Derivative to Arylstannane Derivatives 
 
entry R temp (°C)  
[M] = SnBu3  
(% RCC) 
[M] = B(OH)2  
(% RCC) 
[M] = Bpin  
(% RCC) 
1 Ac 100 73 72 (61*) -- 
2 Ac 140 48 48 -- 
3 MeO 100 30 35 (19*) 28 
4 MeO 140 57 48 35 
5 Ph 100 51 41 (46*) -- 
6 Ph 140 55 65 -- 
Conditions: substrate (0.01 mmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and 
KF (4 equiv) in DMA (0.01 M) at 110 °C for 2 h. Yield determined by 19F NMR 
spectroscopic analysis of the crude reaction mixture using 1,2-difluorobenzene as an 
internal standard. *Reported values from the literature.1 
 
The method was then applied to the preparation of products currently being 
evaluated as radiotracers that are FDA approved or are currently in clinical trials.42,43 
Initial studies were conducted via manual synthesis, which afforded useful RCCs (Figure 
2.5). For instance, this method is effective for the synthesis of protected phenylalanine 
derivatives ([18F]28 and [18F]29) for studying amino acid transport.44 [18F]F-PEB ([18F]18), 
whose previous radiosyntheses suffer from low yields (1−5% RCY, nondecay corrected), 
was also targeted.1,31,32 Metal-free fluorination of an iodonium ylide afforded 20% RCY; 
however, these precursors can be challenging to prepare.45 Our new method, starting 
from the readily available and stable arylstannane precursor 18-SnBu3, delivers the 
product in 11% RCC.  
This method is also effective for the radiofluorination of the protected L-DOPA 
stannane 30-SnMe3, affording [18F]30 in 56% RCC. This result is noteworthy for several 
reasons. First, nucleophilic methods for radiolabeling L-DOPA remain highly sought 
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after,41,44,46,47 and the obtained RCC is among the best reported for this type of 
transformation.2 Second, the precursor 30-SnMe3 is a single step from a commercial 
stannane whose derivatives have been used in the clinical production of [18F]F-DOPA via 
electrophilic radiofluorination.21,22 As such, the successful radiofluorination of 30-SnMe3 
offers the potential for a direct nucleophilic replacement for this method. 
 
Figure 2.5. Substrate Scope of Biologically Relevant Radiotracers 
 
Conditions: aryltrimethylstannane (0.01 mmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 
equiv), and [18F]KF in DMA (0.01 M) at 100 °C for 30 min. RCC determined by radio-TLC 
(n ≥ 2). aaryltributylstannane substrate was used 
 
2.9. Automation of [18F]MPP-FC 
Finally, [18F]MPPF ([18F]31), a serotonin receptor ligand currently synthesized by 
SNAr radiofluorination of the NO2 precursor (Scheme 2.4a), was targeted. Our manual 
Cu-mediated procedure from stannane 31-SnMe3 delivered [18F]31 in 33% RCC. The 
[18F]MPPF synthesis was scaled and automated using a TRACERLab FXFN module 
(Scheme 2.4b). The reaction using 1500 mCi of initial activity afforded a formulated and 
validated 200 mCi dose (13% RCY) after radiolabeling and HPLC purification. (A typical 
clinical scan uses 10 mCi of [18F]MPPF.) The dose prepared by this method passed all 
                                            
C The work in this section was performed with the assistance of Dr. Allen Brooks. 
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cGMP quality control testing necessary for clinical use, as outlined in the US 
Pharmacopeia and 21CFR212, including residual Cu and Sn levels below the allowed 
limits specific in the ICH Guidelines.48,49 As shown in Scheme 2.4, our new method affords 
nearly double the RCY and reduces the overall time from EOB to end of purification by 
one-third relative to the current commercial synthesis of this tracer.50 
 
Scheme 2.4. Comparison of Current Methods to Syntehsize [18F]MPPF ([18F]31)43,50 
 
 
2.10. Conclusion 
This chapter detailed the development of a mild and general Cu-mediated method 
for the radiofluorination of aryl boronic acids and arylstannane substrates with [18F]KF. 
This method represents the first high-yielding nucleophilic fluorination of boronic acids 
and stannanes, is compatible with aryl, heteroaryl, and vinyl boronic acids, and fills an 
important gap in the field of late-stage fluorination. This process can be readily automated 
and scaled on a commercial radiochemistry synthesis module and applied to clinically 
relevant radiotracers. The method is tolerant of a reasonable number of functional groups 
frequently found in common drug targets.  
 
2.11. Outlook 
During the course of this work, two related methods were published, as discussed 
above. Gouverneur’s radiofluorination of aryl pinacol boranes26 was impactful, but had 
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reproducibility issues due to unique reaction setups. The method used a large amount of 
starting material (60 µmol) as opposed to the ≤10 µmol that is more common. To address 
the reproducibility issues, eight radiotracers were made with Gouverneur’s method using 
different laboratories and synthetic platforms.46 To further test the limitations of this 
method, Gouverneur published fragments to analyze what functional groups could be 
tolerated.51 Furthermore, the large amount of base used in the reaction makes automation 
of this method challenging. A “low base” approach and minimization of Kryptofix 222 have 
been developed to improve the translation to automation.29,52 This modified method has 
been used to study the effect of pyridine addition.53 The arylboronic acid method gave 
low automation yields and a large amount of protoarene side product that was difficult to 
separate by HPLC from the desired product. Both of these limitations were investigated 
and addressed in a follow-up report.54 
 Murphy’s fluorination of arylstannanes was thorough, but still used MeCN, and 
therefore they were not able to translate it to a radiofluorination method.38 The pre-stirring 
that was critical in their reaction did not seem to make a large impact in the DMA reaction 
conditions. Neumaier published a modified method for the arylstannane 
[18F]radiofluorination method.55 A recent review covers all the commonly used methods 
and organizes the highlights and limitations of each method.56 Since the initial 
publications, these methods have been used to produce radiotracers that were previously 
inaccessible or gave low RCYs (Figure 2.6).57–62 Conditions have been slightly adjusted 
based on the needs of the radiotracer.  
 
Figure 2.6. New Radiotracers Made with Recent Methods 
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This transformation was used as inspiration for the development of methods for 
forming other types of Ar–X bonds, including the topic of Chapter 3.63,64 Arylstannanes 
are commonly used to make SPECT radiotracers with 123I. A Cu-mediated transformation 
using arylboron derivatives was developed to make Ar–123I products.65 Another method 
was developed that transforms aryl fluorides into aryl pinacol boranes.66 This could be a 
complementary way to go from an Ar–19F to an Ar–18F compound in just two steps 
(Scheme 2.5). 
 
Scheme 2.5. Co-Catalyzed Borylation of Aryl Fluorides Followed By 
Radiofluorination66 
 
 
2.12. Experimental Details 
2.12.1. Instrumental Information 
NMR spectra were obtained on a Varian MR400 (400.52 MHz for 1H; 100.71 MHz for 13C; 
376.87 MHz for 19F), a Varian VNMRS 500 (500.10 MHz for 1H), or a Varian VNMRS 700 
(699.76 MHz for 1H; 175.95 MHz for 13C) spectrometer. 1H and 13C NMR chemical shifts 
are reported in ppm relative to TMS, with the residual solvent peak used as an internal 
reference. 19F NMR spectra are referenced based on an internal standard, 1,d-
difluorobenzene (–140.53 ppm). 1H and 19F multiplicities are reported as follows: singlet 
(s), doublet (d), triplet (t), quartet (q), and multiplet (m). ICP-OES data was obtained from 
Cerium Laboratories, LLC in Austin, TX. Melting point data (mp) were collected on an 
OptiMelt Automated Melting Point System. HPLC was performed using a Shimadzu LC-
2010A HT system equipped with a Bioscan B-FC-1000 radiation detector. Radio-TLC 
analysis was performed using a Bioscan AR 2000 Radio-TLC scanner with EMD Millipore 
TLC silica gel 60 plates (3.0 cm wide x 6.5 cm long). 
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2.12.2. Materials and Methods 
All commercial products were used as received unless otherwise stated. Boronic acid 
precursors were purchased from Frontier Scientific, Oakwood Products and Sigma 
Aldrich. Fluorine-19 reference standards were also sourced commercially. Arylstannane 
precursors were purchased from Frontier Scientific, Oakwood Products and Sigma 
Aldrich or synthesized in the following sections. Fluorine-19 reference standards were 
sourced commercially. Boc-Phe(4-I)-OH (CAS 62129-44-6) was purchased from Fisher. 
TriBoc-L-DOPA methyl ester (CAS: 857502-21-7) was obtained from ABX. HPLC grade 
acetonitrile, anhydrous N,N-dimethylformamide, potassium trifluoromethanesulfonate 
and potassium carbonate were purchased from Fisher Scientific. Pyridinium p-
toluenesulfonate was purchased from Sigma-Aldrich. Sterile product vials were 
purchased from Hollister-Stier. QMA-light Sep-Paks were purchased from Waters 
Corporation. QMA-light Sep-Paks were flushed with 10 mL of ethanol, followed by 10 mL 
of 90 mg/mL potassium trifluoromethanesulfonate solution, and finally 10 mL of sterile 
water prior to use. 
 
2.12.3. Synthesis of [18F]KF 
All loading operations were conducted under an ambient atmosphere. Argon was used 
as a pressurizing gas during automated sample transfers. Potassium [18F]fluoride was 
prepared using a TRACERLab FXFN automated radiochemistry synthesis module 
(General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction 
using a GE PETTrace cyclotron (40 μA beam for 2–5 min generated ca. 150–375 mCi of 
[18F]fluoride). The [18F]fluoride was delivered to the synthesis module in a 1.5 mL bolus 
of [18O]water and trapped on a QMA-light Sep-Pak to remove [18O]water and other 
impurities. [18F]Fluoride was eluted into the reaction vessel using 550 μL of aqueous 
solution containing 5 mg potassium trifluoromethanesulfonate and 50 μg of potassium 
carbonate. Acetonitrile (1.0 mL) was added to the reaction vessel, and the resulting 
solution was dried by azeotropic distillation to provide anhydrous [18F]KF. Azeotropic 
drying/evaporation was achieved by heating the reaction vessel to 100 °C and drawing 
vacuum for 6 min. The reaction vessel was then subjected to an argon stream and 
simultaneous vacuum draw for an additional 6 min. Overall, 70% of activity remained after 
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azeotropic drying (68%; calculated from TRACERLab FXFN reactor radiation detector by 
comparing activity before and after azeotropic drying). DMF (6 mL) was added to the dried 
reagent, and heated at 120 °C with stirring for 5 min. The resulting solution was cooled to 
40 °C and was transferred to a sterile vial for subsequent use in reactions (% activity 
recovery into dose vial: 40%; calculated by comparing activity of recovered solution by 
Capintec with final reading from TRACERLab FXFN reactor radiation detector. As an 
example, approx. 80 mCi of prepared [18F]KF in 6 mL DMF is isolated with a 5 min beam. 
It should be noted that % recovery data is only relevant for manual reactions, not 
automated one-pot syntheses). 
 
For the arylstannane conditions: (same as above) azeotropic drying/evaporation was 
achieved by heating the reaction vessel to 100 ºC and drawing vacuum for 6 min. The 
reaction vessel was then subjected to an argon stream and simultaneous vacuum draw 
for an additional 6 min. DMA (8 mL) was added to the dried reagent, and the sample was 
cooled to 40 ºC and was transferred to a sterile vial for subsequent use in reactions. As 
an example, approximately 80 mCi of prepared [18F]KF in 8 mL DMA is isolated with a 5 
min cyclotron beam. It should be noted that percent recovery data is only relevant for 
manual reactions, not automated one-pot syntheses. 
 
2.12.4. Manual Synthesis of 18F-Labeled Molecules for Arylboronic Acids 
This procedure was used for the synthesis of the [18F] fluorinated substrates described in 
the substrate scope. Stock solutions of boronic acid precursor (40 mM), Cu(OTf)2 (200 
mM), and pyridine (1 M) in DMF were prepared immediately prior to the start of the 
reaction. Aliquots of these solutions were used to carry out subsequent [18F]fluorination 
reactions. In a typical reaction, a 100 μL (20 μmol, 5 equiv) of Cu(OTf)2 aliquot was mixed 
with a 500 μL (500 μmol, 25 equiv) pyridine aliquot in a colorless borosilicate 4 mL 
scintillation vial. The solution was briefly agitated using a vortex shaker (Barnstead® 
Thermolyne Type 16700), then a 100 μL (4 μmol, 1 equiv) aliquot of boronic acid 
precursor was added. The reaction vial was sealed under an atmosphere of ambient air 
with a PTFE/Silicone septum cap, and a 100–300 μL aliquot of [18F]KF (150–3000 μCi, 
depending on the time required for HPLC analysis) was added to the reaction vial through 
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the septum via a syringe. Additional anhydrous DMF was also added (as required) to 
bring the total solution volume to 1000 μL. The vial was then heated in an aluminum block 
(Chemglass Part# CG-1991-04) without stirring at 110 ºC for 20 min. After 20 min, the 
reaction was allowed to cool to room temperature. Radio-TLC analysis was conducted to 
determine RCC. Crude reaction mixture was spotted onto standard silica coated glass 
plates and developed with 1:1 hexane/ethyl acetate in a glass TLC chamber. The RCC 
was determined by dividing the integrated area under the fluorinated product spot by the 
total integrated area of the TLC plate. To prepare samples for HPLC analysis, 50 μL of 
the reaction mixture was mixed with 50 μL acetonitrile or spiked with 50 μL of 1 mg/mL 
fluorinated standard solution in acetonitrile. 
 
2.12.5. Manual Synthesis of 18F-Labeled Molecules for Arylstannanes 
This procedure was used for the synthesis of the [18F]fluorinated substrates described in 
main text. Stock solutions of arylstannane precursor (0.1 M), Cu(OTf)2 (0.2 M), and 
pyridine (1M) in DMA were prepared immediately prior to the start of the reaction. Aliquots 
of these solutions were used to carry out subsequent [18F]fluorination reactions. In a 
typical reaction, a 0.1 mL (0.020 mmol, 2 equiv) aliquot of Cu(OTf)2 was mixed with a 
0.15 mL (0.15 mmol, 15 equiv) aliquot of pyridine in a 4 mL vial. Next, a 0.1 mL (0.01 
mmol, 1 equiv) aliquot of aryl stannane precursor was added along with the remaining 
solvent volume (0.55 mL DMA, total volume 1 mL). The reaction vial was sealed under 
an atmosphere of ambient air with a PTFE/Silicone septum cap, and a 0.1 mL aliquot of 
[18F]KF (150-3000 μCi, depending on the time required for HPLC analysis) was added to 
the reaction vial through the septum via a syringe. The vial was then heated in an 
aluminum block without stirring at 140 ºC for 30 min. After 30 min, the reaction was 
allowed to cool to room temperature. Radio-TLC analysis was conducted to determine 
radiochemical conversion (% RCC). The crude reaction mixture was spotted onto a 
standard silica-coated glass plate and run using 1:1 hexane/ethyl acetate in a glass TLC 
chamber. The RCC was then determined by dividing the integrated area under the 
fluorinated product spot by the total integrated area of the fluorine-18 on the TLC plate. 
To prepare samples for HPLC analysis: 0.1 mL of the reaction mixture or for the co-
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injection analysis 0.1 mL of the reaction mixture spiked with 0.1 mL of 1 mg/mL fluorinated 
standard solution were transferred to an HPLC autosampler vial.  
 
2.12.6. Automated Synthesis of [18F]F-PEB ([18F]18) 
All loading operations were conducted under an ambient atmosphere. Argon was used 
as a pressurizing gas during automated sample transfers. Potassium [18F]fluoride was 
prepared using a TRACERLab FXFN automated radiochemistry synthesis module 
(General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction 
using a GE PETTrace cyclotron. [18F]KF was produced as indicated above. A solution 
containing Cu(OTf)2 (20 μmol, 5 equiv, 0.02 M), pyridine (500 μmol, 125 equiv, 0.5 M), 
and boronic acid (4 μmol, 1 equiv, 0.004 M) precursor in 1 mL anhydrous DMF (prepared 
from separate stock solutions of the three reagents) was added to the reactor containing 
dry [18F]KF by applying Ar gas through the valve containing the reagent solution. Open 
valves leading out of the reactor were closed and the mixture was stirred for 20 min at 
110 ºC. The mixture was then cooled to 50 ºC with compressed air cooling and 5 mL of 
DMF was added to the reactor. Mixture was allowed to stir for approximately 1 min and 
was then transferred to an 8 mL sterile product vial with Ar gas. The dose vial was 
transferred out of the synthesis module in a lead pig. Total activity, RCC, and identity 
were then determined by a capintec dose calibrator, Radio-TLC scanner, and HPLC, 
respectively and as described previously.  
 
2.12.7. Automated Synthesis of [18F]MPPF ([18F]31) 
All loading operations were conducted under an ambient atmosphere. Argon was used 
as a pressurizing gas during automated sample transfers. Potassium [18F]fluoride was 
prepared using a TRACERLab FXFN automated radiochemistry synthesis module 
(General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction 
using a GE PETTrace cyclotron. [18F]KF was produced as indicated above. A solution 
containing aryl stannane precursor (0.01 mmol, 1 equiv, 0.1M stock) in 0.4 mL of 
anhydrous DMA in vial 3 and Cu(OTf)2 (0.02 mmol, 2 equiv, 0.2 M stock), pyridine (0.015 
mmol, 15 equiv, 1 M stock), in 0.25 mL of DMA from vial 4 (prepared from separate stock 
solutions of the three reagents) were added to a reactor containing dry [18F]KF by applying 
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Argon (Ar) gas through the valve containing the reagent solution for a final reaction 
volume of 1 mL of DMA. Open valves leading out of the reactor were closed, and the 
mixture was stirred for 15 min at 100 ºC. The mixture was then cooled to 50 ºC with 
compressed air cooling, and 2 mL of HPLC buffer (50% MeCN, 10 mM NH4OAc, pH 6.0) 
was added to the reactor. This mixture was allowed to stir for approximately 1 min and 
was then transferred to an HPLC loop for injection and purification by semi-preparative 
chromatography (250 x 10 mm, 10µ, 4 mL/min). The product peak (retention time ~12 
min) was collected and diluted into 50 mL of MQ H2O. The product was trapped on a C18 
extraction disk, washed with 10 mL of sterile water, eluted with 1 mL of EtOH, and then 
rinsed with 9 mL of saline solution. The resulting 10 mL solution was passed through a 
sterile filter and submitted to standard quality control tests (tests and results are described 
in detail below). [18F]MPPF was produced in a 13% RCY (200 mCi). 
 
2.12.8. Specific Activity Calculation 
The specific activity of radiofluorinated products was determined by the following method. 
A sample of known volume of the crude reaction mixture was transferred to a vial, and 
the activity of the vial was counted using a calibrated CAPINTEC (CRC-15R) detector. 
The activity in the vial was then multiplied by the RCC (obtained from radio-TLC analysis) 
to determine the total activity of the product in the vial. A concentration of activity in Ci/mL 
was thus obtained. An aliquot of the sample was then injected onto the HPLC using one 
of the four isocratic methods listed above. The UV peak corresponding to the 
radiofluorinated product was determined by overlaying the UV and RAD traces (with a 0.1 
min offset). The UV area was then used to calculate the concentration of the product 
based on linear regression analysis of appropriate [19F]fluoroarene standard. A standard 
curve was generated from standard solutions, each performed in duplicate (1 mg/mL to 
10 μg/mL). This, in turn, was used to determine the concentration of the product in 
mmol/mL. Dividing the activity concentration (Ci/mL) by the HPLC-derived concentration 
of product (mmol/mL) provided the specific activity in Ci/mmol. This reflects an EoS 
specific activity. [18F]MPPF was produced with a specific activity 2,400 Ci/mmol. 
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2.12.9. QC Validation for [18F]MPPF ([18F]31) 
Radiochemical Purity (> or = to 95%): 98.4% 
Total Chemical Content (< or = to 10 μg/mL): Pass 
MPPF Concentration (N/A (μg/mL)): 4.26 μg/mL 
Specific Activity (N/A (Ci/mmol)): 1915 Ci/mmol 
pH (4.5-7.5): 5.0 
Visual Inspection (clear, colorless, no ppt): Pass 
Kryptofix Analysis (< or = to 50 μg/mL): < 50 μg/mL 
Residual Solvent Analysis for Acetone, 5000 μg/mL: Pass 
Methanol < 3000 μg/mL: Pass 
THF < 5000 μg/mL: Pass 
MeCN < 410 μg/mL: Pass 
DMSO < 5000 μg/mL: Pass 
 
Radionuclide Identity (105-115 min half-life): 108.30 min 
Endotoxin Analysis (<17.5 EU/mL): <2.00 EU/mL 
Filter Bubble Point Test (>40 psi): >40 psi 
Radiochemical Identity (0.9-1.10): 1.001  
 
Analysis for Residual Copper and Tin: conformed to ICH guidelines 
Detection limits were 0.019 ppm for Cu and 0.395 ppm for Sn 
Both Sn and Cu were below the limit of detection 
See “Analytical Report” below for more information 
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Analytical Report 
 
 
Title: 
 
Cu & Sn in Buffered Catalyst Solution 
 
 
Date: 
 
August 18, 2016 
 
 
Prepared For: 
 
Katarina Makaravage 
University of Michigan 
 
 
Prepared By: 
 
Chemistry Team 
Cerium Laboratories 
Austin, TX 
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Sample Description: 
 
Sample # Sample ID 
MPPF 
MPPF, 8ml product solution <1mM 
substrate 
 
Samples as received: 
  
Only the yellow labeled sample was analyzed. The other two bottles are extra solvent and 
buffer just in case more analysis is needed. 
 
Analytical Equipment: 
• Varian Liberty Series II Inductively Coupled Plasma Optical Emission 
Spectrometer (ICP-OES). 
 
Instrument Conditions: 
• ICP-OES: 
1. Inlet: HF resistant torch with V-groove type pneumatic nebulizer. 
2. Plasma Flow: 15.0L/min. 
3. Aux Flow: 1.50L/min. 
4. Nebulizer Pressure: 260kPa. 
5. PMT Voltage: 660V. 
6. Method: Custom just for Cu and Sn lines. 
 
43 
 
Test Method: 
1. Sample was diluted 10 times in 10% HNO3 then analyzed by ICPOES. 
2. Tool sensitivity and calibrations performed using NIST traceable standards. 
Data: 
 “nd” implies the analyte was not detected. 
Technique Analyte Units MPP 
Detection 
Limits 
ICPOES-
HFI 
Cu ppm nd 0.019 
ICPOES-
HFI 
Sn ppm nd 0.395 
 
 
2.13.  Synthesis and Characterization  
2.13.1. Boronic Acid Substrates 
 
3-bromo-5-(pyridin-2-ylethynyl)-benzonitrile (Br-PEB, S1) was prepared by the following 
procedure adapted from the literature.67 In a glovebox, 2-((trimethylsilyl)ethynyl)pyridine 
(873.7 mg, 5.0 mmol, 1.0 equiv), 3,5-dibromobenzonitrile (1304.4 mg, 5.0 mmol, 1.0 
equiv), Pd(PPh3)2Cl2 (350.0 mg, 0.50 mmol, 0.1 equiv), CuI (182.6 mg, 1.0 mmol, 0.2 
equiv), and Et3N (1.4 mL, 2.0 mmol, 0.4 equiv) were placed in a 25 mL flask equipped 
with a stir bar. DMF (8.6 mL, 0.6 M) was added to the mixture and the flask was capped 
with a septum and taken out of the glovebox. Under N2, the flask was stirred at 80 °C for 
30 minutes. A solution of (n-Bu)4NF (1.695 g, 6.1 mmol, 1.2 equiv) in THF (1.0 M, 6.0 mL) 
was added dropwise. The reaction mixture was stirred at 80 °C until TLC showed no 
starting material was present (average time 4 hours). The reaction mixture was cooled to 
room temperature and diluted with methyl tert-butyl ether (MTBE, 10 mL) and poured into 
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aqueous NH4OH (1.0 M, 15 mL). The aqueous layer was washed with MTBE (3 x 10 mL). 
The combined organic fractions were dried over MgSO4 and concentrated in vacuo. The 
residue was purified by flash column chromatography on silica gel (15% EtOAc/hexanes), 
which afforded Br-PEB S1 as a yellow powder (687.0 mg, 2.4 mmol, 49 % yield). The 1H 
and 13C NMR spectroscopic data for S1 were identical to that reported.68 HRMS (ESI+) 
[M+H+] Calculated for C14H7BrN2: 282.9865; Found 282.9865.  
 
  
(3-cyano-5-(pyridin-2-ylethynyl)phenyl)boronic acid, pinacol ester (Bpin-PEB, S2) was 
prepared by the following procedure adapted from the literature.69 In a glovebox, Br-PEB 
(S1) (297.5 mg, 1.1 mmol, 1 equiv), B2pin2 (295.0 mg, 1.2 mmol, 1.1 equiv), KOAc (308.1 
mg, 3.1 mmol, 3.0 equiv), and Pd(dppf)Cl2 (116.6 mg, 0.14 mmol, 0.14 equiv) were placed 
in a 20 mL vial equipped with a stir bar. DMSO (5.8 mL, 0.2 M) was added to the mixture 
and the vial was sealed with a Teflon cap and taken out of the glovebox. The vial was 
stirred at 80 °C for 15 hours. The reaction mixture was cooled to room temperature and 
diluted with diethyl ether (10 mL) and filtered through Celite®. The organic layer was 
washed with H2O (3 x 15 mL). The combined organic fractions were dried over MgSO4 
and concentrated in vacuo. The product was washed with NaHCO3 (2 x 10 mL) to remove 
excess pinacol, which afforded substrate S2 as a black oil (200.7 mg, 0.6 mmol, 58% 
yield).  
 
1H NMR (700 MHz, CDCl3): δ 8.63 (d, J = 4.9 Hz, 1H) 8.23 (s, 1H), 8.04 (s, 1H), 7.90 (s, 
1H), 7.70 (td, J = 7.7, 2.1 Hz, 1H), 7.52 (d, J = 7.7 Hz, 1H), 7.28 (dd, J = 4.9, 2.1 Hz, 1H), 
1.33 (s, 12H) 
13C NMR (176 MHz, CDCl3): δ 150.2, 142.7, 142.2, 138.0, 137.0, 136.3, 127.3, 123.3, 
123.3, 117.9, 112.6, 90.5, 86.5, 84.7, 25.0, 24.8. C-CN and CN carbons in bold. 
HRMS (ESI+) [M+H+] Calculated for C20H19BN2O2: 331.1612; Found 331.1617 
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(3-cyano-5-(pyridin-2-ylethynyl)phenyl)boronic acid (B(OH)2-PEB, 18-B(OH)2) was 
prepared by the following procedure adapted from the literature.70 Bpin-PEB (S2) (271.9 
mg, 0.8 mmol, 1 equiv) and sodium periodate (529.9 mg, 2.5 mmol, 3 equiv) were stirred 
in 6.7 mL of a 4:1 mixture of THF/H2O for 30 minutes at room temperature. After that time, 
aqueous hydrochloric acid (1N, 0.6 mL) was added to the suspension. The solution was 
stirred at ambient temperature overnight (18 hr). The reaction mixture was diluted with 
ethyl acetate (10 mL) and washed with water (2 x 20 mL) and brine (20 mL), dried over 
magnesium sulfate, filtered, and concentrated in vacuo. The residue was washed with 
hexanes to give 18-B(OH)2 as a yellow solid (109.2 mg, 54 % yield).  
 
1H NMR (700 MHz, CD3OD and 1 drop of CD3COOD): δ 8.63 (d, J = 4.9 Hz, 1H) 8.15 (s, 
1H), 8.03 (s, 1H), 7.97 (t, J = 1.4 Hz, 1H), 7.91 (td, J = 7.7, 2.1 Hz, 1H), 7.69 (d, J = 8.4 
Hz, 1H), 7.47 (ddd, J = 7.7, 5.3, 1.4, 0.7 Hz, 1H) 
13C NMR (176 MHz, CDCl3): δ 150.20, 142.65, 142.20, 138.02, 137.02, 136.27, 127.29, 
123.28, 117.93, 112.57, 90.55, 86.48, 84.72. C-CN and CN carbons in bold. 
HRMS (ESI+) [M+H+] Calculated for C14H9BN2O2: 248.0830; Found 248.0834 
 
 
2.13.2. Arylstannane Substrates 
General Procedure for Preparation of Trialkylaryl Stannanes: The general procedure is 
adapted from the literature.30,71 In a nitrogen atmosphere glovebox, a 20 mL vial was 
charged with aryl iodide (1 mmol), Pd(PPh3)4 (224.6 mg, 0.19 mmol), and lithium chloride 
(202.9 mg, 4.8 mmol). The combined solids were dissolved in toluene (12.5 mL, 0.08 M) 
at room temperature. Hexabutylditin (2.6 mL, 5.2 mmol) or hexamethylditin (1.1 mL, 5.2 
mmol) was added via syringe, and the vial was sealed and removed from the glovebox. 
The sealed vial was heated to 100 °C using an aluminum block. Once the reaction mixture 
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turned black (generally 2-4 h), it was cooled to room temperature. Aqueous potassium 
fluoride (5.0 mL, 2 M solution) was added, and the mixture was stirred vigorously. After 
30 min, the mixture was filtered through a plug of Celite (eluting with hexanes or toluene). 
The filtrate was washed with brine (25 mL), dried over magnesium sulfate, filtered, and 
concentrated under vacuum. The crude product was purified via flash column 
chromatography. 
 
 
4-Trimethylstannylanisole (14-SnMe3) 
The published procedure was followed with small modifications.72 Under nitrogen 
atmosphere, 4-methoxyaniline (491.7 mg, 4.0 mmol, 1 equiv) and TsOH•H2O (929.0 mg, 
4.9 mmol, 1.2 equiv) were weighed into an oven-dried round bottom flask. 1,2-
Dichloroethane (DCE) (20 mL, 0.2 M) was added, and the flask was cooled to 0 °C. t-
BuONO (0.4 mL, 8.2 mmol, 2.0 equiv) and Sn2Me6 (0.9 mL, 4.3 mmol, 1.1 equiv) were 
added in succession. The resulting reaction solution was stirred for 4 h at 0 °C under 
nitrogen. The solution was then filtered through a silica plug and concentrated under 
reduced pressure. Purification by flash column chromatography eluting with 20% diethyl 
ether in pentanes afforded 14-SnMe3 as a colorless oil (59.3 mg, 22% yield, Rf = 0.8 in 
10% ethyl acetate in hexanes). The 1H and 13C NMR spectra matched those reported 
previously in the literature.72 HRMS (EI) [M–CH3+] Calculated for C9H13OSn: 256.9989; 
Found 256.9979. 
 
 
4-Tributylstannyl-1,1’-biphenyl (8-SnBu3)  
The general procedure was followed using 4-iodo-1,1’-biphenyl (279.5 mg, 1.0 mmol) and 
heating for 3 h. Purification by flash column chromatography eluting with hexanes 
afforded 8-SnBu3 as a colorless oil (191.0 mg, 43% yield, Rf = 0.6 in 100% hexanes). The 
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1H and 13C NMR spectra matched those reported previously in the literature.73 HRMS (EI) 
[M–C4H9+] Calculated for C20H27Sn: 387.1135; Found 387.1135.  
 
 
4-Trimethylstannyl-1,1’-biphenyl (8-SnMe3) 
The general procedure was followed using 4-iodo-1,1’-biphenyl (280.1 mg, 1.0 mmol) and 
heating for 2 h. Purification by flash column chromatography eluting with hexanes 
afforded 8-SnBu3 as a colorless oil (275.0 mg, 87% yield, Rf = 0.5 in 100% hexanes). The 
1H and 13C NMR spectra matched those reported previously in the literature.74 HRMS (EI) 
[M+] Calculated for C15H18Sn: 318.0430; Found 318.0415.  
 
 
4-Tributylstannylacetophenone (1-SnBu3) 
The general procedure was followed using 4-iodoacetophenone (246.3 mg, 1.0 mmol) 
and heating for 4 h. Purification by flash column chromatography eluting with hexanes 
afforded 1-SnBu3 as a colorless oil (284.3 mg, 69 %, Rf = 0.56 in 5% ethyl acetate in 
hexanes). The 1H and 13C NMR spectra matched those reported previously in the 
literature.73 HRMS (ESI+) [M+K+] Calculated for C20H34KOSn: 449.1263; Found 449.1263.  
 
 
4-Trimethylstannylacetophenone (1-SnMe3) 
The general procedure was followed using 4-iodoacetophenone (245.9 mg, 1.0 mmol) 
and heating for 4 h. Purification by flash column chromatography eluting with 20% ethyl 
acetate in hexanes afforded 1-SnMe3 as a colorless oil (147.0 mg, 52% yield, Rf = 0.7 in 
10% ethyl acetate in hexanes). The 1H and 13C NMR spectra matched those reported 
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previously in the literature.72 HRMS (EI) [M–CH3+] Calculated for C10H13OSn: 268.9988; 
Found 268.9984. 
 
 
2-Tributylstannylanisole (21-SnBu3) 
The general procedure was followed using 2-iodoanisole (0.32 mL, 2.5 mmol) and heating 
for 6 h. Purification by flash column chromatography eluting with hexanes afforded 21-
SnBu3 as a colorless oil (604.2 mg, 62% yield, Rf = 0.6 in 100% hexanes). The 1H and 
13C NMR spectra matched those reported previously in the literature.73 HRMS (EI) [M–
C4H9+] Calculated for C15H25OSn: 341.0927; Found 341.0934. 
 
 
(3,4-dimethoxyphenyl)tributylstannane (22-SnBu3) 
The general procedure was followed using 1-iodo-3,4-dimethoxybenzene (265.2 mg, 1.0 
mmol) and heating for 2.5 h. Purification by flash column chromatography eluting with 
20% ethyl acetate in hexanes afforded 22-SnBu3 as a colorless oil (171.7 mg, 40% yield, 
Rf = 0.5 in 10% ethyl acetate in hexanes). The 1H NMR spectra matched that reported 
previously in the literature.75  
 
1H NMR (CDCl3): δ 6.99 (d, J = 7.7 Hz, 1H), 6.94 (s, 1H), 6.89 (d, J = 7.7 Hz, 1H), 3.89 
(s, 3H), 2.87 (s, 3H), 1.56-1.52 (multiple peaks, 6H), 1.36-1.30 (multiple peaks, 6H), 1.05-
1.03 (multiple peaks, 6H), 0.89 (t, J = 7 Hz, 9H) 
13C NMR (CDCl3): δ 149.12, 148.65, 132.52, 129.17, 118.63, 111.20, 55.83, 55.62, 29.10, 
27.37, 13.90, 9.67 
HRMS (ESI) [M+Na+] Calculated for C20H36NaO2Sn: 451.1629; Found 451.1629 
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Tributyl(3,4,5-trimethoxy)stannane (15-SnBu3) 
The general procedure was followed using 5-iodo-1,2,3-trimethoxybenzene (294.5 mg, 
1.0 mmol) and heating for 2 h. Purification by flash column chromatography eluting with 
20% ethyl acetate in hexanes afforded 15-SnBu3 as a colorless oil (326.7 mg, 71% yield, 
Rf = 0.7 in 20% ethyl acetate in hexanes). The 1H and 13C NMR spectra matched those 
reported previously in the literature.76 HRMS (ESI) [M+H+] Calculated for C21H39O3Sn: 
459.1916; Found 459.1915. 
 
 
NHBoc-Phe(4-SnMe3) ethyl ester (28-SnMe3) was prepared by the following 2 step 
procedure. 
 
 
Step 1: 
Iodide S3 was prepared via a modification of a literature procedure.77 To an oven-dried 
flask, Boc-Phe(4-I)-OH (1016.6 mg, 2.6 mmol, 1.0 equiv) was dissolved in 
dichloromethane (22 mL) at room temperature. DMAP (34.3 mg, 0.3 mmol, 0.1 equiv) 
and ethanol (0.3 mL, 5.1 mmol, 2.0 equiv) were added to the solution, and the reaction 
was placed under nitrogen and cooled to 0 °C. DCC (862.5 mg, 4.2 mmol, 1.6 equiv) was 
added slowly. The mixture was allowed to warm up to room temperature and react 
overnight at room temperature under nitrogen. The white precipitate formed was filtered 
off and the organic filtrate was washed with brine (1 x 20 mL), dried using magnesium 
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sulfate, and concentrated. The crude residue was purified by column chromatography 
(silica gel, 20% ethyl acetate in hexane) affording the product (S3) as a white solid (1.01 
g, 93% yield, Rf = 0.2 in 20% ethyl acetate in hexanes, mp = 91–92 °C).  
 
1H NMR (CDCl3): δ 7.57 (d, J = 7.7 Hz, 2H), 6.85 (d, J = 7.7 Hz, 2H), 5.00 (d, J = 7.0 Hz, 
2H), 4.49 (d, J = 7.0 Hz, 2H), 4.11 (q, J = 7.0 Hz, 2H), 3.03 (m, 2H), 1.37 (s, 9H), 1.19 (t, 
J = 7.0 Hz, 3H) 
13C NMR (CDCl3): δ 171.45, 154.90, 137.40, 135.76, 131.30, 92.32, 79.86, 61.38, 54.14, 
37.82, 28.21, 14.06 
HRMS (ESI+) [M+Na+] Calculated for C16H22INNaO4: 442.0486; Found 442.0489 
 
 
 
Step 2: 
The general procedure for stannane synthesis was followed using S3 (404.8 mg, 1.0 
mmol) and heating for 2 h. Purification by flash column chromatography eluting with 20% 
ethyl acetate in hexanes afforded 28-SnBu3 as a colorless oil (73.4 mg, 17% yield, Rf = 
0.5 in 20% ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 7.39 (d, J = 10.5 Hz, 2H), 7.09 (d, J = 10.5 Hz, 2H), 4.96 (d, J = 10.5 
Hz, 1H), 4.53 (d, J = 10.5 Hz, 1H), 4.14 (q, J = 9.8 Hz, 2 H), 3.03 (m, 2H), 1.39 (s, 9H), 
1.22 (t, J = 9.8 Hz, 3H), 0.25 (s, 9H) 
13C NMR (CDCl3): δ 171.59, 155.00, 135.95, 134.63, 130.70, 128.58, 61.47, 54.31, 37.79, 
28.29, 14.13, –0.97, –9.61 
HRMS (ESI) [M+H+] Calculated for C19H32NO4Sn: 458.1348; Found 458.1352 
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NBoc2-Phe(4-SnMe3) ethyl ester (29-SnMe3) was prepared by the following 3 step 
procedure. 
 
 
Step 1: see above procedure 
 
 
Step 2: 
Iodide S4 was prepared via a modified literature procedure.78 To a solution of S3 (546.0 
mg, 1.3 mmol) in dry acetonitrile (25 mL) under nitrogen was added DMAP (75.3 mg, 0.6 
mmol) in dry acetonitrile (10 mL) and then di-tert-butyl dicarbonate (0.7 mL, 3.1 mmol) in 
dry acetonitrile (10 mL). The mixture was stirred at room temperature overnight and then 
concentrated under vacuum. Purification by flash column chromatography eluting with 
20% ethyl acetate in hexanes afforded S4 as a colorless oil (407.9 mg, 60% yield, Rf = 
0.54 in 20% ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 7.56 (d, J = 11.9 Hz, 2H), 6.91 (d, J = 11.9 Hz, 2H), 5.05 (dd, J = 14.2, 
7.3 Hz, 1H), 4.18 (m, 2H), 3.35 (dd, J = 19.6, 7.3 Hz, 1H), 3.13 (dd, J = 19.6, 14.2 Hz, 
1H), 1.38 (s, 18H), 1.25 (t, J = 9.8 Hz, 3H) 
13C NMR (CDCl3): δ 170.08, 151.79, 137.42, 137.32, 131.62, 91.82, 83.04, 61.40, 59.11, 
35.63, 27.84, 14.11 
HRMS (ESI+) [M+Na+] Calculated for C21H30INNaO6: 542.0101; Found 542.0102 
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Step 3: 
The general procedure for stannane synthesis was followed using S4 (407.9 mg, 0.8 
mmol) and heating for 2 h. Purification by flash column chromatography eluting with 20% 
ethyl acetate in hexanes afforded 29-SnBu3 as a yellow oil (230.4 mg, 53% yield, Rf = 0.6 
in 20% ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 7.36 (d, J = 7.7 Hz, 2H), 7.14 (d, J = 7.7 Hz, 2H), 5.08 (dd, J = 10.5, 
4.9 Hz, 1H), 4.18 (m, 2H), 3.38 (dd, J = 14.0, 4.9 Hz, 1H), 3.18 (dd, J = 14.0, 10.5 Hz, 
1H) 1.36 (s, 18H), 1.25 (t, J = 7 Hz, 3H), 0.22 (s, 9H) 
13C NMR (CDCl3): δ 170.38, 151.66, 139.78, 137.71, 135.82, 129.35, 82.83, 61.34, 59.60, 
36.07, 27.86, 14.15, –9.71 
HRMS (ESI) [M+H+] Calculated for C24H40NO6Sn: 558.1883; Found 558.1883 
 
 
Boc4DOPA(2-SnMe3) methyl ester (30-SnMe3)  
Aryl stannane 30-SnMe3 was prepared via a modified literature porcedure.78 To a solution 
of Boc3DOPA-SnMe3 (445.1 mg, 0.7 mmol) in dry acetonitrile (10 mL) under nitrogen was 
added DMAP (32.3.0 mg, 0.28 mmol, 0.4 equiv) in dry acetonitrile (4.6 mL) and di-tert-
butyl dicarbonate (0.3 mL, 1.3 mmol, 2 equiv) in dry acetonitrile (4.4 mL). The reaction 
was stirred at room temperature overnight and then concentrated under vacuum. 
Purification by flash column chromatography eluting with 20% ethyl acetate in hexanes 
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afforded 30-SnMe3 as a yellow oil (407.6 mg, 80% yield, Rf = 0.46 in 20% ethyl acetate 
in hexanes). 
 
1H NMR (CDCl3): δ 7.22 (s, 1H), 7.01, (s, 1H), 5.03 (dd, J = 10.5, 4.2 Hz, 1H), 3.73 (s, 
3H), 3.38 (dd, J = 14.7, 4.2 Hz, 1H), 3.29 (dd, J = 14.7, 10.5 Hz, 1H) 1.52 (s, 9H), 1.50 
(s, 9H), 1.37 (s, 18H), 0.31 (s, 9H)  
13C NMR (CDCl3): δ 170.59, 151.79, 150.72, 150.59, 142.95, 142.44, 141.28, 140.50, 
130.00, 123.82, 83.44, 83.36, 83.19, 59.24, 52.36, 37.98, 27.84, 27.62, 27.61, –8.13  
HRMS (ESI) [M+Na+] Calculated for C33H53NNaO12Sn: 798.2482; Found 798.2491 
 
 
MPP-SnMe3 (31-SnMe3) was prepared by the following 5-step procedure.2D 
 
 
                                            
D Reactions performed and products isolated by Jason Miller. 
 
54 
 
 
The general procedure was followed using S8 (200.0 mg, 0.37 mmol) and heating for 2 
h. Purification by flash column chromatography eluting with 50% ethyl acetate in hexanes 
afforded 31-SnMe3 as a white solid (132.8 mg, 62% yield, Rf = 0.16 in 50% ethyl acetate 
in hexanes, mp = 140–141 °C).  
 
1H NMR (CDCl3): δ 8.41 (dd, J = 4.9, 1.4 Hz, 1H), 7.37 (td, J = 7.7, 2.1 Hz, 1H), 7.30 (d, 
J = 7.7 Hz, 2H), 7.25 (d, J = 7.7 Hz, 2H), 6.84-7.00 (multiple peaks, 5H), 6.82 (dd, J = 8.4, 
1.4 Hz, 1H), 6.75 (d, J = 8.4 Hz, 1H), 4.27 (t, J = 7.0 Hz, 2 H), 3.82 (s, 3H), 2.90 (broad 
peak, 4H), 2.73 (t, J = 7.0 Hz, 2 H), 2.61 (broad peak, 4H), 0.22 (s, 9H)  
13C NMR (CDCl3): δ 170.72, 156.59, 152.22, 148.52, 145.70, 141.39, 136.94, 135.97, 
135.30, 127.93, 122.91, 122.73, 120.90, 120.70, 118.05, 111.17, 56.41, 55.32, 53.32, 
50.62, 45.49, –9.56  
HRMS (ESI+) [M+H+] Calculated for C28H37N4O2Sn: 581.1933; Found 581.1950 
 
 
The general procedure was followed using S1 (263.9 mg, 0.93 mmol) and heating for 7 
h. Purification by flash column chromatography eluting with 30% ethyl acetate in hexanes 
afforded 18-SnBu3 as a yellow oil (245.8 mg, 54% yield, Rf = 0.43 in 20% ethyl acetate in 
hexanes). The 1H and 13C NMR spectra matched those reported previously in the 
literature.68 HRMS (EI) [M+H+] Calculated for C26H35N2Sn: 495.1817; Found 495.1820. 
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2.13.3. Fluorinated Standards 
 
3-fluoro-5-(pyridin-2-ylethynyl)benzonitrile (F-PEB, 18) was prepared by the following 
procedure adapted from the literature.67 In a glovebox, 2-((trimethylsilyl)ethynyl)pyridine 
(177.7 mg, 1.0 mmol, 1.0 equiv), 3,5-dibromobenzonitrile (205.6 mg, 1.0 mmol, 1.0 equiv), 
Pd(PPh3)2Cl2 (74.4 mg, 0.10 mmol, 0.10 equiv), CuI (39.5 mg, 0.2 mmol, 0.20 equiv),and 
Et3N (0.3 mL, 2.1 mmol, 2.1 equiv) were placed in a flask with DMF (1.75 mL, 0.6 M). The 
flask was placed under N2 flow and stirred at 80 °C for 30 min. A solution of (n-Bu)4NF 
(1.129 g, 4.0 mmol, 4.0 equiv) in THF (1.0 M, 4.0 mL,1.1 equiv) was added dropwise. The 
reaction mixture was stirred at 80 °C until TLC showed no starting material was present. 
The reaction mixture was cooled to room temperature and diluted with MTBE (10 mL) 
and poured into aqueous NH4OH (1.0 M, 15 mL). The aqueous layer was washed with 
MTBE (3 x 10 mL). The combined organic fractions were dried over MgSO4 and 
concentrated in vacuo. The residue was purified by flash chromatography on silica gel 
(15% EtOAc/hexanes), which afforded F-PEB 18 as a brown solid (142.9 mg, 0.64 mmol, 
63% yield). The 1H and 13C NMR spectroscopic data for S3 were identical to that 
reported.79 19F NMR (658 MHz, CDCl3): δ –108.9. HRMS (ESI+) [M+H+] Calculated for 
C14H7FN2: 223.0666; Found 223.0664. 
 
 
4-(2-fluorovinyl)-1,1'-biphenyl (17) was prepared by the following procedure adapted from 
literature.6 2-([1,1'-biphenyl]-4-yl)vinyl boronic acid (46 mg, 0.21 mmol, 1.0 equiv) was 
dissolved with a 0.24 M methanolic NaOH solution (1 mL, 0.24 mmol, 2.4 equiv) in a flask. 
The mixture was capped with a septum and stirred for 15 min at room temperature, then 
cooled to 0 °C in an ice water bath. Silver trifluoromethanesulfonate (156 mg, 0.61 mmol, 
56 
 
3.0 equiv) was added to the reaction mixture, and the mixture was capped and stirred for 
an additional 30 min at 0° C. Solvent was then evaporated under reduced pressure using 
a rotary evaporator at 3 °C. Then acetone aliquots (2 x 1mL) were added to the reaction 
mixture and evaporated to remove any additional volatile components. The dry residue 
was dissolved in 1 mL of acetone and approx. 300 mg of 4 Å molecular sieves were added 
to the solution, followed by Selectfluor (75 mg, 0.21 mmol, 1.0 equiv). The mixture was 
capped with a septum and stirred at 0 °C for 60 min. The reaction was quenched with 30 
mL water and extracted with DCM (3 x 30 mL). The organic layer was washed twice with 
brine and passed through silica, thereby decolorizing it. The filtrate was loaded onto silica 
and purified by flash chromatography on silica gel (hexanes). The solvent was removed 
in vacuo to afford the product 17 as a white powder (12 mg, 0.06 mmol, 29% yield). The 
1H and 13C NMR spectroscopic data for 17 were identical to that previously reported.6 19F 
NMR (470 MHz, CDCl3): δ –129.5. HRMS (ESI+) [M+H+] Calculated for C14H11F: 
198.0845; Found 198.08444. 
 
 
(E)-Fluorostyrene (26) 
In a nitrogen atmosphere glovebox, tributyl(phenylethenyl)tin (415.9 mg, 1.1 mmol, 1 
equiv), Cu(OTf)2 (766.2 mg, 2.1 mmol, 2 equiv), KF (245.3 mg, 4.2 mmol, 4 equiv), and 
pyridine (1.3 mL, 16.1 mmol, 15 equiv) were weighed into a flask equipped with a 
magnetic stir bar. DMA (100 mL) was added. The reaction mixture was allowed to stir at 
140 ºC for 4 h. The resulting solution was cooled to room temperature, diluted with diethyl 
ether and washed with water (2 x 200 mL), and brine (200 mL). The organic extracts were 
dried and concentrated. Purification by flash column chromatography eluting with 20% 
diethyl ether in pentane afforded 26 as a colorless oil. The 19F NMR spectroscopic data 
was identical to that reported.80 
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NHBoc-Phe(4-F) ethyl ester (28) 
Authentic standard 28 was prepared by the following procedure via a modification of a 
literature procedure.77 To an oven-dried flask, NHBoc-Phe(4-F)-OH (509.4 mg, 1.8 mmol, 
1.0 equiv) was dissolved in dichloromethane (15 mL, 0.12 M) at room temperature. DMAP 
(22.2 mg, 0.18 mmol, 0.1 equiv) and ethanol (0.21 mL, 3.6 mmol, 2.0 equiv) were added 
to the solution and the reaction was placed under nitrogen and cooled to 0 °C. DCC (595.0 
mg, 2.9 mmol, 1.6 equiv) was added slowly. The mixture was allowed to warm to room 
temperature and was then stirred overnight at room temperature under nitrogen. Over 
this time, a white precipitate formed and was removed by filtration. The filtrate was 
washed with brine (1 x 20 mL), dried over magnesium sulfate, and concentrated. The 
crude residue was purified by column chromatography (silica gel, 20% ethyl acetate in 
hexane) affording the product (28) as a colorless oil (453.1 mg, 81% yield, Rf = 0.44 in 
20% ethyl acetate in hexanes). The 1H and 13C NMR spectra matched those reported 
previously in the literature.81 19F NMR (CDCl3): δ –116.01. HRMS (ESI) [M+H+] Calculated 
for C16H23FNO4: 312.1606; Found 312.1611. 
 
NBoc2-Phe(4-F) ethyl ester (29) 
Authentic standard 29 was prepared via a modification of a literature procedure.78 To a 
solution of 28 (334.5 mg, 1.07 mmol, 1 equiv) in dry acetonitrile (20 mL) under nitrogen 
was added 4-dimethylaminopyridine (DMAP) (54.0 mg, 0.44 mmol, 0.4 equiv) in dry 
acetonitrile (5 mL) and di-tert-butyl dicarbonate (0.5 mL, 2.2 mmol, 2.0 equiv) in dry 
acetonitrile (5 mL). The mixture was stirred at room temperature overnight and then 
concentrated under nitrogen. Purification by flash column chromatography eluting with 
20% ethyl acetate in hexanes afforded 29 as a colorless oil (81.5 mg, 18% yield, Rf = 0.5 
in 20% ethyl acetate in hexanes).  
58 
 
 
1H NMR (CDCl3): δ 7.12 (dd, J = 8.4, 4.9 Hz, 2H), 6.93 (t, J = 8.4 Hz, 2H, 5.06 (dd, J = 
9.8, 4.9 Hz, 1H), 4.18 (m, 2H), 3.37 (dd, J = 14.0, 4.9 1H), 3.16 (dd, J = 14.0, 9.8 Hz, 1H), 
1.38 (s, 18H), 1.25 (t, J = 7.0 Hz, 3H)  
13C NMR (CDCl3): δ 170.24, 162.42, 161.03, 151.83, 133.46, 133.44, 131.00, 130.96, 
115.14, 115.02, 82.98, 61.39, 59.39, 35.27, 27.88, 14.14  
19F NMR (CDCl3): δ –116.93  
HRMS (ESI) [M+H+] Calculated for C21H31FNO6: 412.2130; Found 412.2136 
 
Boc4DOPA(2-F) methyl ester (30) 
In a nitrogen atmosphere glovebox, 30-SnMe3 (311.0 mg, 0.4 mmol, 1 equiv), Cu(OTf)2 
(290.0 mg, 0.8 mmol, 2 equiv), KF (93.3 mg, 1.6 mmol, 4 equiv), and pyridine (0.5 mL, 
6.2 mmol, 15 equiv) were weighed into a flask equipped with a magnetic stir bar. DMA 
(40 mL, 0.01M) was added. The reaction mixture was allowed to stir at 100 ºC for 2 h. 
The resulting solution was cooled to room temperature, diluted with diethyl ether, and 
washed with water (2 x 200 mL) and brine (200 mL). The organic extracts were dried over 
magnesium sulfate and concentrated. Purification by flash column chromatography 
eluting with 20% ethyl acetate in hexanes afforded 30 as a colorless oil (19.1 mg, 8% 
yield, Rf = 0.6 in 40% ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 7.05 (d, J = 9.8 Hz, 1H), 6.97 (d, J = 13.3 Hz, 1H), 5.18 (dd, J = 14.0, 
7.0 Hz, 1H), 3.73 (s, 3H), 3.43 (dd, J = 19.6, 7.0 Hz, 1H), 3.21 (dd, J = 19.6, 14.0 Hz, 1H), 
1.51 (s, 18H), 1.38 (s, 18H)  
13C NMR (CDCl3): δ 170.45, 158.88, 157.46 151.55, 150.57, 150.09, 141.80, 138.39, 
125.37, 122.66, 110.43, 84.05, 83.76, 83.29, 57.73, 52.34, 29.45, 27.81, 27.57  
19F NMR (CDCl3): δ –117.64 
HRMS (ESI) [M+NH4+] Calculated for C30H48FN2O12: 647.3186; Found 647.3184 
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Chapter 3 
 
Cu-Mediated [11C]Cyanation of Organometallic Reagents1,2 
 
 
3.1. Background 
Carbon-11 (t1/2 = 20 min) is a radioisotope that is commonly used for positron 
emission tomography (PET) imaging.3,4 A number of methods have been developed for 
[11C]radiolabeling, most involve introducing a [11C]methyl group onto a molecule of 
interest.5 Recently, new methods have been developed to generate [11C]CN.6 
[11C]Cyanide offers two advantages, (1) it can be readily generated from [11C]CO2,3,4 
allowing for ease of implementation; and (2) the nitrile functionality is common in bioactive 
molecules7 and can be rapidly transformed into other prevalent functional groups, 
including amides, carboxylic acids, and amines (Scheme 3.1). 
 
Scheme 3.1. Diversification of [11C]Nitrile Substrates 
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There are currently two major methods for the [11C]cyanation of aromatic and 
heteroaromatic substrates. The first uses aryl halide precursors in combination with a Pd 
catalyst to engage [11C]cyanide in aryl–CN cross coupling (Scheme 3.2).8–11 These 
reactions often provide high yields, exhibit broad scope, and proceed under mild 
conditions. However, Pd is relatively toxic, having a PDE of 10 μg/day in parenteral drugs, 
considerably lower than Cu (PDE = 340 μg/day) or Sn (PDE = 640 μg/day).12 Due to the 
very low PDE for Pd, more time and specialized equipment is needed to ensure residual 
Pd levels in radiotracer doses are below the allowable limit. Furthermore, the Pd-aryl 
intermediates and phosphine ligands required for these reactions are often not air 
stable,9,11 which needs to be accounted for in radiotracer synthesis. For example, to 
prevent loss in RCY due to oxidation, Pd is commonly added at the last possible moment.9 
However, this is not possible when working with multi-Curie production scale levels of 11C 
in automated synthesis modules which are set up prior to delivery of 11C to the hot-cell. 
 
Scheme 3.2. [11C]-Cyanation Using Biaryl Phosphine Pd(0) Complexes11 
 
 
The other major [11C]radiocyanation method involves the reaction of aryl halides 
with [11C]CuCN (e.g., the Rosenmund-von Braun reaction).13–15 This transformation offers 
the advantages of operational simplicity (e.g., no phosphine ligands, no requirement to 
pre-form organometallic intermediates, no need to remove palladium) and the relatively 
low toxicity of Cu.12 However, it suffers from low yields, modest scope, and forcing 
reaction conditions, often requiring temperatures of 150–250 °C (Scheme 3.3).4 This 
Chapter describes the development of an alternative Cu-mediated [11C]radiocyanation 
that leverages the advantages, while addressing the limitations of the existing Cu method.  
 
Scheme 3.3. [11C]Cyanation Using [11C]CuCN15 
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3.2. Initial Studies and Optimization with [12C]KCN 
Our group has shown aryl trifluoroborates were competent substrates for diverse 
Cu-mediated functionalization with a variety of nucleophiles including cyanide, halides, 
azide, carboxylates, and sulfonates.16,17 The fluorination conditions (4 equiv of Cu(OTf)2 
and 4 equiv of KF in MeCN at 60 °C for 20 h)18 were modified for other nucleophiles, 
which should proceed via a similar mechanism (Scheme 3.4).  
 
Scheme 3.4. Copper-Mediated Functionalization of Aryl Trifluoroborates 
 
 
Preliminary results show that aryl trifluoroborates form 22% of the desired product 
under similar conditions to the previously describe fluorination conditions (4 equiv of 
Cu(OTf)2 and 4 equiv of KCN in MeCN at 60 °C for 20 h, (Table 3.1, entry 1).16,17 
Arylstannanes gave similar yields to the aryltrifluoroborate substrate, but these reactions 
required a shorter time (Table 3.1, entries 2-5), which is highly desirable for radiolabeling. 
Methods to generate [11C]KCN were known, so further optimizations revolved around 
using KCN.  
 
Table 3.1. Initial Attempts in MeCN 
 
entry [M] [CN] 18-crown-6 time (h) yield (%) 
1 BF3K KCN -- 20 22 
2 SnBu3 KCN -- 2 14 
3 SnBu3 TBACN -- 2 21 
4 SnBu3 KCN ✓ 2 14 
5 SnBu3 TBACN ✓ 2 15 
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Conditions: substrate (25 µmol), Cu(OTf)2 (4 equiv), [CN] (4 equiv), and 18-crown-6 (4 
equiv), in MeCN (0.083 M) at 60 ºC for the indicated time. Yield was determined by 19F 
NMR spectroscopy with 1,2-difluorobenzene as an internal standard. 
 
 Changing from the MeCN conditions above to modified [18F]radiofluorination 
conditions (2 equiv Cu(OTf)2, 15 equiv pyridine, 4 equiv KF in DMA at 110 °C for 2 h)19 
gave an increase in yield. Using a slight excess of KCN did not increase the yield of 
product over two hours (Table 3.2, entries 1-3). A similar result is observed when 1 equiv 
of KCN was used (Table 3.2, entry 4), confirming that this transformation is fast and does 
not require an excess of KCN. 
 
Table 3.2. Initial Attempts in DMA 
 
Entry KCN (equiv) time (h) yield (%) 
1 2 0.5 35 
2 2 1 38 
3 2 2 36 
4 1 1 36 
Conditions: arylstannane (10 µmol), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and KCN (X 
equiv) in DMA (10 mM) at 100 ºC for the indicated time. Yield was determined by 19F 
NMR spectroscopy with 1,2-difluorobenzene as an internal standard. 
 
 A time study showed that the reaction stalls after 15 min (Table 3.3, entries 1-2). 
Increasing the temperature increased the yield up to 47% (Table 3.3, entry 3). However, 
to save time with [11C]CN (t1/2 = 20 min), 100 °C was chosen as the temperature to save 
time heating the reaction vessel (the system requires ~1 min per 50 °C). Several other 
copper sources were shown to be competent for this transformation (Table 3.3, entries 4-
5). The reaction was found to give desired product without pyridine, but adding pyridine 
to the reaction increased the yield (Table 3.3, entry 6). Other additives/bases either had 
no effect or gave a slight increase in yield over the control without additives (Table 3.3, 
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entry 7). Using a crown ether increased the yield slightly (Table 3.3, entry 8). Finally, using 
DMF, rather than DMA, as a solvent also gave a small boost in yield (Table 3.3, entry 9). 
 
Table 3.3. Optimization Results with KCN 
 
entry [Cu] additive yield (%) 
1a Cu(OTf)2 pyridine 40 
2 Cu(OTf)2 pyridine 41 
3b Cu(OTf)2 pyridine 47 
4 Cu(BF4)2 6H2O pyridine 39 
5 (MeCN)4Cu(BF4) pyridine 18 
6 Cu(OTf)2 -- 17 
7 Cu(OTf)2 2,6-lutidine 21 
8 Cu(OTf)2 pyridine, 18-c-6 42 
9c Cu(OTf)2 pyridine 52 
Conditions: arylstannane (10 µmol), Cu(OTf)2 (2 equiv), additive (15 equiv), and KCN (2 
equiv) in DMA (10 mM) at 100 ºC for the indicated time. Yield was determined by 19F 
NMR spectroscopy with 1,2-difluorobenzene as an internal standard. aReaction time: 15 
min. bReaction temperature: 120 °C. cSolvent: DMF 
 
 A small substrate scope was used to analyze the effects of DMA versus DMF as 
the solvent. While DMF was a better solvent for the arylstannane precursor (Table 3.4, 
entry 1), DMA gave higher yields for the boronate derivatives (Table 3.4, entries 2-4). The 
boronate ester only reacted to form the desired product in a modest yield. However, the 
yield with the boronate ester could be increased to 41% by the addition of KF. This 
additive likely promotes transmetalation via the formation of a borate intermediate. The 
effect of water in the reaction was analyzed and it was found that small amounts of water 
were tolerated in this reaction (Table 3.4, entry 7).  
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Table 3.4. Comparison of Substrates in DMF and DMA 
 
entry [M] additive yield (%)  
1 SnBu3 -- 44 (52) 
2 B(OH)2 -- 65 (62) 
3 BF3K -- 61 (59) 
4 Bpin -- 15 (12) 
5 Bpin KF (1 equiv) 41 
6 Bpin KF (2 equiv) 40 
7 SnBu3 DMA/H2O (9:1) 45 
Conditions: substrate (10 µmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and KCN 
(2 equiv) in DMA at 100 ºC for 30 min. Yields in parenthesis were performed in DMF. 
Yield was determined by 19F NMR spectroscopy with 1,2-difluorobenzene as an internal 
standard. 
 
3.3. Initial Studies and Optimization with [11C]KCN 
After preliminary studies with KCN, the optimal conditions were translated to 
[11C]KCN. Starting with analogous conditions to the previously reported [18F]KF conditions 
(2 equiv Cu(OTf)2, 15 equiv pyridine in DMA at 100 °C for 5 min) provided the desired 
product in 42% RCC as determined by radio-TLC, with identity confirmed by radio-HPLC 
(Table 3.5, entry 1). Subsequent studies revealed that anhydrous conditions (which were 
essential for the analogous [18F]radiofluorination with [18F]KF) are not necessary for 
[11C]radiocyanation. For example, a comparable 41% RCC was obtained upon the 
addition of exogenous water (0.2 mL, 17% v/v) to the anhydrous [11C]KCN reaction 
mixture (Table 3.5, entry 2). Furthermore, an even higher yield (66% RCC, Table 3.5, 
entry 3) was observed when the [11C]KCN was prepared and used directly as an aqueous 
solution. Importantly, this modification decreased the overall synthesis time by 4 min 
(approximately 20% of the 11C half-life). The improved RCC under these conditions is 
likely due to increased solubility of [11C]KCN. 
Analogous to the KCN conditions, using DMF as a solvent gave lower RCC (Table 
3.5, entry 4) and the boron derivatives gave a higher conversion than the arylstannane 
(Table 3.5, entries 5-7). Interestingly, the aryl pinacol borane substrate gave comparable 
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yields and did not require activating KF, likely due to the decreased amount of KCN 
available in the reactions. Other optimization did not lead to an increase in RCC. Notably, 
while this work was underway, the team of Hooker, Vasdev, and Liang published a related 
method for the Cu-mediated [11C]cyanation of arylboronic acids (for more discussion, see 
Section 3.8).20 
 
Table 3.5. Optimization with [11C]KCN 
 
entry [M] [11C]KCN conditions RCC (%)  
1 SnBu3 anhydrous in DMA 42 
2 SnBu3 anhydrous in DMA, H2Oa 41 
3 SnBu3 [11C]KCN in H2O 66 
4b SnBu3 [11C]KCN in H2O 48 
5 B(OH)2 [11C]KCN in H2O 79 
6 BF3K [11C]KCN in H2O 93 
7 Bpin [11C]KCN in H2O 76 
Conditions: 2-[M] (10 μmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and 
[11C]KCN in DMA (1 mL, 10 mM) at 100 °C, 5 min. Reported values indicate RCC 
determined by radio-TLC (n ≥ 2). aH2O (0.2 mL, 17% v/v). bReaction solvent: DMF. 
 
3.4. Substrate Scope 
The scope of this transformation was evaluated using a variety of organoboron 
and organostannane substrates (denoted by the footnotes in Figure 3.1). These studies 
show that electron-donating ([11C]1-4), -neutral ([11C]5), and -withdrawing ([11C]6-7) 
substituents on the aromatic ring are all well-tolerated. Ortho-substituted substrates 
undergo [11C]radiocyanation in comparable yields to their unsubstituted counterparts 
(compare [11C]8-10).20 In addition, carbonyl-containing groups ([11C]11-14) are 
compatible with the reaction conditions, but minimal uncharacterized side products were 
observed by radio-HPLC. All of these side products were formed in small amounts and 
could be easily separated from the desired product. Significantly, precursors containing 
unprotected benzoic acid ([11C]12) and phenol ([11C]4) substituents also afford modest to 
excellent yields. Aryl bromides are tolerated at various sites around the phenyl ring 
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([11C]16-18), and these could serve as handles for further elaboration of the products. 
Pyridine derivatives and related nitrogen heterocycles also undergo [11C]radiocyanation 
in moderate to high yields ([11C]19-25). Finally, it is noteworthy that a number of the 
products in Figure 3.1 have not been labeled with [11C]CN before, including [11C]3-[11C]4, 
[11C]6, [11C]8-[11C]9, [11C]12, [11C]14-[11C]15, [11C]17-[11C]19, [11C]22, [11C]25, and 
[11C]27. 
 
Figure 3.1. Substrate Scope 
 
Reported values indicate RCC determined by radio-TLC (n ≥ 2). General conditions: 
substrate (10 μmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), and [11C]KCN (in 
H2O) in DMA (10 mM) at 100 °C for 5 min. 
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Overall, the scope of this transformation is broader, and many of the RCCs are 
higher than those of previously reported methods for the [11C]radiocyanation of aromatic 
substrates.11,20 As an example, this method affords quinoline product [11C]20 in 71% RCC 
from 20-B(OH)2 (Scheme 3.5, reaction 1), while recently reported Cu-catalyzed 
[11C]radiocyanation conditions provide 18% RCC for the same substrate (Scheme 3.5, 
reaction 2),20 and a Pd-catalyzed method affords 46% RCC from the analogous aryl 
bromide (Scheme 3.5, reaction 3).11 Notably, subjecting 20-B(OH)2 to the related Cu-
mediated fluorination affords only trace amounts of product (<10% 19F NMR yield, 
Scheme 3.5, reaction 4),17 demonstrating that this cyanation reaction also has an 
improved scope relative to fluorination.  
 
Scheme 3.5. Comparison of [11C]20 via Recent Methodologies 
 
 
3.5. Automation of [11C]PerampanelA 
As a final demonstration of this method, the automation of [11C]perampanel was 
pursued. Perampanel, an FDA-approved drug for epilepsy, has been [11C]radiolabeled 
once before using a Pd-catalyzed method with an aryl bromide precursor to afford [11C]26 
                                            
AAutomation was performed with the assistance of Dr. Allen Brooks and Dr. Xia Shao. 
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in 40% RCC (manual, radio-TLC) and 9.7% RCY (isolated, non-decay corrected), 
(Scheme 3.6).11  
 
Scheme 3.6. Pd-Catalyzed [11C]Cyanation of Perampanel11 
 
 
Our manual method provided 90% RCC of [11C]26 from the arylboronate ester 
using approximately 1 mCi of [11C]KCN per reaction. The synthesis was scaled to 450 
mCi of [11C]KCN, and the [11C]radiocyanation and subsequent HPLC purification of 
[11C]26 were conducted using an automated radiosynthesis module. Without further 
optimization, this procedure afforded [11C]26 in 10.4% non-decay corrected RCY 
(Scheme 3.7). The fully automated synthesis lasted approximately 32 min from the end 
of bombardment.  
 
Scheme 3.7. Automation of [11C]Perampanel 
 
General conditions: 26-Bpin (10 μmol, 1 equiv), Cu(OTf)2 (2 equiv), pyridine (15 equiv), 
and [11C]KCN (in H2O) in DMA at 100 °C for 5 min. RCY determined by isolated material 
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after preparative-HPLC. QC was performed to confirm the correct product was formed 
and purify was >95%. 
 
3.6. Automation of [11C]LY2795050B 
Opioid receptors are involved in a variety of neuropsychiatric diseases, and remain 
popular targets for imaging and drug development.21 These receptors were first imaged in 
humans using PET in the 1980s. Since these early studies, significant work has been 
undertaken to develop radiotracers for quantifying the major opioid receptor subtypes 
(mu, delta, kappa, ORL-1).22 Given that popular opioid pain killers, such as morphine, 
codeine and fentanyl, all act preferentially at MORs,23,24 significant work has been 
undertaken to understand the pharmacology of this receptor. [11C]CFN has been used for 
decades to image the mu opioid system.25 
While mu opioid agonists are some of the most effective pain killers used in modern 
medicine,26 they have been heavily abused, leading to a serious crisis in the US.27 This 
crisis has led a strong motivation to develop opioid painkillers that have fewer side effects, 
such as dependence. One approach for improvement is to develop drugs (and PET 
radiotracers) that target the other opioid subtypes.28 The KOR structure has been recently 
revealed,29 and this is expected to spur development of new drugs for this target.30 
Reflecting this, there is a desire to access to a KOR-selective PET radiotracer 
manufactured according to cGMP and suitable for clinical use. 
The method described in this chapter was modified for a clinical preparation of 
[11C]LY2795050, a promising KOR antagonist.2,31 During the course of the study, it was 
found that [11C]HCN could be used instead of [11C]KCN. As with [11C]2, 28-Bpin provided 
higher RCCs than 28-SnMe3 (Scheme 3.8).  
 
 
 
 
 
                                            
B Automation was performed by Dr. Xia Shao and Lingyun Yang 
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Scheme 3.8. Radiosynthesis of [11C]LY2795050 
 
Using the copper-mediated [11C]cyanation developed in this chapter to produce a 
clinical scale of [11C]LY2795050, further animal studies were performed including rodent 
and non-human primate studies (Figure 3.2). Comparison with [11C]CFN imaging of MOR 
identified regional brain distribution differences consistent with the known distribution of 
opioid receptors in primates. Preparation is ongoing to prepare for a clinical trial.  
 
Figure 3.2. Primate PET images of [11C[LY2795050 (A) and [11C]CFN (B)2 
 
 
3.7. Conclusion 
In conclusion, this chapter describes a Cu-mediated [11C]radiocyanation of diverse 
aryl organometallic reagents. This method is compatible with a wide range of substrates, 
including those containing carboxylic acids, phenols, aldehydes, and heterocycles. This 
method is also amenable to automation on a clinically relevant scale, as demonstrated in 
the synthesis of [11C]perampanel and further applied to [11C]LY2795050. The automation 
of [11C]LY2795050, represents the first validation of the Cu-mediated cyanation of pinacol 
borane esters for the cGMP synthesis of a PET radiotracer for preclinical and clinical 
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applications. The synthesis of [11C]LY2795050, a PET radiotracer for the KOR, was fully 
automated using a commercial radiochemistry synthesis module. Doses met all QC 
criteria for preclinical and clinical use and were used to image rodents and nonhuman 
primates.  
 
3.8. Outlook 
Concomitant with this report, Vasdev and coworkers reported a similar system for 
[11C]aryl cyanation.20 The combination of arylboronic acids, CuI, and base in a DMF/H2O 
mixture yielded moderate RCCs (Scheme 3.9). Additionally, the automation of anisole 
was reported with a low RCY of 4% (non-decay corrected).  
 
Scheme 3.9. Cu-Mediated [11C]Cyanation Method Developed by Vasdev and 
Coworkers20 
 
 
Since this report on the Cu(OTf)2-mediated cyanation of aryl organometallic 
reagents,1 a palladium method utilizing arylboron derivatives was also published.32 The 
reaction was first studied with copper, but homocoupling was a major side product under 
the conditions examined. The optimal conditions used a bench-stable Pd(II) catalyst 
(Scheme 3.10). This method was used to automate and isolate PET tracers in good RCY. 
One limitation of this method is that it uses a relativity large amount of the starting 
precursor (20 µmol, as opposed to the <10 µmol that is commonly used). 
 
Scheme 3.10. Pd-Catalyzed [11C]Cyanation Method Developed by Zhang and 
Coworkers 
 
77 
 
3.9. Experimental Details 
3.9.1. Instrumental Information 
NMR spectra were obtained on a Varian vnmrs700 (699.76 MHz for 1H; 175.95 MHz for 
13C), a Varian vnmr500 (500.09 MHz for 1H; 470.56 MHz for 19F; 125.75 MHz for 13C), or 
a Varian MR400 (400.53 MHz for 1H; 376.87 MHz for 19F) spectrometer. All 13C NMR 
data presented are proton-decoupled 13C NMR spectra, unless noted otherwise. 1H and 
13C NMR chemical shifts (δ) are reported in parts per million (ppm) relative to TMS with 
the residual solvent peak used as an internal reference. 19F NMR spectra are referenced 
based on the internal standard 1,2-difluorobenzene, which appears at –140.53 ppm. 1H 
and 19F NMR multiplicities are reported as follows: singlet (s), doublet (d), triplet (t), 
quartet (q), and multiplet (m). Melting point data (mp) were collected on an OptiMelt 
Automated Melting Point System and are uncorrected. HPLC was performed using a 
Shimadzu LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector. 
Radio-TLC analyses were performed using a Bioscan AR 2000 Radio-TLC scanner with 
EMD Millipore TLC silica gel 60 plates (3.0 cm wide x 6.5 cm long). 
 
3.9.2. Materials and Methods 
Unless otherwise stated, reagents and solvents were commercially available and used 
without further purification. Arylstannane and arylboronic acid precursors were purchased 
from Frontier Scientific, Oakwood Products, Acros Organics, Synthonix, and Sigma 
Aldrich or synthesized in the following sections. Arylnitrile reference standards were 
sourced commercially. 3-Bromo-1-phenyl-5-(pyridine-2-yl)-1,2-dihydropyridin-2-one 
(CAS 381248-06-2) was purchased from Key Organics and used as received. 
Perampanel (CAS 380917-97-5) was purchased from AChemBlock. HPLC-grade 
acetonitrile, anhydrous DMF, anhydrous DMA, potassium trifluoromethanesulfonate, and 
potassium carbonate were purchased from Fisher Scientific. Sterile product vials were 
purchased from Hollister-Stier. QMA-light Sep-Paks were purchased from Waters 
Corporation. QMA-light Sep-Paks were flushed with 10 mL of ethanol, followed by 10 mL 
of 90 mg/mL potassium trifluoromethanesulfonate solution, and finally 10 mL of sterile 
water prior to use. Sodium chloride, 0.9% USP and sterile water for Injection, USP were 
purchased from Hospira; Dehydrated Alcohol for Injection, USP was obtained from Akorn 
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Inc.; Ammonium acetate and acetic acid (glacial) were obtained from Fisher Scientific; 
HPLC columns were acquired from Phenomenex. Other synthesis components were 
obtained as follows: sterile filters were acquired from Millipore; C18 Vac 1cc Sep-Paks 
were purchased from Waters Corporation; Sep-Paks were flushed with 5 mL of ethanol 
followed by 10 mL of sterile water prior to use. 
 
3.9.3. General Procedures for Synthesis and Characterization of Substrates 
General Procedure A: Preparation of Trialkylarylstannane Substrates 
General procedure A was adapted from the literature.19,33,34 In a nitrogen atmosphere 
glovebox, a 20 mL vial was charged with aryl iodide or aryl bromide (1 mmol), Pd(PPh3)4 
(0.1–0.25 mmol), and lithium chloride (4.8 mmol). The combined solids were dissolved in 
toluene (12.5 mL, 0.08 M) at room temperature. Hexabutylditin (2.6 mL, 5.2 mmol) or 
hexamethylditin (1.1 mL, 5.2 mmol) was added via syringe, and the vial was sealed and 
removed from the glovebox. The sealed vial was heated at 100 ºC. Once the reaction 
mixture turned black (generally 2–4 h), it was cooled to room temperature. Aqueous 
potassium fluoride (5.0 mL, 2 M solution) was added, and the mixture was stirred 
vigorously. After 30 min, the mixture was filtered through a plug of Celite (eluting with 
hexanes or toluene). The filtrate was washed with brine (25 mL), dried over magnesium 
sulfate, filtered, and concentrated under vacuum. The crude product was purified via flash 
column chromatography. 
 
General Procedure B: Preparation of Arylboronic Acid Substrates 
General procedure B was adapted from the literature.35 n-BuLi (1.2 equiv, 2.48 M in 
hexane) was added dropwise to a solution of the aryl bromide (1 equiv) in anhydrous THF 
(0.1 M) at –78 ºC under a nitrogen atmosphere in an oven-dried 20 mL vial. The reaction 
was then stirred at –78 ºC for ~1 h. An excess of B(OMe)3 (10 equiv) was added slowly 
under a nitrogen atmosphere via syringe. The resulting solution was allowed to warm 
slowly to room temperature and stirred overnight. The reaction was quenched with 
distilled water and acidified with HCl (1 M solution, pH <3), and the product was extracted 
into EtOAc. The combined organic extracts were washed with brine, dried over MgSO4, 
and concentrated under vacuum. 
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3.9.4. General Procedure for Copper-Mediated Fluorination 
Stock solutions of the aryl organometallic substrate (0.1 mL, 0.1 M solution, 10 µmol, 1 
equiv), Cu(OTf)2 (20 µmol, 2 equiv), pyridine (0.15 mL, 1.0 M solution,150 µmol, 15 
equiv), and KCN (1.5 mg, 20 µmol, 2 equiv) were added to a 4 mL vial and diluted with 
DMA (to 1.0 mL total volume). The vial was sealed with a Teflon-lined cap and the reaction 
mixture was stirred at 100 ºC for 30 min. The resulting solution was cooled to room 
temperature, 1,2-difluorobenzene was added as an internal standard, and the crude 
reaction was analyzed by 19F NMR spectroscopy. 
 
Experimental Details for the Radiosynthesis of [11C]LY2795050.  
No carrier added [11C]HCN was bubbled into a mixture of pyridine (15 equiv) in DMA (0.25 
mL) and H2O (0.05 mL) directly. Cu(OTf)2 (4 equiv) was added followed by 28-Bpin or 
28-SnMe3 (1 equiv) and the reaction was heated at 100 °C for 5 min to generate cyano 
intermediate. The reaction mixture was cooled down to 5 °C and hydrolysis with 30% 
H2O2 (0.2 mL) and 5.0 M NaOH (0.2 mL) at 80 °C for 5 min to generate [11C]LY2795050 
[11C]28). The reaction mixture was quenched with HPLC buffer and analyzed by radio-
HPLC (Phenomenex Luna C18(2), 150 x 4.6 mm, 20:80 MeCN:H2O, 10 mM NH4OAc, 
0.2% acetic acid, pH = 4.5, flow rate = 2.0 mL/min, UV = 254 nm) to determine RCC. 
 
3.9.5. Synthesis of [11C]HCN 
A GE Medical Systems PETtrace cyclotron (40 µA for 30 min) was used to produce 
[11C]CO2 by the 14N(p,α)11C reaction. [11C]HCN was synthesized from [11C]carbon dioxide 
by “gas phase” method utilizing a GE PETtrace Carbon-11 Process Panel as previously 
reported.6 Briefly, [11C]CO2 (3,000 mCi) from the target was trapped on molecular sieves 
at room temperature. The [11C]CO2 was released and mixed with hydrogen gas at 350 ºC 
then passed through a preheated nickel oven at 420 ºC for conversion to [11C]CH4. The 
[11C]CH4 gas was purified by passing it through Ascarite and Sicapent columns to remove 
water and unreacted [11C]CO2. The [11C]CH4 was mixed with anhydrous ammonia and 
passed through a high temperature (950 ºC) platinum oven, resulting in the formation of 
[11C]HCN (non-decay corrected radiochemical yields of ~800 mCi starting from 3000 mCi 
of [11C]CO2).  
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3.9.6. Synthesis of [11C]KCN6 
Modifications were made to a commercial GE TRACERLab FXM. Two electronic valves 
were installed in the front of the chemistry module to direct [11C]HCN from the GE process 
panel to the FXM. V30 and V31 were removed from the HPLC pump and connected to a 
system to capture the [11C]HCN from the process panel. The system consists of a helically 
shaped platinum wire in a Teflon tube inserted between V30 and V31. To capture and 
purify [11C]HCN (removal of excess NH3), the helical platinum wire was treated with 0.2 
mL of a 1 M solution of KOH followed by 2 mL of dry air. The [11C]HCN was trapped on 
the platinum wire, and then the flow was switched from the process panel to N2, which 
removed the ammonia. This purification was carried out because it was hypothesized that 
residual NH3 could have a negative effect on the reaction conditions. The [11C]CN was 
then eluted as [11C]KCN by directing the three way valve from waste to the reactor and 
eluting with H2O. 
 
3.9.7. Synthesis of 11CN-Labeled Molecules (Manual Synthesis) 
Unless otherwise noted, this procedure was used for all [11C]cyanation reactions. Stock 
solutions of precursor (0.1 M), Cu(OTf)2 (0.2 M) and pyridine (1.0 M) in DMA were 
prepared immediately prior to the start of the reaction. Aliquots of these solutions were 
used to carry out subsequent [11C]cyanation reactions. Reactions were typically set up in 
the following order: Cu(OTf)2 (0.1 mL, 20 µmol, 2 equiv) and pyridine (0.15 mL, 0.15 
mmol, 15 equiv) were mixed in a 4 mL vial at room temperature. The resulting solution 
was diluted with DMA (0.55 mL, 1.0 mL total volume) and then charged with substrate 
(0.1 mL, 0.01 mmol, 1 equiv). The reaction vial was sealed under an atmosphere of 
ambient air with a PTFE/Silicone septum cap, and a 0.1 mL aliquot of [11C]KCN (150–
3000 μCi, depending on the time required for HPLC analysis) was added to the reaction 
vial through the septum via a syringe. The vial was heated in an aluminum block without 
stirring at 100 ºC for 5 min and then immediately cooled to room temperature. Radio-TLC 
analysis was conducted to determine the radiochemical conversion (% RCC). The crude 
reaction mixture was spotted onto a standard silica-coated glass plate and the TLC was 
conducted using 1:1 hexane/EtOAc or 100% EtOAc as the eluant. The RCC was then 
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determined by dividing the integrated area under the cyanated product spot by the total 
integrated area of the carbon-11 on the TLC plate. To prepare samples for HPLC analysis: 
0.1 mL of the reaction mixture (or for the co-injection analysis 0.1 mL of the reaction 
mixture spiked with 0.1 mL of 1 mg/mL cyanation authentic standard solution) were 
transferred to an HPLC autosampler vial. Eluent systems and columns used for HPLC 
analysis are described below. 
 
RCC = integration of 11C product peak / sum of integration of all 11C peaks 
 
3.9.8. General Procedure/Methods for Automated Syntheses 
All loading operations were conducted under an ambient atmosphere. Nitrogen was used 
as a pressurizing gas during automated sample transfers. [11C]Cyanide was produced via 
the 14N(p,α)11C nuclear reaction using a GE PETTrace cyclotron and process panel. 
[11C]KCN was produced as indicated above. A solution containing precursor (0.1 mL, 0.1 
M stock, 10 µmol, 1 equiv) in 0.4 mL of anhydrous DMA was prepared in vial 2. Cu(OTf)2 
(0.1 mL, 0.2 M stock, 20 µmol, 2 equiv) and pyridine (0.15 mL, 1.0 M stock, 150 µmol, 15 
equiv) in 0.25 mL of DMA was mixed in the reaction vessel. H2O (0.2 mL in vial 1) was 
used to wash the [11C]KCN into the reaction vessel containing the catalyst solution. After 
vial 2 was added, the mixture was heated at 100 ºC for 4 min (it took approximately 1 min 
to heat to 100 ºC). After 4 min, the reaction was cooled to 40 ºC and vial 4 containing 0.5 
mL of buffer was added. The mixture was then transferred to an HPLC loop for injection 
and purification by semi-preparative chromatography (Phenomenex Luna C18, 250 x 10 
mm, 10µ, 4 mL/min). The product peak (retention time ~12 min) was collected and 
transferred out of the hot cell. Time from EOB ~30–32 min.  
 
Specific Activity Calculation. An aliquot of the purified sample was injected onto an 
analytical HPLC. The UV peak corresponding to the [11C]radionitrile product was 
determined by overlaying the UV and RAD traces (with a 0.2 min offset as described in 
the HPLC section). The UV area was then used to calculate the concentration of the 
product based on linear regression analysis of appropriate arylnitrile standards. A 
standard curve was generated from the standard solutions, each performed in duplicate 
82 
 
(0.0001 mg/mL to 1.0 mg/mL). This provided the concentration of the product in mmol/mL. 
Dividing the activity concentration (Ci/mL) by the HPLC-derived concentration of product 
(mmol/mL) provided the specific activity in Ci/mmol. This reflects an EoS specific activity. 
 
Automated Synthesis of [11C]4-methoxybenzonitrile ([11C]1)  
Starting material: 1-SnBu3 
Activity Isolated, non-decay corrected: 16 mCi/220 mCi 
RCY, non-decay corrected: 7% 
RCY, decay corrected: 22% 
Specific Activity: 1800 Ci/mmol 
 
Automated Synthesis of [11C]4-methoxybenzonitrile ([11C]1)  
Starting material: 1-B(OH)2 
Activity Isolated, non-decay corrected: 71 mCi/400 mCi  
RCY, non-decay corrected: 18% 
RCY, decay corrected: 53% 
Specific Activity: 4400 Ci/mmol 
 
Automated Synthesis of [11C]Perampanel ([11C]26)  
Starting material: 26-Bpin 
Activity Isolated, non-decay corrected: 46 mCi/450 mCi  
RCY, non-decay corrected: 10% 
RCY, decay corrected: 29% 
Specific Activity: 1900 Ci/mmol 
 
3.9.9. Automated Radiosynthesis of [11C]LY2795050  
Pyridine (0.15 mL, 1.0 M DMA stock, 150 μmol, 15 equiv) in 0.1 mL of DMA was mixed 
in the reactor. No carrier added [11C]HCN was bubbled into the reactor directly. Then 
Cu(OTf)2 (0.2 mL, 0.2 M DMA stock, 40 μmol, 4 equiv) through V31 and 28-Bpin (4.9 mg 
in 0.4 mL DMA, 10 μmol,1 equiv) from vial 1 were added. The reaction was allowed to 
heat to 100 °C for 5 min. After the temperature was cooled to 5 °C by liquid nitrogen, 30% 
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H2O2 (0.2 mL) in vial 2 and NaOH (5M, aq, 0.2 mL) in vial 3 were added to the reactor. 
The hydrolysis was performed at 80 °C for 5 min, followed by cooling to 25 °C and 
quenching with acetic acid (0.4 mL, glacial) in vial 4. The reaction mixture was stirred for 
2 min and then injected onto a semi-preparative HPLC column for purification 
(Phenomenex Prodigy C8, 10 μm, 150 x 10 mm, 25:75 MeCN:H2O, 100 mM NH4OAc, 
1.0% acetic acid, pH = 4.8, flow rate = 5.0 mL/min, UV = 254 nm). The product peak at 
~5–7 minutes was collected into 55 mL of water and passed through a C-18 sep-pak to 
remove HPLC solvent. The sep-pak was rinsed with 4 mL of USP water and the product 
was then eluted with 0.5 mL of ethanol followed by 9.5 mL of USP saline for injection. The 
final dose was filtered into a dose vial via a 0.22 μm sterile filter, then submitted for quality 
control testing as outlined below. Total synthesis time was approximately 45 min from 
end of beam. The non-decay radiochemical yield was 48 mCi (6%) based on [11C]HCN 
with radiochemical purity of >99% and specific activity of 914 mCi/μmol. 
 
3.10. Synthesis and Characterization 
3.10.1. Starting Materials 
 
4-Tributylstannyl-1,1’-biphenyl (5-SnBu3). General procedure A was followed using 4-
iodo-1,1’-biphenyl (279.5 mg, 1.0 mmol) and heating for 3 h. Purification by flash column 
chromatography eluting with hexanes afforded 5-SnBu3 as a colorless oil (191.0 mg, 43% 
yield, Rf = 0.6 in 100% hexanes). The 1H and 13C NMR spectra matched those reported 
in the literature.36 HRMS (EI) [M – C4H9]+ Calculated for C20H27Sn: 387.1135; Found 
387.1135.  
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4-Tributylstannylacetophenone (14-SnBu3). General procedure A was followed using 4-
iodoacetophenone (246.3 mg, 1.0 mmol) and heating for 4 h. Purification by flash column 
chromatography eluting with hexanes afforded 14-SnBu3 as a colorless oil (284.3 mg, 
69% yield, Rf = 0.56 in 5% ethyl acetate in hexanes). The 1H and 13C NMR spectra 
matched those reported in the literature.36 HRMS (ESI+) [M+K]+ Calculated for 
C20H34KOSn: 449.1263; Found 449.1263.  
 
 
[1,1’-Biphenyl]-2-ylboronic Acid (8-B(OH)2). 2-Bromobiphenyl (0.25 mL, 1.45 mmol) was 
dissolved in 15 mL of anhydrous THF (0.1 M), and n-BuLi (0.7 mL, 1.75 mmol, 1.2 equiv, 
2.48 M in hexane) and then B(OMe)3 (1.6 mL, 14.4 mmol, 10 equiv) were added 
sequentially according to general procedure B. Triturating the resulting mixture with 
pentanes and a small amount of EtOAc yielded the desired boronic acid (8-B(OH)2) as 
an off-white solid (220.3 mg, 77% yield, mp = 184–185 ºC). The 1H and 13C NMR spectra 
matched those reported in the literature.35 HRMS (EI) [M]+ Calculated for C12H11BO2: 
198.0852; Found 198.0858. 
 
 
4-Tributylstannylbenzophenone (13-SnBu3). In a nitrogen atmosphere glovebox, a 20 mL 
vial was charged with 4-iodobenzopheone (308.6 mg, 1.0 mmol), Pd(PPh3)2Cl2 (175.3 
mg, 0.25 mmol, 0.25 equiv) and dioxane (12.5 mL, 0.08 M) at room temperature. 
Hexabutylditin (1.3 mL, 2.6 mmol) was added via syringe and the vial was sealed and 
removed from the glovebox. The sealed vial was heated at 100 ºC for 4 h. After cooling 
to room temperature, the reaction mixture was filtered through a silica plug that was 
washed with EtOAc. The solvent was removed under vacuum, and the crude product was 
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purified via preparative TLC (5% ethyl acetate in hexanes) affording the product (13-
SnBu3) as a yellow oil (231.5 mg, 59% yield, Rf = 0.5 in 5% ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 7.82 (m, 2H), 7.73 (m, 2H), 7.57–7.63 (multiple peaks, 3H), 7.48 (m, 
2H), 1.56 (m, 6H), 1.35 (m, 6H), 1.11 (m, 6H), 0.90 (m, 9H) 
 
13C NMR (CDCl3): δ 197.05, 149.22, 137.70, 136.92, 136.26, 132.24, 130.04, 128.94, 
128.18, 29.04, 27.34, 13.66, 9.66 
 
HRMS (ESI+) [M+K]+ Calculated for C25H36KOSn: 511.1420; Found 511.1418 
 
 
6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoxaline (21-Bpin). The following 
procedure was adapted from the literature.37 In a nitrogen atmosphere glovebox, a 20 mL 
vial was charged with 6-bromoquinoxaline (419 mg, 2.0 mmol, 1 equiv), Pd(dppf)Cl2 
dichloromethane complex (186.0 mg, 0.23 mmol, 0.11 equiv), KOAc, (394.2 mg, 4.0 
mmol, 2.0 equiv), bis(pinacoloato)diboron (612.5 mg, 2.4 mmol, 1.2 equiv) and dioxane 
(10 mL, 0.2 M). The resulting solution was heated at 90 ºC for 1.5 h. The reaction mixture 
was allowed to cool to room temperature and then concentrated in vacuo. The resulting 
residue was dissolved in CH2Cl2 and filtered through a plug of celite. After removing the 
CH2Cl2 under vacuum, the product was purified by column chromatography (20% ethyl 
acetate in hexane), affording 21-Bpin as a yellow oil (103.2 mg, 15% yield, Rf = 0.3 in 
20% ethyl acetate in hexanes). The 1H and 13C NMR spectra matched those reported in 
the literature.37 HRMS (ESI+) [M+H]+ Calculated for C14H18BN2O2: 257.1456; Found 
257.1463.  
 
86 
 
 
Perampanel-Bpin (26-Bpin) was prepared via the following 2 step procedure that was 
adapted from the literature.11,38 
 
 
Step 1: Aryl bromide S1 was prepared via a literature procedure. In a nitrogen-filled 
glovebox, the pyridine bromide (319.2 mg, 0.98 mmol, 1 equiv), 2-bromophenylboronic 
acid (1651.6 mg, 8.2 mmol, 8.4 equiv), tetrakis(triphenylphosphine)palladium(0) (180.5 
mg, 0.16 mmol, 0.16 equiv), copper(I) iodide (48.9 mg, 0.26 mmol, 0.26 equiv), and 
potassium carbonate (1653.6 mg, 12.0 mmol, 12.3 equiv) were dissolved in dioxane (6 
mL, 0.16 M) at room temperature. This solution was heated at 100 ºC for 15 h with 
vigorous stirring. The reaction was cooled to room temperature and quenched with water 
(5 mL). The aqueous phase was extracted with EtOAc (2 x 25 mL) and the combined 
organic extracts were dried over MgSO4, and concentrated. The crude residue was 
purified by column chromatography (silica gel, 35% ethyl acetate in hexanes) to afford S1 
as a yellow oil (210.0 mg, 53% yield, Rf = 0.4 in 50% ethyl acetate in hexanes). The 1H 
and 13C NMR spectra matched those reported in the literature.11 HRMS (ESI+) [M+H]+ 
Calculated for C22H16BrN2O: 403.0441; Found 403.0444.  
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Step 2: In a nitrogen-atmosphere glovebox, a suspension of aryl bromide (S1, 60.8 mg, 
0.15 mmol), Pd(dppf)Cl2 dichloromethane complex (20.3 mg, 0.02 mmol, 0.16 equiv), 
KOAc, (372.9 mg, 1.5 mmol, 9.7 equiv), and bis(pinacoloato)diboron (214.8 mg, 2.2 
mmol, 14.5 equiv) in dioxane (3.8 mL, 40 mM) was heated at 80 ºC for 16 h. The reaction 
mixture was allowed to cool to room temperature, quenched with water, and washed with 
EtOAc (3 x 25 mL). The combined organic extracts were washed with brine, dried over 
MgSO4, and concentrated under vacuum. The crude residue was purified by column 
chromatography (20% ethyl acetate in hexane with 1–5% NEt3) to afford 26-Bpin as a 
white solid (31.7 mg, 47% yield, Rf = 0.2 in 70% ethyl acetate in hexanes with 15% NEt3, 
melting point: decomposes above 138 ºC).  
 
1H NMR (CDCl3): δ 8.84 (d, J = 1.3 Hz, 1H), 8.66 (dt, J = 0.8, 2.5, 1H), 8.35 (d, J = 1.3 
Hz, 1H), 7.80–7.83 (multiple peaks, 3H), 7.72 (d, J = 4.6 Hz, 1H), 7.52–7.57 (multiple 
peaks, 5H), 7.37 (dtd, J = 18.0, 7.4, 0.8 Hz, 2H), 7.30 (dd, J = 2.5, 9.8 Hz, 1H), 1.11 (s, 
12H) 
 
13C NMR (CDCl3): δ 161.1, 152.3, 150.0, 140.4, 137.3, 134.6, 133.7, 133.5, 133.2, 129.6, 
129.4, 129.0, 127.9, 127.5, 126.8, 123.4, 123.0, 122.9, 122.8, 119.3, 80.49, 25.89 
 
HRMS (ESI+) [M+H]+ Calculated for C28H28BN2O3: 451.2187; Found 451.2175 
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PEB-Bpin,F (27-Bpin) was prepared by the following 2 step procedure adapted from the 
literature.39–41 
 
 
Step 1: In a nitrogen filled glovebox, 2-((trimethylsilyl)ethynyl)pyridine (177.0 mg, 1.01 
mmol, 1 equiv), 1-bromo-3-fluoro-5-iodobenzene (316.9 mg, 1.05 mmol, 1 equiv), 
Pd(PPh3)Cl2 (87.1 mg, 0.12 mmol, 0.1 equiv), CuI (43.0 mg, 0.23 mmol, 0.2 equiv), and 
NEt3 (0.3 mL, 2.2 mmol, 2.1 equiv) were dissolved in dioxane at room temperature. The 
reaction mixture was heated to 80 ºC under nitrogen for 15 min. TBAF (1 M solution in 
THF, 1.1 mL, 1.2 mmol, 1.1 equiv) was added dropwise over 10 min via syringe through 
a septum. The resulting solution was allowed to stir for an additional 30 min at 80 ºC 
under nitrogen before being cooled to room temperature. The reaction was filtered 
through a celite plug, concentrated under vacuum, and dissolved in DCM. The organic 
later was washed with H2O (2 x 25 mL) and brine, dried over MgSO4, and concentrated 
under vacuum. The crude residue was purified by column chromatography (5% ethyl 
acetate in hexanes) to afford S2 as a yellow oil (182.2 mg, 65% yield, Rf = 0.43 in 20% 
ethyl acetate in hexanes).  
 
1H NMR (CDCl3): δ 8.63 (m, 1H), 7.70 (m, 1H), 7.52–7.54 (multiple peaks, 2H), 7.26–7.29 
(multiple peaks, 2H), 7.23 (m, 1H) 
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13C NMR (CDCl3): δ 162.11, 150.24, 142.57, 136.28, 130.84, 127.38, 125.41, 123.35, 
122.44, 119.99, 117.76, 90.45, 86.07 
 
19F NMR (CDCl3): δ –110.46 
 
HRMS (ESI+) [M+H]+ Calculated for C13H8BrFN: 275.9819; Found 275.9821 
 
 
Step 2: In a nitrogen atmosphere glovebox, aryl bromide (S2, 430.8 mg, 1.6 mmol), 
Pd(dppf)Cl2 dichloromethane complex (179.4 mg, 0.02 mmol, 0.14 equiv), KOAc (459.7 
mg, 4.7 mmol, 3.0 equiv), and bis(pinacoloato)diboron (436.3 mg, 1.7 mmol, 1.1 equiv) 
were suspended in DMSO (8.8 mL, 0.18 M). The reaction mixture was heated at 80 ºC 
for 15 h. The reaction was allowed to cool to room temperature and quenched with water, 
and the product was extracted into EtOAc (3 x 50 mL). The combined organic extracts 
were washed with brine, dried over MgSO4, and concentrated under vacuum. Triturating 
the resulting mixture with pentanes and a few drops of EtOAc yielded 27-Bpin as a yellow 
solid (386.1 mg, 76% yield, Rf = 0.32 in 20% ethyl acetate in hexanes, mp = 77–78 °C).  
 
1H NMR (CDCl3): δ 8.62 (dq, J = 4.9, 1.0 Hz, 1H), 7.84 (s, 1H), 7.68 (td, J = 7.7, 2.0 Hz, 
1H), 7.50 (dt, J = 7.7, 1.0 Hz, 1H), 7.47 (dd, J = 8.9, 2.0 Hz, 1H), 7.35 (dq, J = 8.9, 1.3 
Hz, 1H), 7.24 (dd, J = 4.9 1.3 Hz, 1H), 1.34 (s, 12H) 
 
13C NMR (CDCl3): δ 161.98, 150.11, 143.10, 136.16, 134.38, 127.18, 123.71, 122.93, 
121.66, 121.00, 89.27, 87.74, 84.32, 29.68, 24.83 
 
19F NMR (CDCl3): δ –113.84 
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HRMS (ESI+) [M+H]+ Calculated for C19H20BFNO2: 324.1566; Found 324.1575 
 
 
 
Aryl-I (S3) was prepared2 and used to synthesize 28-Bpin. In a nitrogen atmosphere 
glovebox, aryl iodide (S3, 430.8 mg, 1.6 mmol), Pd(dppf)Cl2 dichloromethane complex 
(179.4 mg, 0.02 mmol, 0.14 equiv), KOAc (459.7 mg, 4.7 mmol, 3.0 equiv), and 
bis(pinacoloato)diboron (436.3 mg, 1.7 mmol, 1.1 equiv) were suspended in DMSO (8.8 
mL, 0.18 M). The reaction mixture was heated at 80 ºC for 15 h. The reaction was allowed 
to cool to room temperature and quenched with water, and the product was extracted into 
EtOAc (3 x 50 mL). The combined organic extracts were washed with brine, dried over 
MgSO4, and concentrated under vacuum. Triturating the resulting mixture with pentanes 
and a few drops of EtOAc yielded 28-Bpin as a yellow solid (386.1 mg, 76% yield, Rf = 
0.32 in 20% ethyl acetate in hexanes, mp = 77–78 °C).  
 
To a mixture of (S)-3-(1-(4-(2-chloro-4-iodophenoxy)benzyl)pyrrolidin-2-yl)pyridine 5 
(0.54 g, 1.1 mmol), bis(pinacolato)-diboron (0.36 g, 1.4 mmol), Pd(dppf)Cl (0.048 g, 0.066 
mmol) and potassium acetate (0.32 g, 3.3 mmol) in DMSO (6.0 mL) was reacted at 85 °C 
under argon atmosphere for 12 h. Then the mixture was diluted with saturated ammonium 
chloride solution and EtOAc, and the insoluble material was filtered through Celite. The 
organic layer of the filtrate was washed with water (30 mL) and brine (30 mL), dried over 
Na2SO4, and evaporated in vacuo. The residue was purified by column chromatography 
(MeOH:DCM, 1:100 to 1:30) to give 28-Bpin (0.35 g, 65%) as a brown oily product.  
 
1H NMR (CDCl3): δ: 8.62 (d, J = 1.6 Hz, 1H), 8.50 (dd, J = 4.8, 1.6 Hz, 1H), 7.88 (d, J = 
1.4 Hz, 1H), 7.80 (dt, J = 7.8, 1.8 Hz, 1H), 7.60 (dd, J = 8.1, 1.5 Hz, 1H), 7.31–7.27 (m, 
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1H), 7.22 (d, J = 8.4 Hz, 2H), 6.92–6.82 (m, 3H), 3.74 (d, J = 13.1 Hz, 1H), 3.41 (t, J = 
8.2 Hz, 1H), 3.16–3.08 (m, 2H), 2.29–2.19 (m, 2H), 1.97–1.87 (m, 1H), 1.86–1.78 (m, 
1H), 1.76–1.66 (m, 1H), 1.24 (s, 12H) 
 
13C NMR (CDCl3): δ 160.09, 159.37, 154.93, 152.26, 150.51, 141.40, 134.87 (2C), 128.47 
(2C), 125.68, 115.15, 112.92, 112.77, 107.77, 107.61, 105.86, 83.74 (2C), 62.07, 51.09, 
49.46, 27.19, 24.89 (4C), 18.66 
 
HRMS (ESI+) [M+H]+ Calculated for C28H33BClN2O3: 491.2267; Found 491.2276 
 
 
Aryl-I (S3) was prepared2 and used to synthesize 28-SnMe3. In a nitrogen atmosphere 
glovebox, aryl iodide (S3, 0.11 g, 0.21 mmol), (Me3Sn)2 (0.084 g, 0.26 mmol), Pd(PPh3)4 
(0.025 g, 0.021 mmol) and lithium chloride (0.014 g, 0.32 mmol) in toluene (15 mL) was 
reacted at 100 °C under nitrogen atmosphere for 4 h. Then the mixture was diluted with 
water and EtOAc, and the insoluble material was filtered through Celite. The organic layer 
of the filtrate was washed with water (30 mL) and brine (30 mL), dried over Na2SO4, and 
evaporated in vacuo. The residue was purified by column chromatography (MeOH:DCM, 
1:100 to 1:30) to give 28-SnMe3 (0.086 g, 76%) as a brown oily product.  
 
1H NMR (CDCl3): δ: : 8.62 (d, J = 1.7 Hz, 1H), 8.50 (dd, J = 4.8, 1.7 Hz, 1H), 7.79 (dt, J = 
7.8, 1.9 Hz, 1H), 7.66 (dd, J = 12.0, 1.4 Hz, 1H), 7.58–7.52 (m, 1H), 7.47 (dd, J = 7.6, 2.9 
Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 6.92–6.85 (m, 3H), 3.73 (d, J = 13.1 Hz, 1H), 3.41 (t, J 
= 8.1 Hz, 1H), 3.15–3.07 (m, 2H), 2.25 (d, J = 8.8 Hz, 2H), 1.96–1.87 (m, 1H), 1.86–1.79 
(m, 1H), 1.75–1.67 (m, 1H), 0.31 (s, 9H) 
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13C NMR (CDCl3): δ 155.72, 152.75, 149.63, 148.80, 139.39, 138.37, 137.48, 135.00, 
134.34, 132.12, 129.90 (2C), 128.51, 123.56, 120.21, 117.84 (2C), 66.93, 57.51, 53.54, 
35.28, 22.54, –9.36 (3C) 
 
HRMS (ESI+) [M+H]+ Calculated for C25H30ClN2OSn+: 529.1063; Found 529.1055 
 
 
3.10.2. Arylnitrile Standards 
 
Quinoxaline-6-carbonitrile (21) was prepared via an adapted literature procedure.42 In a 
nitrogen atmosphere glovebox, Pd(PPh3)4 (110.7 mg, 0.10 mmol, 0.1 equiv) was added 
to a vial and removed from the glovebox. The same vial was charged with 6-
bromoquinoxaline (210.6 mg, 1.0 mmol, 1 equiv) and K4[Fe(CN)6]●3H2O (174.5 mg, 0.41 
mmol, 0.4 equiv). The vial was placed under N2. A solution of t-BuOH/H2O (1:1, 3 mL, 
0.33 M) and DBU (0.05 mL, 0.33 mmol, 0.33 equiv) was added via syringe, and the 
resulting mixture was stirred at room temperature for 10 min and then at 85 ºC for 15 h. 
The reaction mixture was allowed to cool to room temperature and filtered through a celite 
plug that was washed with methanol and DCM. The organic solution was washed with 
H2O and brine, was dried over MgSO4, and was then concentrated under vacuum. The 
crude residue was purified by flash chromatography on silica gel (25% ethyl acetate in 
hexanes), which afforded 21 as a white solid (55.0 mg, 21% yield Rf = 0.4 in 50% ethyl 
acetate in hexanes, mp = 173–174 ºC). The 1H and 13C NMR spectra matched those 
reported in the literature.43 HRMS (ESI+) [M+H]+ Calculated for C9H6N3: 156.0562; Found 
156.0553. 
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F-PEB (27) was prepared via a literature procedure.19,39 The product was purified by flash 
chromatography on silica gel (15% ethyl acetate in hexanes), to afford 27 as a brown 
solid (142.9 mg, 63% yield Rf = 0.15 in 20% ethyl acetate in hexanes, mp = 75–77 °C). 
The 1H and 13C NMR spectra matched those reported in the literature.39,44 19F NMR 
(CDCl3): δ –108.9. HRMS (ESI+) [M+H]+ Calculated for C14H8FN2: 223.0666; Found 
223.0664 
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Chapter 4 
 
Cu-Catalyzed [18F]Fluorination via Directed C(sp2)–H 
Functionalization1  
 
 
4.1. Background 
Current methods for arene radiofluorination require pre-functionalized starting 
materials, which can limit the accessibly of complex radiotracer targets. A complementary 
approach would involve the direct radiofluorination of C(sp2)–H bonds. Several strategies 
have been developed for the radiofluorination of aliphatic2,3 and benzylic4–6 C–H bonds; 
however, analogous transformations of C(sp2)–H substrates have proven considerably 
more challenging. The development of nucleophilic C(sp2)–H radiofluorination methods 
has proven elusive due to the inertness of C(sp2)–H bonds and the electronic mismatch 
between nucleophilic 18F– and most arene substrates. There are two known examples 
that have overcome these challenges. The first involves electrochemical 
[18F]radiofluorination (Scheme 4.1).7 This method works best for benzene, as there are 
selectivity issues when substituted arenes are used.8,9 Additionally, common functional 
groups, such as bromoarenes, undergo decomposition during the course of the reaction.8  
 
Scheme 4.1. Electrochemical [18F]Radiofluorination7 
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An alternative method uses electrophilic aromatic substitution (SEAr) to generate 
an aryliodonium salt in situ (Scheme 4.2).10 From there, previously developed chemistry 
was utilized to produce the desired product.11 This method worked well for a variety of 
substrates, but the relatively harsh conditions limited the functional group tolerance.  
 
Scheme 4.2. Cu-Mediated C−H [18F]Fluorination of Electron-Rich Arenes10 
 
 
Removable directing groups have been successfully utilized for directed C(sp2)–H 
fluorination, but there are currently no examples of the translation to 
[18F]radiofluorination.12,13 When considering nucleophilic fluorine sources, AgF is 
commonly used, but it is challenging for [18F]radiofluorination applications due to the 
limited solubility. To overcome this limitation, a method was developed to generate 
[18F]AgF in a soluble way that is necessary for PET chemistry.14 
 
4.2. Initial Results and Optimization with 18FA 
In 2013, the Daugulis group successfully employed 8-aminoquinoline as a directing 
group with catalytic copper, excess oxidant (NMO), and AgF for the fluorination of 
C(sp2)−H bonds (Scheme 4.3).15 To achieve difluorination, a larger excess of all reagents 
can be used. This method was limited to AgF as the fluorinating reagent.15 
 
 
 
 
 
                                            
A The work in this section was done in collaboration with Dr. So Jeong Lee. Most of the radiofluorination 
optimization was performed by her except for the glovebox reactions in Table 4.1 
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Scheme 4.3. Daugulis’ Conditions for Directed C–H Fluorination15 
 
 
 Initially, conditions analogous to Daugulis’ reported conditions were analyzed with 
[18F]AgF.14 However, these did not afford detectable quantities of 118F as determined by 
radio-TLC and radio-HPLC analysis (Table 4.1, entry 1). Notably, the Ag19F likely serves 
two roles in the original Daugulis reaction. First, it acts as the nucleophile to install the 
C(sp2)–F bond. Second, it serves as a base to sequester the proton that is generated 
during C–H activation. Since Ag19F is present in 3- to 4-fold excess relative to 1H, there 
is sufficient fluoride available for both of these functions. In contrast, under the 
radiofluorination conditions, the [18F]AgF is the limiting reagent. It was hypothesized that 
an exogeneous base might be needed to sequester protons while preserving a reservoir 
of nucleophilic fluoride for the desired C(sp2)–F coupling reaction. Consistent with this 
hypothesis, the addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (1 equiv relative to 
1H) led to the formation of the desired product 118F in 26 ± 1% RCC as determined by 
radio-TLC and confirmed by radio-HPLC (Table 4.1, entry 2). Further optimization 
revealed that switching from CuI to more soluble (MeCN)4CuOTf resulted in a slightly 
improved RCC (29 ± 0%; Table 4.1, entry 3). Under these conditions, the [18F]fluoride 
source could be changed to readily accessible [18F]KF16 to afford 33 ± 0% RCC of 118F 
(Table 4.1, entry 4). In the Ag19F reaction (which is conducted under inert atmosphere), 
NMO acts as the terminal oxidant for Cu. However, the radiochemical reactions are 
conducted under ambient air, which could directly oxidize the Cu. Indeed, excluding NMO 
from the [18F]KF reaction under otherwise identical conditions resulted in a comparable 
RCC (52 ± 17%, entry 5), although it did negatively impact the run-to-run reproducibility. 
When Table 4.1, entry 5 was set up in a glovebox and kept under an inert atmosphere 
the RCC dropped prohibitively (Table 4.1, entry 6), consistent with the role of air as the 
oxidant.  
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Table 4.1. Initial Results with Daugulis-like Conditions 
 
entry [Cu] [18F]MF condition notes 118F (% RCC) 
1 CuI [18F]AgF no DBU Nd 
2 CuI [18F]AgF -- 26 ± 1 
3 (MeCN)4CuOTf [18F]AgF -- 29 ± 0 
4 (MeCN)4CuOTf [18F]KF -- 33 ± 0 
5 (MeCN)4CuOTf [18F]KF no NMO 52 ± 17 
6 (MeCN)4CuOTf [18F]KF inert atmosphere 6 ± 4 
Conditions: 1H (20 µmol), Cu source (0.25 equiv), NMO (4.5 equiv), K2.2.2 (0.067 equiv), 
DBU (1 equiv), M18F (2.5–3.5 mCi), DMF (1 mL). RCC was determined by radio-TLC (n 
≥ 3); nd = not detected. The identity of 118F was confirmed by radio-HPLC. 
 
 The inert reaction conditions in entry 6 were conducted to confirm an observation 
that was made when the analogous reactions were performed using [19F]AgF. The original 
[19F]AgF reaction conditions (0.25 equiv CuI, 4.5 equiv NMO, and 3.5 equiv AgF at 105 
°C for 75 min) were set up in a glovebox and kept inert during the reaction.15 The crude 
NMR spectrum of this reaction mixture shows the starting material, the mono-fluorinated 
product, the di-fluorinated product, and various other unidentified species (B, Figure 4.1). 
Modified [18F]radiofluorination reaction conditions (0.25 equiv (MeCN)4Cu(OTf), 4.5 equiv 
NMM, 1 equiv DBU, and 3.5 equiv AgF at 140 °C for 30 min) provided a clean crude NMR 
spectrum, showing only starting material and monofluorinated product (A, Figure 4.1). 
When [19F]KF was used instead of [19F]Ag19F, no product was observed in the glovebox 
reactions. If the glovebox reaction was open air for <3 min then trace product was 
observed. No change in product formation was observed when setting up the reaction on 
the bench top compared to an inert atmosphere. In the absence of DBU, trace product is 
observed. 
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Figure 4.1. NMR Reactions Using AgF 
 
Conditions: (A) 1H (50 µmol), (MeCN)4Cu(OTf) (0.3 equiv), DBU (1 equiv), NMM (4.5 
equiv), AgF (4 equiv), DMF (0.3 mL), 140 °C, 30 min. (B) 1H (50 µmol), CuI (0.3 equiv), 
NMO (4.5 equiv), AgF (3 equiv), DMF (0.3 mL), 105 °C, 75 min. 
 
 Reproducibility is critical for radiochemical labeling reactions, and the reaction in 
Table 4.1, entry 5 showed poor reproducibility. To address this issue, several additives 
were evaluated (Table 4.2, entry 1), and it was found that the addition of the reduced form 
of NMO, N-methylmorpholine (NMM) resulted in enhanced reproducibility (Table 4.2, 
entry 2). Other bases were screened to investigate the role of DBU. Daugulis proposed 
that adding pyridine to the difluorination reactions slowed the decomposition of the 
starting material.15 Upon addition of pyridine, no product was detected (Table 4.2, entry 
3). DMAP provided some of the desired product and DBN also gave comparable results 
(Table 4.2, entries 4–5). Other Cu sources gave product with [18F]AgF and [18F]KF (Table 
4.2, entries 6–8). Other solvents gave product, but DMF was the highest yielding (Table 
4.2, entry 9). 
 
 
 
(A) 
(B) 
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Table 4.2. Optimization of C–H Radiofluorination 
 
entry conditions 118F (% RCC) 
1 no NMM 52 
2 -- 50 
3 no DBU, pyridine (1 equiv) nd 
4 no DBU, DMAP 10 
5 no DBU, DBN 46 
6 (MeCN)4Cu(BF4) 44 
7 Cu(OAc)2 19 
8 CuI 24 
9 DMA 37 
Conditions: 1H (20 µmol), (MeCN)4Cu(OTf) (0.25 equiv), K2.2.2 (0.067 equiv), DBU (1 
equiv), NMM (4.5 equiv), [18F]KF (2.5–3.5 mCi), DMF (1 mL). RCC was determined by 
radio-TLC (n ≥ 3); nd = not detected. The identity of 118F was confirmed by radio-HPLC. 
 
 To confirm that the desired C–H fluorination product was being generated, a series 
of control reactions were conducted. All control reactions indicated that the expected 
product was being formed (Figure 4.2). Removing the arene ring (S1), the quinoline motif 
(S2), and blocking the N–H group (S3) resulted in no detectable products in a range of 
conditions. If both ortho sites were blocked (3F), no radiofluorination was detected, 
indicating that fluorination was not occurring on the quinoline ring and further that the 19F 
atoms were not exchanging with the 18F atoms. To further confirm this, five different 
regioisomers (1H, 1F, 3F, 14H, 14F) were synthesized and separated on HPLC. As 
suspected 3F and 14H were challenging to get baseline separation. A co-injection with 
the crude reaction mixture showed that the desired ortho-fluorination product was formed 
selectively.  
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Figure 4.2. Control Reactions 
 
Conditions: substrate (20 μmol, 1 equiv), (MeCN)4CuOTf (0.25 equiv), DBU (1 equiv), 
NMM (4.5 equiv), [18F]KF/K2.2.2., DMF (1mL), 70–140 ºC, 30 min.  
 
4.3. Effects of DBU 
The effects of DBU in this reaction were investigated in the context of the 
analogous [19F]AgF reaction. The Daugulis report used pyridine to achieve 
difluorination.15 Their hypothesis was that the pyridine slowed down the rate of 
decomposition of the starting material, but also slowed down the rate of the reaction. The 
requirement for the glovebox was also investigated. For the first set of reactions, p-fluoro 
substrate 4H was investigated. The control reaction (Table 4.3, entry 1) showed some 
product (mono and difluorination) as well as unreacted starting material. Opening the 
reaction to air decreased the amount of monofluorinated product and increased the 
difluorinated product (Table 4.3, entry 2). Adding pyridine to the reaction slowed the rate 
of the reaction to where trace product was detected (Table 4.3, entry 3). Notably, there is 
no detectable starting material present, which conflicts with Daugulis’s hypothesis.15 
Adding DBU to the reaction led to a large increase in the yield of difluorinated product 
with some monofluorinated product obtained. To study this effect further, a substrate was 
chosen that could only produce the monofluorinated product. Substrate 4H was shown in 
the original report to undergo difluorination preferentially over monofluorination. 
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Table 4.3. Effects of DBU with 4H 
 
entry additives 4F (%) 4F2 (%) 4H (%) 
1 -- 17 6 4 
2a -- 7 12 nd 
3 pyridine 1 5 nd 
4 DBU 8 25 nd 
Conditions: 4H (20 µmol), CuI (0.25 equiv), NMO (5 equiv), AgF (4 equiv), additives 
[pyridine (2 equiv), DBU (2 equiv)], DMF (1 mL). aopen to air <5 min at rt. Crude reaction 
analyzed by NMR with 1,2-difluorobenzene as an internal standard. Nd = not detected 
 
The effect of DBU was investigated with a substrate that could only give the 
monofluorinated product (Table 4.4, entries 1–4). The original conditions were performed 
on a 10-fold scale and gave 80% of the monofluorinated product.15 Under the control 
reaction, 52% of the monofluorinated product was obtained (Table 4.4, entry 1). With this 
substrate, there was a stark difference on the glovebox reaction versus the reaction open 
to air (Table 4.4, entry 2). Additionally, pyridine had no effect on this reaction, but DBU 
gave a large increase in product (Table 4.4, entries 3–4). 
Next a substrate that gave monofluorination and difluorination product was 
investigated (Table 4.4). A similar trend was found with the standard conditions giving 
36% of the desire product with a large amount of starting material remaining (Table 4.4, 
entry 5). Exposing the reaction to air deceased the yield of the desired product and 
pyridine had no effect on the reaction (Table 4.4, entries 6–7). The addition of DBU 
increased the yield of the desired product significantly as well as increased the amount 
of difluorinated product present (Table 4.4, entry 8).  
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Table 4.4. Effects of DBU 
 
Entry R additives temperature (°C) time (h) A (%) B (%) C (%) 
1 2-CF3 -- 120  1.5 23 52 -- 
2a 2-CF3 -- 120  1.5 15 33 -- 
3 2-CF3 pyridine 120  1.5 23 54 -- 
4 2-CF3 DBU 120  1.5 trace 72 -- 
5 4-CF3 -- 80 0.5 52 36 2 
6a 4-CF3 -- 80 0.5 63 19 3 
7 4-CF3 pyridine 80 0.5 33 38 3 
8 4-CF3 DBU 80 0.5 11 67 15 
Conditions: substrate (20 µmol), CuI (0.25 equiv), NMO (5 equiv), AgF (4 equiv), additives 
[pyridine (2 equiv), DBU (2 equiv)], DMF (1 mL). aopen to air <5 min at rt. Crude reaction 
analyzed by NMR with 1,2-difluorobenzene as an internal standard. 
 
4.4. Substrate Scope 
The scope of this reaction was examined using aminoquinolines derived from a 
variety of substituted benzoic acids. Product identities were confirmed by radio-HPLC. As 
shown in Figure 4.3, electron-neutral (118F–418F), -withdrawing (518F–1018F), and -
donating (1118F) substituents were well tolerated. Some arenes bearing electron-
withdrawing substituents give rise to minor side products. The formation of side products 
derived from competing SNAr reactions were ruled out, but the unknown side products 
have not been positively identified to date. Many functional groups, including benzylic C–
H bonds, trifluoromethyl, cyano, nitro, ester, amide, and sulfonamide substituents, were 
compatible. This C(sp2)–H radiofluorination was also effective on pyridine- and indole-
derived substrates, providing 1218F and 1318F in moderate RCC. A substrate containing 
a fluorine substituent at the activated 4-position on the quinoline reacted to afford the 
ortho-18F-labelled product 1418F in 50% RCC.17,18  
This method was applied to the late-stage radiofluorination of a series of 
biologically relevant molecules. Four carboxylic acid-containing drugs, Probenecid (15H), 
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Ataluren (16H), Tamibarotene (17H), and AC261066 (18H), were converted to the 
corresponding 8-aminoquinoline benzamides and then subjected to the optimal 
conditions. The [18F]fluorinated analogues (1518F–1818F, respectively) were obtained in 
13–37% RCC. Products 1518F–1818F contain functional groups that could potentially 
direct C–H fluorination elsewhere in the molecule (e.g. 17H contains 2 amide groups). 
Small impurity peaks were detected in the crude radio-HPLC traces of these products; 
however, 1518F–1818F were the major products in each case, and they appear to be 
readily separable from the side products formed in the reaction. Performed as part of the 
optimization and similar to the Ag19F reaction,15 temperature was optimized for each 
substrate. For most substrates, the reaction was performed with and without NMM to 
analyze if there are any effects with NMM. Several substrates had a large standard 
deviation when NMM was excluded, indicating that this reagent could be increasing 
reproducibility. Most substrates had the same RCC with or without NMM except 318F 
(large increase without NMM) and 618F (large increase with NMM).  
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Figure 4.3. Substrate Scope 
 
Conditions: Substrate (20 µmol), (MeCN)4Cu(OTf) (5 µmol), NMM (90 µmol), K2.2.2 (1.33 
µmol), DBU (20 µmol), [18F]KF (2.5–3.5 mCi), DMF (1.0 mL), 90–110 °C, 30 min. 
Reported values indicate RCC determined by radio-TLC for n ≥ 3 runs. The identity of all 
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products was confirmed by radio-HPLC. In cases where other products were observed 
by radio-HPLC analysis, RCCs from radio-TLC analysis were corrected.  
 
4.5. AutomationB 
For automation, two substrates were analyzed for their efficiency of 
radiofluorination and hydrolysis. Initial automated studies were conducted with 1H, and 
afforded 118F in 28% automated RCC or, by incorporating semi-preparative HPLC 
purification, 9% isolated decay-corrected RCY and >98% radiochemical purity. Starting 
with 1.7 Ci of [18F]fluoride 118F was obtained in 42 mCi with high specific activity (6 Ci 
µmol–1). Hydrolysis of the aminoquinoline protecting group was then achieved with 4M 
NaOH to afford 1918F in 90% RCC from 118F (manual) and 21% RCC based upon starting 
[18F]fluoride (Scheme 4.4). 
 
Scheme 4.4. Automation of 1H 
 
 
An analogous method was applied to the synthesis of [18F]AC261066 (2018F), a 
RARβ2 agonist (Scheme 4.5).19 Subjecting 18H to the C–H radiofluorination conditions 
afforded 1818F in 12% automated RCC. Starting with 1.7 Ci of [18F]fluoride, 1818F was 
obtained in 36 mCi after sep-pak purification, corresponding to 3% isolated decay-
corrected RCY. Manual hydrolysis of the amide with 4M NaOH formed [18F]AC261066 
(2018F) in 98% RCC from 1818F (determined by radio-TLC). Overall, the isolated decay-
corrected RCY of 2018F was 9 mCi (2% based upon starting [18F]fluoride). The product 
was obtained in high chemical and radiochemical (>98%) purity and high specific activity 
(0.80 Ci µmol–1). These unoptimized automation results demonstrate that this method can 
                                            
B All reactions performed by So Jeong Lee 
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be used to prepare sufficient amounts of radiotracers for pre-clinical evaluation in rodents 
and non-human primates. The yields could be further improved through careful 
optimization of the automated method. 
 
Scheme 4.5. Automation of 18H 
 
 
4.6. Conclusion 
In summary, a Cu-catalyzed, 8-aminoquinoline-directed C(sp2)–H radiofluorination 
method of arene C(sp2)–H bonds with [18F]KF is reported. The method has been applied 
to a variety of substrates, including the active pharmaceutical ingredients of Probenecid, 
Ataluren, and Tamibarotene. In addition, it has been translated to an automated synthesis 
of high specific activity doses of RARβ2 agonist [18F]AC261066. Further optimization will 
be required to make the automation and subsequent deprotection efficient for a clinical 
scale. However, overall this operationally simple procedure demonstrates proof-of-
concept that metal-catalyzed nucleophilic C(sp2)–H radiofluorination is feasible, and that 
this approach shows promise for the late-stage radiofluorination of bioactive molecules. 
 
4.7. Outlook 
This transformation serves as inspiration for using other directing groups to 
achieve (radio)fluorination (Chapter 5). The effects of NMM and DBU on the reaction 
will be investigated more thoroughly. 
 
4.8. Experimental Details 
4.8.1. Instrumental Information 
NMR spectra were obtained on a Varian vnmrs700 (699.76 MHz for 1H; 175.95 MHz for 
13C), a Varian vnmr500 (500.09 MHz for 1H; 470.56 MHz for 19F; 125.75 MHz for 13C), or 
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a Varian MR400 (400.53 MHz for 1H; 376.87 MHz for 19F) spectrometer. All 13C NMR data 
presented are proton-decoupled 13C NMR spectra, unless noted otherwise. 1H and 13C 
NMR chemical shifts (δ) are reported in parts per million (ppm) relative to TMS with the 
residual solvent peak used as an internal reference. 1H and 19F NMR multiplicities are 
reported as follows: singlet (s), doublet (d), triplet (t), quartet (q), and multiplet (m). Melting 
point data (mp) were collected on an OptiMelt Automated Melting Point System and are 
uncorrected. HPLC was performed using a Shimadzu LC-2010A HT system equipped 
with a Bioscan B-FC-1000 radiation detector. Radio-TLC analyses were performed using 
a Bioscan AR 2000 Radio-TLC scanner with EMD Millipore TLC silica gel 60 plates (3.0 
cm wide x 6.5 cm long). 
 
4.8.2. Materials and Methods 
All commercial products were used as received and reagents were stored under ambient 
conditions unless otherwise stated. 8-aminoquinonline was purchased from Synthonix. 
Acid chlorides and benzoic acid derivatives were purchased from Frontier Scientific, 
Oakwood Products, Acros Organics, Synthonix, Chem Impex, TCI America, Matrix 
Scientific, Alfa Aesar, Ark Pharm, and Sigma Aldrich. Oxalyl chloride was purchased from 
Acros Organics. Silver fluoride was purchased from Oakwood. NMO, CuI, and probenecid 
were purchased from Sigma Aldrich. Tamibarotene was purchased from AAChemPharm. 
Ataluren was purchased from ArkPharm. 4-[4-(2-butoxyethoxy)-5-methyl-1,3-thiazol-2-
yl]benzoic acid (CAS 920269-72-3) and 4-[4-(2-butoxyethoxy)-5-methyl-1,3- thiazol-2-
yl]benzoic acid (AC261066, CAS: 920269-72-3) were purchased from Atomax Chemicals 
Co., Ltd. The manipulation of solid reagents was conducted on the benchtop unless 
otherwise stated. Reactions were conducted under an ambient atmosphere unless 
otherwise stated. Reaction vessels were sealed with either a septum (flask) or a Teflon-
lined cap (4 mL or 20 mL vial). Reactions conducted at elevated temperatures were 
heated on a hot plate using an aluminum block. Temperatures were regulated using an 
external thermocouple. For TLC analysis, RF values are reported based on normal phase 
silica plates with fluorescent indicator. 
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HPLC grade acetonitrile, potassium trifluoromethanesulfonate, and anhydrous 
dimethylformamide were purchased from Fisher Scientific. Silver 
trifluoromethanesulfonate, sodium bicarbonate, Kryptofix® 2.2.2 (K2.2.2), anhydrous 
acetonitrile, N,N-dimethylacetamine, N-methylmorpholine (NMM), N-methylmorpholine 
N-oxide (NMO), and 1,8-diazabicyclo[5.4.0]undec-7-ene were purchased from Sigma-
Aldrich. Sterile product vials (10 mL) were purchased from Hollister-Stier. QMA-light Sep-
Paks were purchased from Waters Corporation. QMA-light Sep-Paks were flushed with 
10 mL of ethanol, followed by 90 mg/mL of an aqueous solution of potassium 
trifluoromethanesulfonate, and rinsed with 10 mL of MQ water prior to use for the 
generation of [18F]AgF. QMA-light Sep-Paks were flushed with ethanol (10 mL), 0.5 M 
aqueous sodium bicarbonate (10 mL), and MQ water (10 mL) prior to use for the 
generation of [18F]KF. 
 
4.8.3. Synthesis of 18F 
Generation of [18F]AgF. All loading operations were conducted under ambient 
atmosphere. Automated sample transfers utilized argon gas. Silver [18F]fluoride was 
prepared with a TRACERLab FXFN automated radiochemistry synthesis module (General 
Electronic, GE). [18F]Fluoride was produced via the proton beam bombardment of 18O-
target water (18O(p,n)18F) using a GE PETTrace cyclotron (40 µA beam for 5–10 min 
generated ca. 315–620 mCi of [18F]fluoride). The [18F]fluoride was delivered to the 
automated synthesis module in a 1.5 mL bolus of [18F]target water and trapped on the 
preconditioned QMA-light Sep-Pak to remove [18O]target water and other aqueous 
impurities. [18F]Fluoride was eluted into the reaction vessel using silver 
trifluoromethanesulfonate in MQ water (10 mg, 0.5 mL, 0.08 M) and K2.2.2 in acetonitrile 
(15 mg, 1 mL, 0.04 M). Azeotropic drying was achieved by heating to 100 ºC and drawing 
vacuum for 6 min. The reaction vessel was then subjected to an argon stream and 
simultaneous vacuum draw for an additional 6 min to produce anhydrous [18F]AgF/K2.2.2.. 
Overall 70% of radioactivity remained after azeotropic drying (66%; calculated from 
TRACERLab FXFN reactor radiation detector by comparing radioactivity in the reaction 
vessel before and after azeotropic drying process). The reaction vessel was cooled to 
room temperature via an argon stream, and anhydrous dichloromethane (3.5 mL) was 
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added to dissolve the dried reagents. The mixture was heated to 37 °C with stirring for 5 
min to suspend the Ag[18F]F/K2.2.2. The resulting solution was cooled to room temperature 
and transferred to a sterile vial. 
 
Generation of [18F]KF. [18F]Fluoride was produced by the same protocol described in 
generation of [18F]AgF (above). The [18F]fluoride was delivered to the automated 
synthesis module (TRACERLab FXFN, GE) in a 1.5 mL bolus of [18F]target water and was 
trapped on the preconditioned QMA-light Sep-Pak to remove [18O]target water and other 
aqueous impurities. [18F]Fluoride was eluted into the reaction vessel using potassium 
trifluoromethanesulfonate (5 mg, 0.5 mL, 0.05 M) and K2.2.2 in acetonitrile (15 mg, 1 mL, 
0.04 M). Azeotropic drying/evaporation was achieved by heating the reaction vessel to 
100 ºC and drawing vacuum for 6 min. Azeotropic drying was achieved by heating to 100 
ºC and drawing vacuum for 6 min. The reaction vessel was then subjected to an argon 
stream and simultaneous vacuum draw for an additional 6 min to produce anhydrous 
[18F]KF/K2.2.2. The reaction vessel was cooled to room temperature under an argon 
stream, and anhydrous DMF (6 mL) was added. The mixture was heated to 50 °C with 
stirring for 5 min to suspend the [18F]KF/ K2.2.2. The resulting solution was cooled to room 
temperature and was transferred to a sterile vial. 
 
4.8.4. Manual Synthesis of 18F-Labeled Molecules 
A stock solution of each of the following reagents, the quinoline benzamide precursor (0.2 
M), (MeCN)4CuOTf (0.05 M), DBU (0.2 M), and NMM (0.9 M), in DMF was prepared. To 
a 4 mL vial containing a stir bar were added 0.1 mL aliquots of each stock solution 
[quinoline benzamide precursors (20 μmol, 1 equiv), (MeCN)4CuOTf (5 μmol, 0.25 equiv), 
DBU (20 μmol, 1 equiv), and NMM (90 μmol, 4.5 equiv)]. [18F]KF/K2.2.2 in 0.2 mL of DMF 
(2.5–3.5 mCi of radioactivity) was used for each manual reaction, and additional DMF 
(0.4 mL) was also added to bring the total solution volume to 1 mL. The reaction vial was 
sealed and pre-stirred (1500 rpm) at room temperature for 5 min. The reaction vial was 
heated in an aluminum block with vigorous stirring (1500 rpm) at 90–110 °C for 30 min. 
After 30 min, the reaction was cooled to room temperature and the radiochemical 
conversion (RCC, %) was determined by radio-TLC analysis. The crude reaction mixture 
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was spotted onto standard silica-coated glass plates and developed with hexanes:ethyl 
acetate (1:1) in a glass TLC chamber. The RCC was determined by dividing the integrated 
area of radiation under the fluorinated product spot by the total integrated area of radiation 
on the TLC plate. In reactions where the radio-HPLC traces show multiple peaks, the 
RCC (determined by radio-TLC) was corrected by dividing the integrated area of radiation 
under the desired F-18 labeled product peak by the total integrated area of radiation on 
the analytical radio-HPLC. To prepare samples for HPLC analysis, 80 μL of the reaction 
mixture was spiked with 20 μL of 2 mg/mL fluorinated standard solution in DMF.  
 
Manual Synthesis of 2018F 
[18F]Fluorination of 18H was carried out according to the procedure described above. The 
reaction was cooled to room temperature and a portion of the crude mixture (80 μL) was 
used for radio-TLC (hexanes:ethyl acetate = 1:1) and HPLC analysis. The crude reaction 
was then diluted with DI water (50 mL) and loaded onto a preconditioned QMA-C18 light 
Sep-Pak [EtOH (10 mL), D.I water (10 mL)]. The organic portions were eluted with EtOH 
(1 mL). The eluent quality was confirmed by radio-TLC analysis (hexanes:ethyl acetate = 
1:1). To the eluent in EtOH (0.5 mL) was added 4 M NaOH (1 mL). The reaction was 
heated to 100 °C for 30 min with stirring at 1500 rpm. The reaction was cooled to room 
temperature, and the crude mixture was acidified with 1 N HCl (4 mL). The organic portion 
was extracted with ethyl acetate (1 mL). The RCC of the final product was determined by 
radio-TLC (hexanes:ethyl acetate = 1:1). A portion of the reaction mixture (80 μL) was 
spiked with 20 μL of 2 mg/mL AC 261066 standard in DMF.  
 
4.8.5. Automated Synthesis  
Automated synthesis of 118F followed by semi-preparative HPLC purification.  
All loading operations were conducted under ambient atmosphere. Argon gas and 
vacuum were used for automated sample transfers. [18F]Fluoride was produced via the 
18O(p, n)18F nuclear reaction using a General Electronic (GE) PETTrace cyclotron (40 μA 
beam for 3 min generated ca. 200 mCi of [18F]fluoride, and 30 min generated ca. 1.7 Ci 
of [18F]fluoride). [18F]KF was produced as described in Generation of [18F]KF using a GE 
TRACERLab FXFN automated synthesis module. DMF (0.5 mL) was added to the dried 
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[18F]KF in the reactor, and the solution was stirred for 5 min at room temperature. A 
solution containing 1H (5.3 mg, 20 μmol, 1 equiv), (MeCN)4CuOTf (2 mg, 5 μmol, 0.25 
equiv), DBU (3 μL, 20 μmol, 1 equiv), and NMM (10 μL, 90 μmol, 4.5 equiv) in 0.8 mL of 
anhydrous DMF was added to the reactor containing 0.5 mL of a [18F]KF solution in DMF 
by applying Ar gas through the valve containing the reagent solution. The open valves 
leading out of the reactor were closed, and the reaction mixture was pre-stirred for 5 min 
at room temperature. The mixture was heated to 100 ºC and stirred for 30 min. The 
mixture was cooled to 30 ºC with compressed air cooling, and the resulting mixture was 
diluted by 3 mL of semipreparative HPLC buffer (60% acetonitrile in water, 0.1% (v/v) 
trifluoroacetic acid) then loaded onto the HPLC injection loop by passing through a Sep-
Pak alumina N plus light cartridge to remove unreacted residual [18F]fluoride. The diluted 
mixture was injected onto the semi-prep HPLC for purification. The peak for the desired 
18F-labeled organic product was collected for 2 min (tR = 16.5 min, collected volume: 8 
mL) in a 10 mL sterile product vial. The dose vial was transferred out of the synthesis 
module product identity were then determined using a Capintec dose calibrator and 
analytical HPLC (Table 4.5). 
 
Table 4.5. Automated Synthesis of 118F 
entry 
starting activity 
(mCi) 
final activity 
(mCi) 
RCY, NDC 
(%) 
total time 
(min) 
RCY, DC 
(%) 
1 194 12 6 104 12 
2 194 12 6 103 12 
3 194 13 7 102 13 
4 1700 40 2 110 5 
5 1700 40 2 98 4 
6 1700 45 3 104 5 
 
Automated synthesis of 118F followed by manual hydrolysis to provide 1918F. 
All loading operations were conducted under ambient atmosphere. Argon gas and 
vacuum was used for automated sample transfers. [18F]Fluoride was produced via the 
18O(p, n)18F nuclear reaction using a GE PETTrace cyclotron (40 μA beam for 30 min 
generated ca. 1.7 Ci of [18F]fluoride). [18F]KF was produced as described in Generation 
of [18F]KF using an automated synthesis module, TRACERLab FXFN (General Electronic, 
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GE). DMF (0.2 mL) was added to the dried [18F]KF in the reactor, and the solution was 
stirred for 5 min at room temperature. A solution containing 1H (5.3 mg, 3.8 μmol, 1 equiv), 
(MeCN)4CuOTf (2 mg, 0.1 μmol, 0.25 equiv), DBU (3 μL, 3.8 μmol, 1 equiv), and NMM 
(10 μL, 17 μmol, 4.5 equiv) in 0.8 mL of anhydrous DMF was added to the reactor 
containing 0.2 mL of a [18F]KF solution in DMF by applying Ar gas through the valve 
containing the reagent solution. The open valves leading out of the reactor were closed, 
and the reaction mixture was pre-stirred for 5 min at room temperature. The mixture was 
heated to 100 ºC and stirred for 30 min. The RCC of 118F from 1H was determined by 
radio-TLC (28%), and product identity was determined using analytical HPLC. The 
mixture was cooled to 30 ºC with compressed air cooling, and for 3 runs the resulting 
mixture was transferred to the dilution flask containing 50 mM of EDTA solution (70 mL). 
The diluted mixture was slowly loaded onto the Sep-Pak C18 plus cartridge to trap 18F-
labeled organic products by removing unreacted residual [18F]fluoride and copper. 
Radiochemical purity of 118F following this purification was 83%. The trapped 118F was 
eluted with ethanol (2 mL) and collected in an 8 mL sterile product vial. An aliquot of the 
collected 118F in ethanol (0.5 mL) was then added to 4 M NaOH (1 mL) in a 4 mL vial. 
The reaction vial was transferred to a hot plate and stirred for 30 min at 100 ºC. The 
resulting mixture was cooled to room temperature and neutralized by the addition of 6 N 
HCl (0.7 mL). Ethyl acetate (1 mL) was used to extract the organic portion from the 
mixture. The RCC of 1918F from 118F was determined by radio-TLC (90%) and the product 
identity was determined using analytical HPLC. The overall RCC to 1918F from 
[18F]fluoride was 21%. 
 
Automated synthesis of 1818F followed by manual hydrolysis to provide 2018F. 
All loading operations were conducted under ambient atmosphere. Argon gas and 
vacuum was used for automated sample transfers. [18F]Fluoride was produced via the 
18O(p, n)18F nuclear reaction using a GE PETTrace cyclotron (40 μA beam for 30 min 
generated ca. 1.7 Ci of [18F]fluoride). [18F]KF was produced as described in Generation 
of [18F]KF using an automated synthesis module, TRACERLab FXFN (General Electronic, 
GE). DMF (0.5 mL) was added to the dried [18F]KF in the reactor, and the solution was 
stirred for 5 min at room temperature. A solution containing 18H (3.5 mg, 7.8 μmol, 1 
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equiv), (MeCN)4CuOTf (0.76 mg, 2 μmol, 0.25 equiv), DBU (1.14 μL, 7.8 μmol, 1 equiv), 
and NMM (3.6 μL, 34 μmol, 4.5 equiv) in 1 mL of anhydrous DMF was added to the reactor 
containing 0.5 mL of a [18F]KF solution in DMF by applying Ar gas through the valve 
containing the reagent solution. The open valves leading out of the reactor were closed, 
and the reaction mixture was pre-stirred for 5 min at room temperature. The mixture was 
heated to 100 ºC and stirred for 30 min. The mixture was cooled to 30 ºC with compressed 
air cooling, and the resulting mixture was transferred to the dilution flask containing DI 
water (70 mL) by passing through a Sep-Pak alumina N plus light cartridge to remove 
unreacted residual [18F]fluoride. DI water (3 mL) was added to the reactor and transferred 
by argon gas to the dilution flask to rinse the residue from the reactor. The diluted mixture 
was allowed to stir for approximately 1 min then slowly loaded onto the Sep-Pak C18 1cc 
vac cartridge. The trapped 18F-labeled organic products were eluted with ethanol (1 mL) 
and collected in an 8 mL sterile product vial. The dose vial was transferred out of the 
synthesis module in a lead pig. Total activity of 1818F (36 mCi, 3% RCY, decay-corrected) 
and product identity were then determined using a Capintec dose calibrator and analytical 
HPLC (Table 4.6). The automated synthesis time of 1818F was 100 min. The collected 
1818F in ethanol (1 mL) was then added to 4 M NaOH (2 mL) in a 4 mL vial. The reaction 
vial was transferred to a hot plate and stirred for 30 min at 100 ºC. The resulting mixture 
was cooled to room temperature and neutralized by the addition of 2 N HCl (2 mL). Ethyl 
acetate (1 mL) was used to extract the organic portion from the mixture. The RCC of 
2018F from 1818F (98%) was determined by radio-TLC. The isolated decay-corrected RCY 
of 2018F at EOS was also determined to be 2% and RCP (>98%) was determined by 
analytical HPLC. Total synthesis time of 2018F from 18H was 155–160 min. 
 
Table 4.6. Automated Synthesis of 1818F and 2018F 
entry 
starting 
activity (mCi) 
activity of 
1818F (mCi) 
activity of 
2018F (mCi) 
total time 
(min) 
RCY, DC 
(%) 
1 1700 30 5 155 1 
2 1700 32 5 160 1 
3 1700 45 17 155 3 
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4.9. Synthesis and Characterization 
4.9.1. Preparation and characterization of starting materials 
 
N-(4-Methylbenzoyl)-8-aminoquinoline (1H) was prepared according to the literature 
procedure.15 8-Aminoquinoline (290.1 mg, 2.0 mmol, 1 equiv) and NEt3 (0.36 mL, 2.6 
mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (6.0 mL, 0.34 M) followed by a 
dropwise addition of 4-methylbenzoyl chloride (0.34 mL, 2.6 mmol, 1.3 equiv). The 
resulting mixture was stirred at room temperature overnight. The mixture was washed 
with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (10% ethyl acetate in hexanes), affording the product (1H) as a white 
solid (474.1 mg, 90% yield, Rf = 0.3 in 20% ethyl acetate in hexanes, mp = 119–120 °C). 
The 1H and 13C NMR spectra matched those reported in the literature.20 HRMS (ESI+) 
[M+H]+ Calculated for C17H15N2O: 263.1179; Found 263.1186.  
 
 
N-(2-Methylbenzoyl)-8-aminoquinoline (2H) was prepared according to the literature 
procedure.21 8-Aminoquinoline (434.4 mg, 3.0 mmol, 1 equiv) and NEt3 (0.55 mL, 4.0 
mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (9.0 mL, 0.33 M) followed by a 
dropwise addition of 2-methylbenzoyl chloride (0.52 mL, 4.0 mmol, 1.3 equiv). The 
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resulting mixture was stirred at room temperature overnight. The mixture was washed 
with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (10% ethyl acetate in hexanes), affording the product (2H) as a white 
solid (709.4 mg, 90% yield, Rf = 0.6 in 20% ethyl acetate in hexanes, mp = 94–95 °C). 
The 1H and 13C NMR spectra matched those reported in the literature.20 HRMS (ESI+) 
[M+H]+ Calculated for C17H15N2O: 263.1179; Found 262.1177. 
 
 
2-Fluoro-4-methyl-N-(quinolin-8-yl)benzamide (3H/1F) was prepared according to the 
literature procedure.21 8-Aminoquinoline (290.5 mg, 2.0 mmol, 1 equiv) and NEt3 (0.35 
mL, 2.5 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (7.0 mL, 0.29 M), followed 
by a dropwise addition of 2-fluoro-4-methylbenzoyl chloride (408.0 mg, 2.4 mmol, 1.2 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with water, saturated aqueous NaHCO3, and brine. The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (10% ethyl acetate in hexanes), affording the product (3H/1F) 
as a white solid (199.1 mg, 35% yield, Rf = 0.4 in 20% ethyl acetate in hexanes, mp = 
131–132 °C). The 1H and 13C NMR spectra matched those reported in the literature.15 19F 
NMR (377 MHz, CDCl3, ppm): δ –112.8 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for 
C17H14FN2O: 281.1085; Found 281.1088.  
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N-(4-Fluorobenzoyl)-8-aminoquinoline (4H) was prepared according to the literature 
procedure.21 8-Aminoquinoline (146.1 mg, 1.0 mmol, 1 equiv) and NEt3 (0.18 mL, 1.3 
mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.34 M) followed by a 
dropwise addition of 4-fluorobenzoyl chloride (0.16 mL, 1.3 mmol, 1.3 equiv). The 
resulting mixture was stirred at room temperature overnight. The mixture was washed 
with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (6% ethyl acetate in hexanes), affording the product (4H) as a white solid 
(257.6 mg, 96% yield, Rf = 0.54 in 30% ethyl acetate in hexanes, mp = 117–118 °C). The 
1H and 13C NMR spectra matched those reported in the literature.21 19F NMR (377 MHz, 
CDCl3, ppm): δ –107.7 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for C16H12FN2O: 
267.0928; Found 267.0930.  
 
 
N-(4-Cyanobenzoyl)-8-aminoquinoline (5H) was prepared according to the literature 
procedure.21 8-Aminoquinoline (1.44 g, 10 mmol, 1 equiv) and NEt3 (1.8 mL, 13 mmol, 
1.3 equiv) were dissolved in anhydrous CH2Cl2 (70 mL, 0.14 M) followed by a dropwise 
addition of 4-cyanobenzoyl chloride (2.4 g, 13 mmol, 1.3 equiv). The resulting mixture 
was stirred at room temperature overnight. The mixture was washed with 1 N HCl (2 x 15 
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mL), saturated aqueous NaHCO3 (2 x 15 mL), and brine (25 mL). The organic layers were 
combined, dried over NaSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (gradient of 100% hexanes to 40% ethyl acetate in hexanes), 
affording the product (5H) as an off-white solid (2.49 g, 91% yield, Rf = 0.3 in 20% ethyl 
acetate in hexanes, mp = 182–183 °C). The 1H and 13C NMR spectra matched those 
reported in the literature.15 HRMS (ESI+) [M+H]+ Calculated for C17H11N3O: 274.0975; 
Found 274.0975.  
 
 
N-(4-Nitrobenzoyl)-8-aminoquinoline (6H) was prepared according to the literature 
procedure.21 8-Aminoquinoline (1 g, 6.94 mmol, 1 equiv) and NEt3 (1.26 mL, 9.02 mmol, 
1.3 equiv) were dissolved in anhydrous CH2Cl2 (50 mL, 0.14 M) followed by a dropwise 
addition of 4-nitrobenzoyl chloride (1.5 g, 9.02 mmol, 1.3 equiv). The resulting mixture 
was stirred at room temperature overnight. The mixture was washed with 1 N HCl (2 x 15 
mL), saturated aqueous NaHCO3 (2 x 15 mL), and brine (25 mL). The organic layers were 
combined, dried over NaSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (gradient of 100% hexanes to 40% ethyl acetate in hexanes), 
affording the product (6H) as a yellow solid (1.91 g, 94% yield, Rf = 0.4 in 20% ethyl 
acetate in hexanes, mp = 178–179 °C). The 1H and 13C NMR spectra matched those 
reported in the literature.15 HRMS (ESI+) [M+H]+ Calculated for C16H11N3O3: 294.0873; 
Found 294.0873. 
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Methyl 4-(quinolin-8-ylcarbamoyl)benzoate (7H) was prepared according to the 
literature procedure.22 To an oven-dried vial, monomethyl terephthalate (359.9 mg, 2.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (4.0 mL, 0.5 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 mmol, 1.2 equiv) 
was added dropwise at 0 °C, resulting in vigorous bubbling. The mixture was allowed to 
warm to room temperature under N2 and stirred for 4 h. The solvent was removed in 
vacuo and the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (384.2 mg, 2.7 mmol, 1.3 equiv) and NEt3 
(0.56 mL, 4.0 mmol, 2.0 equiv) were dissolved in anhydrous CH2Cl2 (4.0 mL, 0.67 M). A 
solution of acid chloride in CH2Cl2 (2.0 mL, 6.0 mL total, 0.44 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (20% ethyl acetate in hexanes), affording the 
product (7H) as an off-white solid (421.6 mg, 69% yield, Rf = 0.4 in 20% ethyl acetate in 
hexanes, mp = 125–126 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.22 HRMS (ESI+) [M+H]+ Calculated for C18H14N2O3: 307.1077; Found 307.1084 
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N-(4-Trifluorobenzoyl)-8-aminoquinoline (8H) was prepared according to the literature 
procedure.23 8-Aminoquinoline (533 mg, 3.7 mmol, 1 equiv) and NEt3 (0.67 mL, 4.8 mmol, 
1.3 equiv) were dissolved in anhydrous CH2Cl2 (11 mL, 0.33 M) followed by a dropwise 
addition of 4-trifluoromethylbenzoyl chloride (0.71 mL, 4.8 mmol, 1.3 equiv). The resulting 
mixture was stirred at room temperature overnight. The mixture was washed with 1 N 
HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo. Recrystallization from hexanes/ethyl acetate 
(4:1) afforded the product (8H) as an off-white solid (995 mg, 85% yield, mp = 84–85 ºC). 
The 1H and 13C NMR spectra matched those reported in the literature.23 19F NMR (470 
MHz, CDCl3, ppm): δ –63.07 (s, 3F). HRMS (ESI+) [M+H]+ Calculated for C17H11F3N2O: 
317.0896; Found 317.0899. 
 
 
N-(3-Trifluoromethylbenzoyl)-8-aminoquinoline (9H) was prepared according to the 
literature procedure.21 8-Aminoquinoline (288.7 mg, 2.0 mmol, 1 equiv) and NEt3 (0.36 
mL, 2.6 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (6.0 mL, 0.33 M) followed 
by a dropwise addition of 3-(trifluoromethyl)benzoyl chloride (0.39 mL, 2.6 mmol, 1.3 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were 
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combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (10% ethyl acetate in hexanes), affording the product (9H) as 
a white solid (586.9 mg, 93% yield, Rf = 0.4 in 20% ethyl acetate in hexanes, mp = 80–81 
°C). The 1H and 13C NMR spectra matched those reported in the literature.22 19F NMR 
(377 MHz, CDCl3, ppm): δ –62.7 (s, 3F). HRMS (ESI+) [M+H]+ Calculated for 
C17H12F3N2O: 317.0896; Found 317.0899. 
 
 
N-(2-Trifluoromethylbenzoyl)-8-aminoquinoline (10H) was prepared according to the 
literature procedure.21 8-Aminoquinoline (290.1 mg, 2.0 mmol, 1 equiv) and NEt3 (0.36 
mL, 2.6 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (6.0 mL, 0.34 M) followed 
by a dropwise addition of 2-(trifluoromethyl)benzoyl chloride (0.38 mL, 2.6 mmol, 1.3 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (10% ethyl acetate in hexanes), affording the product (10H) 
as a white solid (609.8 mg, 96% yield, Rf = 0.3 in 20% ethyl acetate in hexanes, mp = 
105–106 °C). The 1H and 13C NMR spectra matched those reported in the literature.24 19F 
NMR (377 MHz, CDCl3, ppm): δ –58.9 (d, J = 4 Hz, 3F). HRMS (ESI+) [M+H]+ Calculated 
for C17H12F3N2O: 317.0896; Found 317.0904. 
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4-Methoxy-N-(quinolin-8-yl)benzamide (11H) was prepared according to the literature 
procedure.15 8-Aminoquinoline (286.6 mg, 2.0 mmol, 1 equiv) and NEt3 (0.35 mL, 2.5 
mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (6.0 mL, 0.33 M) followed by a 
dropwise addition of 4-methyoxybenzoyl chloride (0.35 mL, 2.6 mmol, 1.3 equiv). The 
resulting mixture was stirred at room temperature overnight. The mixture was washed 
with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (1% ethyl acetate in dichloromethane), affording the product (11H) as a 
white solid (370.9 mg, 67% yield, Rf = 0.31 in 20% ethyl acetate in hexanes, mp = 113–
114 °C). The 1H and 13C NMR spectra matched those reported in the literature.22 HRMS 
(ESI+) [M+H]+ Calculated for C17H15N2O2: 301.0947; Found 301.0950. 
 
 
N-(Quinolin-8-yl)isonicotinamide (12H) was prepared according to the literature 
procedure.25 To an oven dried vial, isonicotinic acid (245.0 mg, 2.0 mmol, 1 equiv) was 
placed under N2. DMF (5 drops) and CH2Cl2 (4.4 mL, 0.45 M) were added, and the 
solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 mmol, 1.2 equiv) was added 
dropwise at 0 °C, resulting in vigorous bubbling. The mixture was allowed to warm to 
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room temperature under N2 and stirred for 3 h. The solvent was removed in vacuo, and 
the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (324.8 mg, 2.3 mmol, 1.1 equiv) and 4-
dimethylaminopyridine (24.9 mg, 0.20 mmol, 0.1 equiv) were placed under N2. Anhydrous 
CH2Cl2 (7.0 mL, 0.32 M) was added and the solution was cooled to 0 °C. NEt3 (0.35 mL, 
2.5 mmol, 1.3 equiv) was added at 0 °C. A solution of acid chloride in CH2Cl2 (4.0 mL, 
11.0 mL total, 0.2 M) was added dropwise. The resulting mixture was allowed to warm to 
room temperature and left to stir overnight. The mixture was diluted with CH2Cl2 and 
washed with brine. Saturated aqueous NaHCO3 was added to the brine layer to raise the 
pH from 5 to 7. The organic layers were combined, dried over MgSO4, and concentrated 
in vacuo. The crude residue was purified by column chromatography (10% ethyl acetate 
in hexanes), affording the product (12H) as a peach solid (323.8 mg, 65% yield, Rf = 0.3 
in 75% ethyl acetate in hexanes, mp = 122–123 °C). The 1H and 13C NMR spectra 
matched those reported in the literature.25 HRMS (ESI+) [M+H]+ Calculated for 
C15H12N3O: 250.0975; Found 250.0978. 
 
 
1-Methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (13H) was prepared according to 
the literature procedure.22 To an oven-dried vial, 1-methyl-1H-indole-3-carboxylic acid 
(351.5 mg, 2.0 mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (4.0 mL, 
0.5 M) were added, and the solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 
mmol, 1.2 equiv) was added dropwise at 0 °C, resulting in vigorous bubbling. The mixture 
was allowed to warm to room temperature under N2 and stirred for 6 h. The solvent was 
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removed in vacuo, and the resulting acid chloride was used immediately without further 
purification. 
 
To another oven-dried vial, 8-aminoquinoline (376.7 mg, 2.6 mmol, 1.3 equiv) and NEt3 
(0.55 mL, 4.0 mmol, 2.0 equiv) were dissolved in anhydrous CH2Cl2 (4.0 mL, 0.65 M). A 
solution of acid chloride in CH2Cl2 (4.0 mL, 8.0 mL total, 0.33 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with saturated aqueous NaHCO3, HCl (1 N), and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (30% ethyl acetate in hexanes), affording the 
product (13H) as an off-white solid (370.8 mg, 61% yield, Rf = 0.15 in 30% ethyl acetate 
in hexanes, mp = 182–183 °C). The 1H and 13C NMR spectra matched those reported in 
the literature.15 HRMS (ESI+) [M+H]+ Calculated for C19H16N3O: 302.1288; Found 
302.1295 
 
 
N-(5-Fluoroquinolin-8-yl)-4-methylbenzamide (14H) was prepared according to the 
literature procedure.21 5-Fluoro-8-aminoquinoline (193.9 mg, 1.2 mmol, 1 equiv) and NEt3 
(0.22 mL, 1.6 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.6 mL, 0.33 M), 
followed by a dropwise addition of 4-methylbenzoyl chloride (0.2 mL, 1.5 mmol, 1.3 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (10% ethyl acetate in hexanes), affording the product (14H) 
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as a white solid (243.4 mg, 73% yield, Rf = 0.5 in 20% ethyl acetate in hexanes, mp = 
131–132 °C). The 1H and 13C NMR spectra matched those reported in the literature.17 19F 
NMR (470 MHz, CDCl3, ppm): δ –129.3 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for 
C17H14FN2O: 281.1085; Found 281.1090. 
 
 
4-(N,N-Dipropylsulfamoyl)-N-(quinolin-8-yl)benzamide (15H) was prepared according 
to the literature procedure.22 To an oven-dried vial, Probenecid (580.3 mg, 2.0 mmol, 1 
equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (4.4 mL, 0.5 M) were added, and 
the solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 mmol, 1.2 equiv) was added 
dropwise at 0 °C, resulting in vigorous bubbling. The mixture was allowed to warm to 
room temperature under N2 and stirred for 6 h. The solvent was removed in vacuo, and 
the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (324.1 mg, 2.3 mmol, 1.1 equiv) and NEt3 
(0.35 mL, 2.5 mmol, 1.2 equiv) were dissolved in anhydrous CH2Cl2 (4.0 mL, 0.56 M). A 
solution of acid chloride in CH2Cl2 (3.0 mL, 7.0 mL total, 0.32 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with brine, and the organic layers were combined, dried over MgSO4, 
and concentrated in vacuo. The crude residue was purified by column chromatography 
(15% ethyl acetate in hexanes), affording the product (15H) as a white solid (589.0 mg, 
70% yield, Rf = 0.4 in 30% ethyl acetate in hexanes, mp = 125–126 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 10.75 (s, 1H), 8.88 (dd, J = 7.7, 2.1 Hz, 1H), 8.83 (dd, 
J = 4.2, 2.1 Hz, 1H), 8.15–8.18 (multiple peaks, 3H), 7.95 (d, J = 8.4 Hz, 2H), 7.54–7.58 
(multiple peaks, 2H), 7.47 (dd, J = 7.7, 4.2 Hz, 1H), 3.11 (t, J = 7.7 Hz, 4H), 1.55 (m, J = 
7.7 Hz, 4H), 0.87 (t, J = 7.7 Hz, 6H) 
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13C NMR (176 MHz, CDCl3, ppm): δ 163.73, 148.40, 143.15, 138.62, 138.40, 136.44, 
134.03, 127.93, 127.941, 127.42, 127.33, 122.19, 121.81, 116.69, 50.00, 21.97, 11.13 
HRMS (ESI+) [M+H]+ Calculated for C22H26N3O3S: 412.1689; Found 412.1689 
 
 
3-(5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl)-N-(quinolin-8-yl)benzamide (16H) was 
prepared according to the literature procedure.22 To an oven-dried vial, Ataluren (284.0 
mg, 1.0 mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.2 mL, 0.45 
M) were added, and the solution was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 
1.2 equiv) was added dropwise at 0 °C, resulting in vigorous bubbling. The mixture was 
allowed to slowly warm to room temperature under N2 and stirred for 4.5 h. The solvent 
was removed in vacuo, and the resulting acid chloride was used immediately without 
further purification. 
 
To another oven-dried vial, 8-aminoquinoline (170.4 mg, 1.2 mmol, 1.2 equiv) and NEt3 
(0.20 mL, 1.4 mmol, 1.4 equiv) were dissolved in anhydrous CH2Cl2 (1.6 mL, 0.74 M). A 
solution of acid chloride in CH2Cl2 (4.0 mL, 5.6 mL total, 0.21 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with brine. The organic layers were combined, dried over MgSO4, 
and concentrated in vacuo. The crude residue was purified by column chromatography 
(5% ethyl acetate in dichloromethane), affording the product (16H) as a white solid (317.3 
mg, 77% yield, Rf = 0.63 in 40% ethyl acetate in hexanes, mp = 170–171 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 10.80 (s, 1H), 8.94 (d, J = 7.7 Hz, 1H), 8.88 (s, 1H), 
8.86 (d, J = 4.2 Hz, 1H), 8.37 (d, J = 7.0 Hz, 1H), 8.24 (t, J = 7.0 Hz, 1H), 8.22 (d, J = 8.4 
Hz, 1H), 8.18 (d, J = 8.4 Hz, 1H), 7.69 (t, J = 7.7 Hz, 1H), 7.58–7.62 (multiple peaks, 2H), 
7.55 (d, J = 8.4 Hz, 1H), 7.47 (dd, J = 8.4, 4.2 Hz, 1H), 7.34 (t, J = 7.7 Hz, 1H), 7.29 (t, J 
= 9.5 Hz, 1H) 
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13C NMR (176 MHz, CDCl3, ppm): δ 173.02 (d, J = 5.3 Hz), 168.14, 164.63, 160.81 (d, J 
= 261 Hz), 148.40, 138.77, 136.37, 136.07, 134.69 (d, J = 7.0 Hz), 134.41, 130.97, 
130.68, 129.97, 129.44, 217.98, 217.56, 127.42, 126.46, 124.72 (d, J = 3.5 Hz), 121.82 
(d, J = 31.7 Hz), 117.18 (d, J = 21.1 Hz), 116.72, 112.77, 112.70 
19F NMR (377 MHz, CDCl3, ppm): δ –108.16 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C24H16FN4O2: 411.1252; Found 411.1259 
 
 
N1-(Quinolin-8-yl)-N4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-
yl)terephthalamide (17H) was prepared according to the literature procedure.22 To an 
oven-dried vial, Tamibarotene (360.5 mg, 1.0 mmol, 1 equiv) were placed under N2. DMF 
(5 drops) and CH2Cl2 (5.4 mL, 0.2 M) were added, and the solution was cooled to 0 °C. 
Oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 equiv) was added dropwise at 0 °C, resulting in 
vigorous bubbling. The mixture was allowed to warm to room temperature under N2 and 
stirred for 4.5 h. The solvent was removed in vacuo, and the resulting acid chloride was 
used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (169.4 mg, 1.2 mmol, 1.2 equiv) and NEt3 
(0.20 mL, 1.4 mmol, 1.4 equiv) were dissolved in anhydrous CH2Cl2 (1.6 mL, 0.73 M). A 
solution of acid chloride in CH2Cl2 (4.0 mL, 5.6 mL total, 0.21 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with brine. The organic layers were combined, dried over MgSO4, 
and concentrated in vacuo. The crude residue was purified by column chromatography 
(20% ethyl acetate in hexanes), affording the product (17H) as an off-white solid (184.3 
mg, 38% yield, Rf = 0.67 in 40% ethyl acetate in hexanes, mp = 155–156 °C).  
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1H NMR (700 MHz, CDCl3, ppm): δ 10.74 (s, 1H), 8.86 (dd, J = 6.3, 2.8 Hz, 1H), 8.80 (dd, 
J = 4.2, 1.4 Hz, 1H), 8.29 (s, 1H), 8.14 (dd, J = 7.7, 1.4 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 
7.97 (d, J = 8.4 Hz, 2H), 7.62 (s, 1H), 7.49–7.54 (multiple peaks, 3H), 7.43 (dd, J = 8.4, 
4.2 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 1.68 (s, 4H), 1.29 (s, 6H), 1.27 (s, 6H) 
13C NMR (176 MHz, CDCl3, ppm): δ 164.92, 164.39, 148.36, 145.76, 141.59, 138.63, 
138.24, 137.57, 136.35, 135.26, 134.13, 127.91, 127.55, 127.31, 127.21, 122.03, 121.74, 
118.28, 118.22, 116.63, 35.03, 34.99, 34.41, 33.98, 31.83, 31.78 
HRMS (ESI+) [M+H]+ Calculated for C31H32N3O2: 478.2489; Found 478.2499 
 
 
4-(4-(2-Butoxyethoxy)-5-methylthiazol-2-yl)-N-(quinolin-8-yl)benzamide (18H) was 
prepared according to the literature procedure.22 To an oven-dried vial, 4-[4-(2-
butoxyethoxy)-5-methyl-1,3-thiazol-2-yl]benzoic acid (332.9 mg, 1.0 mmol, 1 equiv) was 
placed under N2. DMF (5 drops) and CH2Cl2 (2.0 mL, 0.5 M) were added, and the solution 
was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 equiv) was added dropwise at 
0 °C, resulting in vigorous bubbling. The mixture was allowed to slowly warm to room 
temperature under N2 and stirred for 6 h. The solvent was removed in vacuo and the 
resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (200.9 mg, 1.4 mmol, 1.4 equiv) and NEt3 
(0.30 mL, 2.2 mmol, 2.2 equiv) were dissolved in anhydrous CH2Cl2 (2.0 mL, 0.70 M). A 
solution of acid chloride in CH2Cl2 (2.0 mL, 4.0 mL total, 0.35 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (15% ethyl acetate in hexanes), affording the 
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product (18H) as a yellow solid (366.5 mg, 80% yield, Rf = 0.4 in 20% ethyl acetate in 
hexanes, mp = 78–79 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 10.75 (s, 1H), 8.91 (d, J = 7.7 Hz, 1H), 8.82 (d, J = 
4.2 Hz, 1H), 8.15 (d, J = 7.7 Hz, 1H), 8.07 (d, J = 8.4 Hz, 2H), 7.97 (d, J = 8.4 Hz, 2H), 
7.57 (t, J = 7.7 Hz, 1H), 7.51 (d, J = 8.4, 1H), 7.44 (dd, J = 7.7, 4.2 Hz, 1H), 4.51 (t, J = 
4.9 Hz, 2H), 3.77 (t, J = 4.9 Hz, 2H), 3.52 (t, J = 7.1 Hz, 2H), 2.31 (s, 3H), 1.58 (m, J = 
7.1 Hz, 2H), 1.38 (m, J = 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H) 
13C NMR (176 MHz, CDCl3, ppm): δ 164.60, 159.99, 157.68, 148.26, 138.67, 136.87, 
136.31, 135.16, 134.41, 127.92, 137.80, 127.40, 125.41, 121.71, 121.67, 116.48, 108.63, 
71.15, 69.74, 69.43, 31.72, 19.25, 13.91, 9.41 
HRMS (ESI+) [M+H]+ Calculated for C26H28N3O3S: 462.1846; Found 462.1848 
 
 
N-(Quinolin-8-yl)acetamide (S1) was prepared according to the literature procedure.26 
8-Aminoquinoline (144.3 mg, 1.0 mmol, 1 equiv) was dissolved in acetic anhydride (5.0 
mL, 0.2 M) and stirred overnight at room temperature. The mixture was concentrated and 
washed with brine and CH2Cl2 (2 x 20 mL). The organic layers were combined, dried over 
MgSO4, and concentrated in vacuo, affording the product (S1) as a white solid (171.1 mg, 
94% yield, Rf = 0.2 in 20% ethyl acetate in hexanes, mp = 94–96 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 9.75 (bs, 1H), 8.76 (dd, J = 4.2, 1.4 Hz, 1H), 8.73 (dd, 
J = 7.7, 1.4 Hz, 1H), 8.10 (dd, J = 8.4, 1.4 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.46 (dd, J = 
8.4, 1.4 Hz, 1H), 7.40 (dd, J = 7.7, 4.2 Hz, 1H), 2.32 (s, 3H) 
13C NMR (175 MHz, CDCl3, ppm): δ 168.67, 148.03, 137.17, 136.29, 134.47, 127.85, 
127.33, 121.51, 121.37, 116.33, 25.07 
HRMS (ESI+) [M+H]+ Calculated for C11H10N2O: 187.0866; Found 187.0866 
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4-Methyl-N-(naphthalen-1-yl)benzamide (S2) was prepared according to the literature 
procedure.21 1-Aminonaphthalene (215.0 mg, 1.5 mmol, 1 equiv) and NEt3 (0.3 mL, 2.2 
mmol, 1.4 equiv) were dissolved in anhydrous CH2Cl2 (4.6 mL, 0.33 M), followed by a 
dropwise addition of 4-methylbenzoyl chloride (0.25 mL, 1.9 mmol, 1.3 equiv). The 
resulting mixture was stirred at room temperature overnight. The mixture was washed 
with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (10% ethyl acetate in hexanes), affording the product (S2) as an off-
white solid (266.0 mg, 67% yield, Rf = 0.3 in 20% ethyl acetate in hexanes, mp = 170–
171 °C). The 1H and 13C NMR spectra matched those reported in the literature.27 HRMS 
(ESI+) [M+H]+ Calculated for C18H16NO: 262.1226; Found 262.1231.  
 
 
N,4-Dimethyl-N-(quinolin-8-yl)benzamide (S3) was prepared according to the modified 
literature procedure.28 A suspension of sodium hydride (43.5 mg, 1.8 mmol, 3.0 equiv) in 
DMF (3.0 mL) was added to a solution of 4-methyl-N-(quinolin-8-yl)benzamide (154.0 mg, 
0.60 mmol, 1 equiv) in DMF (3.0 mL, 6.0 mL total, 0.10 M) in an oven-dried vial at 0 °C 
under N2. The reaction mixture was warmed to room temperature and stirred for 3 h. 
Methyl iodide (0.05 mL, 0.80 mmol, 1.4 equiv) was added, and the reaction was stirred 
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an additional 1 h at room temperature under N2. The reaction was diluted with CH2Cl2 (40 
mL), washed with water (40 mL), dried over MgSO4, and concentrated in vacuo, affording 
the product (S3) as a colorless oil (49.7 mg, 31% yield, Rf = 0.12 in 40% ethyl acetate in 
hexanes).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 8.96 (d, J = 4.2 Hz, 1H), 8.09 (d, J = 8.4 Hz, 1H), 7.64 
(dd, J = 7.0, 2.1, 1H), 7.39 (dd, J = 8.4, 4.2 Hz, 1H), 7.31–7.35 (multiple peaks, 2H), 7.15 
(d, J = 7.7 Hz, 2H), 6.75 (d, J = 7.7 Hz, 2H), (s, 3H), 2.10 (s, 3H) 
13C NMR (175 MHz, CDCl3, ppm): δ 172.09, 150.51, 143.87, 142.68, 139.34, 136.18, 
133.66, 129.20, 129.12, 128.05, 128.01,127.39, 126.21, 121.62, 38.49, 21.17 
HRMS (ESI+) [M+H]+ Calculated for C18H17N2O: 277.1335; Found 277.1341 
 
4.9.2. Preparation and characterization of fluorinated standards 
 
2-Fluoro-4-methyl-N-(quinolin-8-yl)benzamide (3H/1F) was prepared according to the 
literature procedure.21 8-Aminoquinoline (290.5 mg, 2.0 mmol, 1 equiv) and NEt3 (0.35 
mL, 2.5 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (7.0 mL, 0.29 M), followed 
by a dropwise addition of 2-fluoro-4-methylbenzoyl chloride (408.0 mg, 2.4 mmol, 1.2 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with water, saturated aqueous NaHCO3, and brine. The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (10% ethyl acetate in hexanes), affording the product (3H/1F) 
as a white solid (199.1 mg, 35% yield, Rf = 0.4 in 20% ethyl acetate in hexanes, mp = 
131–132 °C). The 1H and 13C NMR spectra matched those reported in the literature.15 19F 
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NMR (377 MHz, CDCl3, ppm): δ –112.8 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for 
C17H14FN2O: 281.1085; Found 281.1088.  
 
 
2-Fluoro-6-methyl-N-(quinolin-8-yl)benzamide (2F) was prepared according to the 
literature procedure.15 In a glovebox, 2-methyl-N-(quinolin-8-yl)benzamide (129.0 mg, 0.5 
mmol, 1 equiv), copper(I) iodide (24.0 mg, 0.13 mmol, 0.26 equiv), silver fluoride (245.2 
mg, 1.9 mmol, 3.9 equiv), and N-methylmorpholine oxide (295.8 mg, 2.5 mmol, 5.1 equiv) 
were dissolved in DMF in the dark. The mixture was allowed to stir for 5 min. The reaction 
was then heated to 120 °C for 20 min. The solution was cooled to room temperature, 
diluted with ethyl acetate, filtered through a celite plug, and concentrated in vacuo. The 
crude residue was purified by column chromatography (10% ethyl acetate in hexanes), 
affording the product (2F) as a white solid (27.5 mg, 20% yield, Rf = 0.5 in 20% ethyl 
acetate in hexanes, mp = 122–123 °C). The 1H and 13C NMR spectra matched those 
reported in the literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –115.9 (m, 1F). HRMS 
(ESI+) [M+H]+ Calculated for C17H15N2O: 281.1085; Found 281.1087.  
 
 
2,6-Difluoro-N-(quinolin-8-yl)-4-methylbenzamide (3F) was prepared according to the 
literature procedure.22 To an oven-dried vial, 2,6-difluoro-4-methylbenzoic acid (197.7 
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mg, 1.2 mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.3 mL, 0.5 M) 
were added, and the solution was cooled to 0 °C. Oxalyl chloride (0.12 mL, 1.4 mmol, 1.2 
equiv) was added dropwise at 0 °C. The mixture was allowed to warm to room 
temperature under N2 and stirred for 4 h. The solvent was removed in vacuo, and the 
resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (232.1 mg, 1.6 mmol, 1.4 equiv) and NEt3 
(0.35 mL, 2.5 mmol, 2.20 equiv) were dissolved in anhydrous CH2Cl2 (2.0 mL, 0.80 M). A 
solution of acid chloride in CH2Cl2 (3.2 mL, 5.2 mL total, 0.31 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (10% ethyl acetate in hexanes), affording the 
product (3F) as a white solid (97.2 mg, 28% yield, Rf = 0.4 in 20% ethyl acetate in 
hexanes, mp = 136–137 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 10.34 (s, 1H), 8.92 (dd, J = 7.0, 1.4 Hz, 1H), 8.77 (dd, 
J = 4.2, 1.4 Hz, 1H), 8.14 (dd, J = 8.0, 2.1 Hz, 1H), 7.57–7.52 (multiple peaks, 2H), 7.43 
(dd, J = 8.4, 4.2 Hz, 1H), 6.82 (d, J = 8.4 Hz, 2H), 2.38 (s, 3H)  
13C NMR (175 MHz, CDCl3, ppm): δ 160.80 (d, J = 7.0 Hz), 159.37 (d, J = 7.0 Hz), 158.75, 
148.33, 143.71 (t, J = 10.6 Hz), 138.40, 136.28, 134.25, 127.89, 127.34, 122.16, 121.66, 
116.95, 112.79 (d, J = 3.5 Hz), 112.67 (d, J = 3.5 Hz), 111.76 (t, J = 19.4 Hz), 21.52 
19F NMR (377 MHz, CDCl3, ppm): δ –112.7 (d, J = 8 Hz, 2F) 
HRMS (ESI+) [M+H]+ Calculated for C17H13F2N2O : 299.0990; Found 299.0990 
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2,4-Difluoro-N-(quinolin-8-yl)benzamide (4F) was prepared according to the literature 
procedure.15 8-Aminoquinoline (145.2 mg, 1.0 mmol, 1 equiv) and NEt3 (0.18 mL, 1.3 
mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.34 M) followed by a slow 
dropwise addition of 2,4-difluorobenzoyl chloride (0.15 mL, 1.2 mmol, 1.2 equiv). The 
resulting mixture was stirred at room temperature exposed to air overnight. The mixture 
was washed with 1 N HCl, sat. NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (8% ethyl acetate in hexane) affording the product (4F) as a white solid 
(261.4 mg, 49% yield, Rf = 0.58 in 20% ethyl acetate in hexanes, mp = 136–137 °C). The 
1H and 13C NMR spectra matched those reported in the literature.29 19F NMR (377 MHz, 
CDCl3, ppm): δ –103.69 (m, 1F), –107.49 (m, 1F). HRMS (ESI+) [M+H] + Calculated for 
C16H11F2N2O: 285.0834; Found 285.0834. 
 
 
4-Cyano-2-fluoro-N-(quinolin-8-yl)benzamide (5F) was prepared according to the 
literature procedure.22 To an oven-dried vial, 4-cyano-2-fluorobenzoic acid (165.5 mg, 1.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.0 mL, 0.50 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 equiv) 
was added dropwise at 0 °C. The mixture was allowed to warm to room temperature 
137 
 
under N2 and stirred for 5 h. The solvent was removed in vacuo, and the resulting acid 
chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (209.8 mg, 1.5 mmol, 1.5 equiv) and NEt3 
(0.28 mL, 2.0 mmol, 2.0 equiv) were dissolved in anhydrous CH2Cl2 (2.0 mL, 0.73 M). A 
solution of acid chloride in CH2Cl2 (4.0 mL, 7.0 mL total, 0.21 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (10% ethyl acetate in hexanes), affording the 
product (5F) as an off-white solid (13.3 mg, 5% yield, Rf = 0.8 in 20% ethyl acetate in 
hexanes, mp = 205–206 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –109.59 (m, 1F). HRMS (ESI+) [M+H]+ 
Calculated for C17H11FN3O: 292.0881; Found 292.0887.  
 
 
2-Fluoro-N-(quinolin-8-yl)-4-nitrobenzamide (6F) was prepared according to the 
literature procedure.22 To an oven-dried vial, 2-fluoro-4-nitrobenzoic acid (191.5 mg, 1.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.0 mL, 0.52 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 1.1 equiv) 
was added dropwise at 0 °C. The mixture was allowed to warm to room temperature 
under N2 and stirred for 5 h. The solvent was removed in vacuo, and the resulting acid 
chloride was used immediately without further purification. 
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To another oven-dried vial, 8-aminoquinoline (196.3 mg, 1.4 mmol, 1.3 equiv) and NEt3 
(0.28 mL, 2.0 mmol, 1.9 equiv) were dissolved in anhydrous CH2Cl2 (2.0 mL, 0.68 M). A 
solution of acid chloride in CH2Cl2 (3.0 mL, 5.0 mL total, 0.27 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (10% ethyl acetate in hexanes), affording the 
product (6F) as a yellow solid (10.6 mg, 3% yield, Rf = 0.9 in 20% ethyl acetate in hexanes, 
mp = 200–201 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –108.04 (m, 1F). HRMS (ESI+) [M+H]+ 
Calculated for C16H11FN3O3: 312.0779; Found 312.0776.  
 
 
Methyl 3-fluoro-4-(quinolin-8-ylcarbamoyl)benzoate (7F) was prepared according to 
the literature procedure.15 In a glovebox, methyl 4-(quinolin-8-ylcarbamoyl)benzoate 
(228.1 mg, 0.74 mmol, 1 equiv), copper(I) iodide (16.5 mg, 0.09 mmol, 0.12 equiv), silver 
fluoride (390.3 mg, 3.1 mmol, 4.1 equiv), and N-methylmorpholine oxide (441.3 mg, 3.8 
mmol, 5.1 equiv) were dissolved in DMF in the dark. The mixture was allowed to stir for 
5 min at room temperature. The reaction was heated to 90 °C for 1 h. The solution was 
cooled to room temperature, diluted with ethyl acetate, filtered through a celite plug, and 
concentrated in vacuo. The crude residue was purified by column chromatography (10% 
ethyl acetate in hexanes), affording the product (7F) as an off-white solid (13.2 mg, 6% 
yield, Rf = 0.4 in 20% ethyl acetate in hexanes, mp = 142–143 °C). The 1H and 13C NMR 
spectra matched those reported in the literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –
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111.56 (s, 1F). HRMS (ESI+) [M+H]+ Calculated for C18H14FN2O3: 325.0983; Found 
325.0985. 
 
 
2-Fluoro-N-(quinolin-8-yl)-4-trifluorobenzamide (8F) was prepared according to the 
literature procedure.21 8-Aminoquinoline (144 mg, 1.0 mmol, 1 equiv) and NEt3 (0.18 mL, 
1.3 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.33 M) followed by a 
dropwise addition of 2-fluoro-4-(trifluoromethyl)benzoyl chloride (0.2 mL, 1.3 mmol, 1.3 
equiv). The resulting mixture was stirred at room temperature overnight. The mixture was 
washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic layers were 
combined, dried over MgSO4, and concentrated in vacuo. The crude residue was purified 
by column chromatography (8% ethyl acetate in hexanes), affording the product (8F) as 
an off-white solid (304 mg, 91% yield, Rf = 0.32 in 10% ethyl acetate in hexanes, mp = 
82–84 °C). The 1H and 13C NMR spectra matched those reported in the literature.15 19F 
NMR (377 MHz, CDCl3, ppm): δ –63.14 (s, 3F), –110.13 (m, 1F). HRMS (ESI+) [M+H]+ 
Calculated for C17H10F4N2O: 335.0802; Found 335.0805. 
 
 
2-Fluoro-N-(quinolin-8-yl)-5-(trifluoromethyl)benzamide (9F) was prepared according 
to the literature procedure.21 8-Aminoquinoline (145.3 mg, 1.0 mmol, 1 equiv) and NEt3 
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(0.18 mL, 1.3 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3 mL, 0.34 M), 
followed by a dropwise addition of 2-fluoro-5-(trifluoromethyl)benzoyl chloride (0.2 mL, 
1.3 mmol, 1.3 equiv). The resulting mixture was stirred at room temperature overnight. 
The mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The 
organic layers were combined, dried over MgSO4, and concentrated in vacuo. The crude 
residue was purified by column chromatography (10% ethyl acetate in hexanes), affording 
the product (9F) as a white solid (251.8 mg, 75% yield, Rf = 0.6 in 20% ethyl acetate in 
hexanes, mp = 143–140 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –62.26 (s, 3F), –107.21 (m, 1F). HRMS 
(ESI+) [M+H]+ Calculated for C17H11F4N2O: 335.0802; Found 335.0811.  
 
 
2-Fluoro-N-(quinolin-8-yl)-6-(trifluoromethyl)benzamide (10F) was prepared 
according to the literature procedure.15 In a glovebox, N-(quinolin-8-yl)-2-
(trifluoromethyl)benzamide (155.0 mg, 0.49 mmol, 1 equiv), copper(I) iodide (19.3 mg, 
0.10 mmol, 0.21 equiv), silver fluoride (254.4 mg, 2.0 mmol, 4.1 equiv), and N-
methylmorpholine oxide (300.5 mg, 2.6 mmol, 5.2 equiv) were dissolved in DMF in the 
dark. The mixture was allowed to stir for 5 min at room temperature. The reaction was 
heated to 120 °C for 90 min. The solution was cooled to room temperature, diluted with 
ethyl acetate, filtered through a celite plug, and concentrated in vacuo. The crude residue 
was purified by column chromatography (10% ethyl acetate in hexanes), affording the 
product (10F) as a white solid (20.0 mg, 12% yield, Rf = 0.4 in 20% ethyl acetate in 
hexanes, mp = 173–174 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –59.24 (s, 3F), –113.14 (m, 1F). HRMS 
(ESI+) [M+H]+ Calculated for C17H11F4N2O: 335.0802; Found 335.0806.  
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2-Fluoro-N-(quinolin-8-yl)-4-methoxybenzamide (11F) was prepared according to the 
literature procedure.22 To an oven-dried vial, 2-fluoro-4-methoxybenzoic acid (171.1 mg, 
1.0 mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.2 mL, 0.46 M) 
were added, and the solution was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 
equiv) was added dropwise at 0 °C. The mixture was stirred at 0 °C for 1 h and then 
slowly warm to room temperature under N2 and stirred for 6 h. The solvent was removed 
in vacuo, and the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (159.7 mg, 1.1 mmol, 1.1 equiv) and NEt3 
(0.20 mL, 1.4 mmol, 1.4 equiv) were dissolved in anhydrous CH2Cl2 (1.4 mL, 0.79 M). A 
solution of acid chloride in CH2Cl2 (2.0 mL, 3.4 mL total, 0.33 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with saturated aqueous NaHCO3, 1 N HCl, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (100% dichloromethane), affording the product 
(11F) as a white solid (187.5 mg, 63% yield, Rf = 0.4 in 20% ethyl acetate in hexanes, mp 
= 147–148 °C). The 1H and 13C NMR spectra matched those reported in the literature.30 
19F NMR (377 MHz,s CDCl3, ppm): δ –109.1 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for 
C17H14FN2O2: 297.1034; Found 297.1037.  
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3-Fluoro-N-(quinolin-8-yl)isonicotinamide (12F) was prepared according to the 
literature procedure.22 To an oven-dried vial, 3-fluoroisonicotinic acid (140.7 mg, 1.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (2.0 mL, 0.50 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.1 mL, 1.2 mmol, 1.2 equiv) 
was added dropwise at 0 °C. The mixture was allowed to warm to room temperature 
under N2 and stirred for 4 h. The solvent was removed in vacuo, and the resulting acid 
chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (206.3 mg, 1.4 mmol, 1.4 equiv) and NEt3 
(0.30 mL, 2.2 mmol, 2.2 equiv) were dissolved in anhydrous CH2Cl2 (2.0 mL, 0.72 M). A 
solution of acid chloride in CH2Cl2 (4.0 mL, 6.0 mL total, 0.24 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (10% ethyl acetate in hexanes), affording the 
product (12F) as an off-white solid (30.6 mg, 12% yield, Rf = 0.4 in 50% ethyl acetate in 
hexanes, mp = 155–156 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –127.46 (m, 1F). HRMS (ESI+) [M+H]+ 
Calculated for C15H11FN3O: 268.0881; Found 268.0887.  
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2-Fluoro-1-methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (13F) was prepared 
according to the literature procedure.15 In a glovebox, a 1 dram vial was charged with 1-
methyl-N-(quinolin-8-yl)-1H-indole-3-carboxamide (13H) (75.3 mg, 0.25 mmol, 1 equiv), 
copper(I) iodide (5.7 mg, 0.030 mmol, 0.12 equiv), N-methylmorpholine oxide (152.9 mg, 
1.3 mmol, 5.2 equiv) and AgF (129.3 mg, 1.0 mmol, 4.1 equiv). The solids were dissolved 
in anhydrous DMF (1.0 mL, 0.25 M). The sealed vial was stirred at room temperature for 
5 min, covered with aluminum foil, and then heated to 50 °C for 1 h. The reaction was 
cooled to room temperature, diluted with ethyl acetate (2 mL), filtered through a pad of 
celite, and then the solid phase was washed with ethyl acetate (2 x 10 mL). The crude 
residue was purified by column chromatography (10% ethyl acetate in hexanes), affording 
the product (13F) as a yellow solid (11.5 mg, 14% yield, Rf = 0.38 in 30% ethyl acetate in 
hexanes, mp >210 °C). The 1H and 13C NMR spectra matched those reported in the 
literature.15 19F NMR (377 MHz, CDCl3, ppm): δ –124.0 (m, 1F). HRMS (ESI+) [M+H]+ 
Calculated for C19H15FN3O: 320.1194; Found 320.1198.  
 
 
2-Fluoro-N-(5-fluoroquinolin-8-yl)-4-methylbenzamide (14F) was prepared according 
to the literature procedure.21 5-Fluoro-8-aminoquinoline (101.6 mg, 0.63 mmol, 1.4 equiv) 
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and NEt3 (0.11 mL, 0.79 mmol,1.7 equiv) were dissolved in anhydrous CH2Cl2 (2.2 mL, 
0.78 M), followed by a dropwise addition of a solution of 2-fluoro-4-methylbenzoyl chloride 
(136.0 mg, 0.46 mmol, 1.0 equiv) in CH2Cl2 (1.4 mL, 2.2 mL total, 0.21 M). The resulting 
mixture was stirred at room temperature overnight. The mixture was washed with 1 N 
HCl, saturated aqueous NaHCO3, and brine. The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (10% ethyl acetate in hexanes), affording the product (14F) as a white 
solid (113.7 mg, 48% yield, Rf = 0.6 in 20% ethyl acetate in hexanes, mp = 177–178 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 10.97 (d, J = 14 Hz, 1H), 8.94 (d, J = 5.6 Hz, 1H), 
8.92 (dd, J = 4.2, 1.4 Hz, 1H), 8.45 (dd, J = 8.4, 1.4 Hz, 1H), 8.11 (t, J = 8.4 Hz, 1H), 7.54 
(dd, J = 8.4, 4.2 Hz, 1H), 7.26 (t, J = 4.2 Hz, 1H), 7.13 (d, J = 5.6 Hz, 1H), 7.04 (d, J = 14 
Hz, 1H), 2.44 (s, 3H)  
13C NMR (175 MHz, CDCl3, ppm): δ 161.58 (d, J = 3.5 Hz), 160.49 (d, J = 248.2 Hz), 
153.11 (d, J = 249.9 Hz), 149.27, 145.08 (d, J = 8.8 Hz), 139.05 (d, J = 1.8 Hz), 131.83 
(d, J = 1.8 Hz), 131.48 (d, J = 3.5 Hz), 129.66 (d, J = 3.5 Hz), 125.73 (d, J = 3.5 Hz), 
121.69 (d, J = 1.8 Hz), 118.88 (d, J = 12.3 Hz), 118.75 (d, J = 17.6 Hz), 116.70 (d, J = 3.5 
Hz), 116.61 (d, J = 12.3 Hz), 110.42 (d, J = 19.4 Hz), 21.38 
19F NMR (377 MHz, CDCl3, ppm): δ –112.97 (m, 1F), –128.97 (m, 1F)  
HRMS (ESI+) [M+H]+ Calculated for C17H12F2N2O: 299.0990; Found 299.0992 
 
 
4-(N,N-Dipropylsulfamoyl)-2-fluoro-N-(quinolin-8-yl)benzamide (15F) was prepared 
according to the literature procedure.15 In a glovebox, a 1 dram vial was charged with N-
(8-quinolinyl)benzamide 13H (104.0 mg, 0.25 mmol, 1 equiv), copper(I) iodide (4.7 mg, 
0.025 mmol, 0.10 equiv), N-methylmorpholine oxide (118.4 mg, 1.0 mmol, 4.0 equiv) and 
AgF (94.1 mg, 0.74 mmol, 2.9 equiv). The solids were dissolved in anhydrous DMF (1.0 
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mL, 0.25 M). The sealed vial was stirred at room temperature for 5 min, covered with 
aluminum foil, and then heated to 75 °C for 30 min. The reaction was cooled to room 
temperature, diluted with ethyl acetate (2 mL), filtered through a pad of celite, and then 
the solid phase was washed with ethyl acetate (2 x 1 mL). The crude residue was purified 
by column chromatography (8% ethyl acetate in hexanes), affording the product (15F) as 
a white solid (29.3 mg, 27% yield, Rf = 0.3 in 20% ethyl acetate in hexanes, mp = 176–
177 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 11.15 (d, J = 12 Hz, 1H), 8.93 (dd, J = 6.3, 2.8 Hz, 
1H), 8.87 (dd, J = 4.2, 2.1 Hz, 1H), 8.32 (t, J = 7.7 Hz, 1H), 8.19 (dd, J = 7.7, 2.1 Hz, 1H), 
7.73 (dd, J = 8.4, 2.1 Hz, 1H), 7.69 (dd, J = 10.5, 1.4 Hz, 1H), 7.57–7.60 (multiple peaks, 
2H), 7.48 (dd, J = 8.4, 4.2 Hz, 1H), 3.13 (t, J = 7.7 Hz, 4H), 1.57 (m, J = 7.7 Hz, 4H), 0.88 
(t, J = 7.7 Hz, 6H) 
13C NMR (176 MHz, CDCl3, ppm): δ 160.36 (d, J = 100.3 Hz), 160.06, 159.20, 148.64, 
145.09 (d, J = 7.0 Hz), 138.72, 136.37, 134.36, 133.10, 133.09, 127.99, 127.34, 125.49 
(d, J = 10.6 Hz), 123.08 (d, J = 3.5 Hz), 122.58, 121.84, 117.45, 115.54, 115.38, 50.05, 
21.99, 11.16 
19F NMR (377 MHz, CDCl3, ppm): δ –109.41 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C22H25FN3O3S: 430.1595; Found 430.1591 
 
 
 
2-Fluoro-5-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-N-(quinolin-8-yl)benzamide 
(16F) was prepared according to the literature procedure.15 In a glovebox, a 1 dram vial 
was charged with N-(8-quinolinyl)benzamide 16H (98.2 mg, 0.24 mmol, 1 equiv), 
copper(I) iodide (6.2 mg, 0.03 mmol, 0.14 equiv), N-methylmorpholine oxide (120.5 mg, 
1.0 mmol, 4.3 equiv), and AgF (93.1 mg, 0.73 mmol, 3.1 equiv). The solids were dissolved 
in anhydrous DMF (1.0 mL, 0.24 M). The sealed vial was stirred at room temperature for 
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5 min, covered with aluminum foil, and then heated to 75 °C for 1 h. The reaction was 
cooled to room temperature, diluted with ethyl acetate (2 mL), filtered through a pad of 
celite, and then the solid phase was washed with ethyl acetate (2 x 20 mL). The crude 
residue was purified by column chromatography (4% ethyl acetate in dichloromethane), 
affording the product (16F) as a white solid (27.2 mg, 20% yield, Rf = 0.50 in 30% ethyl 
acetate in hexanes, mp = 201–202 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 11.15 (d, J = 4.9 Hz, 1H), 9.04 (d, J = 7.7 Hz, 1H), 
8.99 (d, J = 7.7 Hz, 1H), 8.87 (d, J = 4.2, 1H), 8.35 (m, 1H), 8.24 (t, J = 7.7 Hz,1H), 8.19 
(d, J = 8.4 Hz, 1H), 7.56–7.63 (multiple peaks, 3H), 7.48 (dd, J = 8.4, 4.2 Hz, 1H), 7.39 
(t, J = 9.8 Hz, 1H), 7.35 (t, J = 7.7 Hz, 1H), 7.29 (t, J = 9.8 Hz, 1H) 
13C NMR (176 MHz, d7-DMF, 75 °C, ppm): δ 173.54, 167.60, 161.59, 160.61, 160.12, 
149.40, 138.85, 136.90, 135.87 (d, J = 10.6 Hz), 134.87, 132.99 (d, J = 10.6 Hz), 131.27, 
131.04, 128.51, 127.28, 125.63 (d, J = 5.3 Hz), 124.24, 123.44 (d, J = 12.3 Hz), 122.91, 
122.53, 118.18 (d, J = 22.9 Hz), 117.46 (d, J = 22.9 Hz), 117.21, 112.48 (d, J = 12.3 Hz), 
19F NMR (377 MHz, CDCl3, ppm): δ –108.15 (m, 1F), –108.41 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C24H15F2N4O2: 429.1158; Found 429.1158 
 
 
2-Fluoro-N1-(quinolin-8-yl)-N4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-
yl)terephthalamide (15F) was prepared according to the literature procedure.15 In a 
glovebox, a 1 dram vial was charged with N-(8-quinolinyl)benzamide 17H (118.0 mg, 0.25 
mmol, 1 equiv), copper(I) iodide (4.1 mg, 0.02 mmol, 0.09 equiv), N-methylmorpholine 
oxide (119.7 mg, 1.0 mmol, 4.1 equiv), and AgF (99.0 mg, 0.78 mmol, 3.2 equiv). The 
solids were dissolved in anhydrous DMF (1.0 mL, 0.25 M). The sealed vial was stirred at 
room temperature for 5 min, covered with aluminum foil, and then heated to 75 °C for 1 
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h. The reaction was cooled to room temperature, diluted with ethyl acetate (2 mL), filtered 
through a pad of celite, and then the solid phase was washed with ethyl acetate (2 x 20 
mL). The crude residue was purified by column chromatography (18% ethyl acetate in 
hexanes), affording the product (17F) as a white solid (16.5 mg, 12% yield, Rf = 0.52 in 
30% ethyl acetate in hexanes, mp = 190–191 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 11.19 (d, J = 14.0 Hz, 1H), 8.94 (m, 1H), 8.86 (m, 
1H), 8.28 (m, 1H), 8.17 (d, J = 7.7 Hz, 1H), 7.91 (m, 1H), 7.78 (d, J = 10.5 Hz, 1H), 7.73 
(d, J = 8.4 Hz, 1H), 7.54–7.58 (multiple peaks, 3H), 7.44–7.48 (multiple peaks, 2H), 7.31 
(d, J = 8.4 Hz, 1H), 1.68 (s, 4H), 1.29 (s, 6H), 1.27 (s, 6H) 
13C NMR (176 MHz, CDCl3, ppm): δ 163.35, 161.11, 160.62, 159.68, 148.61, 145.91, 
141.98, 140.27 (d, J = 7.0 Hz), 138.72, 136.28, 134.81, 134.46, 132.58, 127.95, 127.34, 
127.30, 124.64 (d, J = 12.3 Hz), 122.60, 122.43, 121.79, 118.26 (d, J = 19.4 Hz), 117.36, 
115.92 (d, J = 26.4 Hz), 34.99, 34.96, 34.44, 34.03, 31.83, 31.80 
19F NMR (377 MHz, CDCl3, ppm): δ –110.5 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C31H31FN3O2: 496.2395; Found 496.2396 
 
 
4-(4-(2-Butoxyethoxy)-5-methylthiazol-2-yl)-2-fluoro-N-(quinolin-8-yl)benzamide 
(18F) was prepared according to the literature procedure.15 In a glovebox, a 1 dram vial 
was charged with N-(8-quinolinyl)benzamide 18H (109.5 mg, 0.24 mmol, 1 equiv), 
copper(I) iodide (5.2 mg, 0.03 mmol, 0.12 equiv), N-methylmorpholine oxide (141.6 mg, 
1.2 mmol, 5.1 equiv), and AgF (127.5 mg, 1.0 mmol, 4.2 equiv). The solids were dissolved 
in anhydrous DMF (1.0 mL, 0.24 M). The sealed vial was stirred at room temperature for 
5 min, covered with aluminum foil, and then heated to 75 °C for 1 h. The reaction was 
cooled to room temperature, diluted with ethyl acetate (2 mL), filtered through a pad of 
celite, and then the solid phase was washed with ethyl acetate (2 x 1 mL). The crude 
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residue was purified by column chromatography (9% ethyl acetate in hexanes), affording 
the product (18F) as a yellow solid (44.7 mg, 39% yield, Rf = 0.4 in 20% ethyl acetate in 
hexanes, mp = 96–97 °C).  
 
1H NMR (700 MHz, CDCl3, ppm): δ 11.15 (d, J = 14 Hz, 1H), 8.96 (dd, J = 7.7, 1.4 Hz, 
1H), 8.86 (dd, J = 4.2, 1.4 Hz, 1H), 8.22 (t, J = 8.4, 1H), 8.16 (dd, J = 8.4, 1.4 Hz, 1H), 
7.71–7.74 (multiple peaks, 2H), 7.58 (t, J = 7.7 Hz, 1H), 7.54 (dd, J = 8.4, 1.4 Hz, 1H), 
7.51 (d, J = 8.4 Hz, 1H), 7.45 (dd, J = 8.4, 4.2 Hz, 1H), 4.51 (t, J = 4.9 Hz, 2H), 3.77 (t, J 
= 4.9 Hz, 2H), 3.52 (t, J = 7.1 Hz, 2H), 2.32 (s, 3H), 1.58 (m, J = 7.1 Hz, 2H), 1.38 (m, J 
= 7.4 Hz, 2H), 0.91 (t, J = 7.4 Hz, 3H) 
13C NMR (176 MHz, CDCl3, ppm): δ 161.3 (d, J = 74 Hz), 161.06, 160.26, 160.08, 156.14 
(d, J = 3.5 Hz), 148.51, 139.00 (d, J = 10.6 Hz), 138.80, 136.26, 134.81, 132.66 (d, J = 
1.8 Hz), 127.98, 127.38, 122.09, 121.89 (d, J = 10.6 Hz), 121.69, 121.32 (d, J = 1.8 Hz), 
117.28, 112.67 (d, J = 28 Hz), 109.56, 71.20, 69.83, 69.44, 31.76, 19.28, 13.92, 9.47 
19F NMR (377 MHz, CDCl3, ppm): δ –111.48 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C26H27FN3O3S: 480.1752; Found 480.1753 
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Chapter 5  
 
Cu-Mediated Fluorination of Aryl Iodides and Other Applications 
 
This chapter includes projects that are incomplete. Each section will have a brief 
introduction, the results of the project to date, and an outlook of where these projects 
could go when complete. 
 
5.1. [18F]Radiofluorination of Aryl Iodides  
Most commonly used precursors for PET imaging are synthesized from an aryl 
iodide starting material (see Chapter 1 for more details). Instead of transforming the aryl 
iodide into a more complex starting material, utilizing the aryl iodide would be 
advantageous. They are commonly used to make other precursors and are known to be 
stable to various other chemical transformations. Thus, a method that involves a 
[18F]radiofluorination of aryl iodides would be ideal, allowing for a quick screening of drug 
candidate and preliminary radiotracers. A target could be synthesized and initial studies 
performed even if the overall yield of the reaction is low; confirming that the target is worth 
pursuing.  
In 2012, Hartwig and coworkers developed a fluorination method using aryl iodides 
and a specialized Cu(I) complex.1 This reported methodology used a large excess of AgF 
and Cu(I) complex, required high temperatures, and long reaction times. The reaction 
had good functional group tolerance but formed the dehalogenated side products which 
made the purification difficult. 
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5.1.1. Initial Results and OptimizationA 
One of the main challenges in the Hartwig method was the long reaction time 
relative to a PET time scale (the reported conditions required 22 hours).1 An initial result 
discovered by Dr. Naoko Ichiishi found that the desired product was formed in 5% RCC 
(confirmed by a HPLC co-injection with the authentic standard, Scheme 5.1).2  
 
Scheme 5.1. Preliminary Hit2 
 
 
 
It was hypothesized that the low RCC observed was due to slow reaction rates. 
The main strategy investigated was to make the Cu catalyst more reactive. Various 
ligands were screened but most of them produced unstable Cu-18F complexes or [18F]side 
product that could not be isolated and yielded no desired product. To overcome the slow 
oxidative addition, the Cu catalyst and the substrate were pre-stirred overnight at room 
                                            
AThe work this section was done in collaboration with Dr. Naoko Ichiishi and Dr. Allen Brooks. 
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temperature. At the point, when I joined the project, there had been several attempts to 
optimize the reaction that raised the radio-TLC conversion, but later found that the desired 
product was not being formed (by radio-HPLC, Scheme 5.2). The conditions when I took 
over the product are depicted in Scheme 5.2. Radio-TLC provided a 12% RCC, but when 
subjected to radio-HPLC, the desired product was not formed (Scheme 5.2).  
 
Scheme 5.2. Initial “Optimized” Conditions  
 
Conditions: aryl iodide (10 µmol) and (MeCN)4Cu(OTf) (1.5 equiv) were stirred in tBuCN 
(0.3 mL) at room temperature overnight. [18F]AgF in MeCN (0.1 mL) was added and the 
reaction was set to 140 °C for 1 h. RCC was determined by radio-TLC. HPLC traces of 
the crude reaction mixture with a co-inject of the authentic product are included below: 
 
 
To confirm that the reaction was feasible for [18F]radiofluorination, the initial 
conditions discovered by Dr. Naoko Ichiishi were re-investigated. The commercially 
available Cu catalyst (MeCN)4Cu(OTf) was found to form the desired product with and 
without AgF carrier (Scheme 5.3). HPLC co-injection confirmed the desired product was 
UV 
Gamma 
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being formed. To further ascertain the formation of the product, the same [18F]product 
was made via the iodonium salt method3 and the authentic [18F]product was spiked in the 
reaction conditions (Scheme 5.3).  
 
Scheme 5.3. Investigation of [18F]Radiofluorination of Aryl Iodides 
 
Conditions: aryl iodide (50 µmol), (MeCN)4Cu(OTf) (3 equiv), and AgF (2 equiv) were 
stirred in DMF (0.3 mL) at room temperature overnight. [18F]AgF in DMF (0.1 mL) was 
added and the reaction was set to 140 °C for 1 h. RCC was determined by radio-TLC and 
product identity was confirmed by radio-HPLC. 
 
In summary, this transformation could be possible with further optimization. The 
methodology currently suffers from low RCC (<5%). The strategies listed above could still 
be used to address the limitations, but careful consideration will need to be made to 
ensure the correct product is being formed. 
 
5.1.2. Directed [18F]Radiofluorination of Aryl Iodides  
As shown above, Hartwig’s conditions were limited to aryl iodides, needed high 
temperatures, long reaction times, an excess of an activated metal salt, and excess 
fluoride.1 Our attempts at [18F]radiofluorination encountered similar limitations. In 2013, 
Liu and coworkers had demonstrated that catalytic Cu(I) could be used for aryl bromide 
fluorination with AgF, but required coordinating directing groups such as pyridine  
(Scheme 5.4).4 Previous attempts found that this methodology was specific for pyridine 
directing groups and could not be extended to other removeable groups.5  
 
155 
 
Scheme 5.4. Liu and Coworkers Pyridine Assisted Fluorination4 
 
 
Inspired by the 8-aminoquinoline directed fluorination6 and subsequent 
[18F]radiofluorination developed in Chapter 4,7 we sought to develop a general Cu-
mediated fluorination of aryl halides. The model substrate, with blocked ortho C–H 
positions, formed no product when subjected to Hartwig’s optimized conditions (Table 
5.1, entry 1). Daugulis’s optimized conditions gave a 14% of the product (Table 5.1, entry 
2). A more soluble copper source (Cu(OAc)2) gave a similar yield of desired product 
(Table 5.1, entry 3). To further optimize the reaction, a shorter time point was analyzed 
on half scale reaction (Table 5.1, entry 4), which boosted the yield to 37%. Ar-Br 
substrates were also amenable to this reaction and gave a slight increase in the NMR 
yield (Table 5.1, entry 5). 
 
Table 5.1. Initial Results with Directed Fluorination of Aryl Iodides 
 
entry [Cu] AgF (equiv) NMO (equiv) yield 2 (%) 
1 (tBuCN)2Cu(OTf) 2 -- nd 
2 CuI 3.5 4.5 14 
3 Cu(OAc)2 3.5 4.5 12 
4a Cu(OAc)2 3.5 4.5 37 
5b Cu(OAc)2 3.5 4.5 54 
Conditions: Substrate 1 (0.1 mmol), Cu source [(tBuCN)2Cu(OTf) (3 equiv), CuI (0.25 
equiv), Cu(OAc)2 (0.25 equiv)], AgF (X equiv), and NMO (4.5 equiv) were stirred in DMF 
(0.5 mL, 0.2 M) at 140 ⁰C for 24 h. Yields determined by 19F NMR spectroscopy using 
1,2-difluorobenzene as standard. aSubstrate 1 (0.05 mmol), heated at 140 ⁰C for 2 h. 
bAryl-Br (3, 0.05 mmol) was used. 
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With preliminary conditions in hand, other fluoride sources were investigated. KF 
gave no product except when an excess of 18-crown-6 was used and only trace product 
was observed with a large amount of protodehalogenated product formed as the major 
product (Table 5.2, entries 2-3). More soluble CsF gave product with and without NMO 
and decreased the amount of protodehalogenated side product formed (Table 5.2, entries 
4-6). As seen with AgF, when Ar─Br was used as a substrate, a slight increase in yield 
was obtained (Table 5.2, entry 6). Anhydrous TMAF also gave product and no 
protodehalogenated side product that was observed with the other fluoride sources (Table 
5.2, entry 7). The addition of AgOTf with the alternative fluoride sources gave a decrease 
of yield in all cases. 
 
Table 5.2. Optimization with other fluoride sources 
 
entry [F] yield 2 (%) yield 4 (%) 
1 AgF 37 nd 
2 KF nd 20 
3a KF 4 31 
4 CsF 18 12 
5b CsF 16 17 
6bc CsF 22 11 
7 TMAF 21 nd 
Conditions: Substrate 1 (0.05 mmol), Cu(OAc)2 (0.25 equiv), [F] source (3.5 equiv), and 
NMO (4.5 equiv) were stirred in DMF (0.5 mL, 0.1 M) at 140 ⁰C for 2 h. Yields determined 
by 19F NMR spectroscopy using 1,2-difluorobenzene as standard. a18-crown-6 (3 equiv). 
bno NMO added. cAryl-Br (3, 0.05 mmol) was used. 
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5.1.3. Outlook for Fluorination of Aryl Iodides 
More optimization is needed to fully understand the above scaffold. Preliminary 
results with the following cleavable directing groups were investigated with both C–H and 
C–Br bonds. Using similar conditions as above did not form any product for an oxime 
ether directing group (Reaction A, Scheme 5.5), but did for oxazoline (Reaction B). An 
internal standard was not included to determine how much was formed. 
 
Scheme 5.5. Fluorination of Other Directing Groups 
 
Conditions: Substrates (0.02 mmol), Cu(OAc)2 (0.25 equiv), AgF (3.5 equiv), and NMO 
(4.5 equiv) were stirred in DMF (0.5 mL, 0.1 M) at 140 ⁰C for 2 h.  
 
Other directing groups that could potentially be used for this chemistry were tried 
but yielded no detectable product in the above conditions (Figure 5.1). These substrates 
might need further optimization of their own to determine if these reagents are feasible 
for this transformation. 
 
Figure 5.1. Other Directing Groups 
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5.2.  [18F]4F-MHPG Background and Clinical Studies  
As of 2016, the leading cause of death in the US was heart disease.8 Cardiac 
autonomic dysfunction contributes to the morbidity by changing in the outflow of nervous 
impulses to the parasympathetic and sympathetic branches of the autonomic nervous 
system.9 This regional degeneration of the nerve fibers in the heart is a complicated 
interaction that often evolves with the progression of the disease.10 This imbalance leads 
to chronically elevated levels of the neurotransmitter norepinephrine which contribute to 
the heart failure.10 Derivatives of the endogenous neurotransmitter norepinephrine 
(Figure 5.2) have been radiolabeled to study the cardiac sympathetic nerves, such as 
[123I]MIBG for SPECT imaging and [11C]HED for PET imaging.10–12 Norepinephrine and 
analogues are transferred into the nerve terminals by NET and NET expression is only 
associated with sympathetic nerves levels; therefore, the retention of these tracers can 
be used to measure the regional sympathetic nerve density.10 Clinical trials with these 
two tracers have demonstrated that cardiac sympathetic denervation is associated with a 
significant increased risk of sudden cardiac death.10 Specifically the sympathetic 
denervation in the left ventricle was the strongest predictor of sudden cardiac arrest 
among all imaging parameters measured.10 
 
Figure 5.2. Norepinephrine Derivatives for SPECT and PET Imaging 
 
 
The key component successful radiotracers need to address are: slow NET 
transport rates, vulnerability to intraneuronal enzyme metabolism, efficiency of vesicular 
storage, and diffusion rates from the neurons.13 As of early 2000s, the known radiotracers 
all suffered the same limitation: rapid uptake rates into cardiac sympathetic neurons. This 
rapid uptake cannot allow for a robust and reliable compartmental modeling of their 
kinetics, limiting the quantitative information that can be obtained from clinical studies with 
these tracers.13 When designing the next generation of cardiac sympathetic nerve tracers, 
159 
 
certain kinetic properties are needed in the tracer for an ideal quantitative analyses: (1) a 
slower neuronal uptake rate, providing more favorable kinetic data and (2) a very long 
neuronal retention time, through trapping inside norepinephrine storage vesicles.13 A 
slower neuronal uptake rate paired with efficient trapping of the tracer intraneuronally 
would  maximize the amount of radioactivity retained in the neurons, increasing image 
quality and providing better kinetic modeling data.13 Additionally, complete trapping of the 
tracer in the neuron following its neuronal uptake allows a simpler kinetic model to be 
used, reducing the number of parameters that need to be estimated from this data.13 This 
allows the new tracer to be more compatible with current PET practices.13 Since neuronal 
transport rate by NET is highly sensitive to changes in nerve density, accurate estimates 
of the rate constant would effectively provide quantitative regional estimates of cardiac 
sympathetic nerve density, a major advance in this branch of nuclear cardiology since it 
could be used to provide truly quantitative measures of regional nerve density.13  
Towards this goal, phenethylguanidines are known to have a high vesicular 
retention and be potent depletors of cardiac norepinephrine stores in vivo, but have been 
vastly understudied as imaging agents.14 Initial scaffolds were designed as [11C]tracers, 
but incorporated fluorine and iodine atoms on the molecule during SAR studies for future 
labeling opportunities. Several derivatives were studied and all were found to have slower 
neuronal uptake rates than [11C]HED and [123I]MIBG. Almost half of the substrates 
analyzed had the desired long retention times (Figure 5.3). It was found that the hydroxy 
group on the arene was a key component to a long retention time, but it did not affect the 
uptake rate.13 In contrast, a fluorine on the arene slowed both the uptake and reduced 
the retention time.13 The transport kinetics and binding affinity for the human 
norepinephrine transporter were studies for the five promising leads in Figure 5.3 
compared to [11C]HED, [3H]dopamine, and [3H] norepinephrine.15 It was found that 
[11C]4F-MHPG had the desired properties of a slower NET transport rate, long neuronal 
retention time, and favorable in vivo imaging properties.15,16 These favorable properties 
led to more studies that required a longer imaging time than was possible with 11C (t1/2 = 
20 min).10,17 
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Figure 5.3. [11C]Phenethylguanidines With Favorable Imaging Properties 
 
 
Progressing with [18F]4F-MHPG, the first-generation synthesis was modified from 
the 11C synthesis (Scheme 5.6).16 The synthesis introduces [18F]fluoride early via SNAr 
with five step post introducing and had a total time of 200-220 min with the overall decay-
corrected RCY of 1–2%.16 There are several opportunities for improvement, besides the 
overall yield and time. The late-stage introduction of the guanidine proved to be 
troublesome leading to the use of cyanogen bromide, which is highly toxic.  
 
Scheme 5.6. First-Generation Synthesis of [18F]4F-MHPG16 
 
 
The second-generation synthesis of [18F]4F-MHPG uses a (2-thienyl)iodonium salt 
precursor. Initial attempts to [18F]radiofluorinate the protected precursor were not 
successful using multiple [18F]fluoride sources, conventional and microwave heating, 
various temperature and solvents, with and without H2O, and with and without TEMPO 
(Scheme 5.7).18 
 
 
161 
 
Scheme 5.7. First Attempt at Second-Generation Synthesis of [18F]4F-MHPG18 
 
 
To overcome this limitation an earlier intermediate was used for the 
[18F]radiofluorination, followed by a three step structure elaboration to get to the final 
product (Scheme 5.8).18 This set-up required two radiosynthesis modules in adjacent hot 
cells.18 The total time was ~150 min and could produce an overall decay-corrected RCY 
of 7% (55–125 mCi) of [18F]4F-MHPG.18 While this is an improvement upon the first-
generation synthesis, the complexity of the [18F]radiosynthesis has increased due to the 
duel hot cell set-up, causing reproducibility issues. Additionally, time, yield, and 
reproducibility could be improved by limiting the number of steps post [18F]fluoride 
introduction to include only a deprotection step. 
 
Scheme 5.8. Second-Generation Synthesis of [18F]4F-MHPG18 
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The third-generation, and current synthesis for [18F]4F-MHPG is shown in Scheme 
5.9. While the previous intermediate was unable to undergo [18F]radiofluorination, 
creating a tetraBoc protected intermediate provided [18F]4F-MHPG. The constitutional 
isomer, [18F]3F-PHPG, has shown favorable imaging results and can be synthesized in a 
similar manner.10 The new improved synthesis has a total time of 90 min and could 
produce an overall decay-corrected RCY of 7% (16–54 mCi) of [18F]4F-MHPG and 8% 
(27–64 mCi) of [18F]3F-PHPG.10 The current synthesis greatly reduces the total time, but 
the yield and reproducibility of the overall system could still be improved.  
 
Scheme 5.9. Current Synthesis for [18F]4F-MHPG 
 
 
As the synthetic routes were being optimized, kinetics were performed throughout 
and found the [18F]4F-MHPG behaved similarly to the initial reports with [11C]4F-MHPG 
in terms of neuronal uptake and retention times (a large improvement upon [123I]MIBG, 
[11C]HED, and other radiotracers being used at the time).16 Notably, [18F]4F-MHPG had 
a lower background in other organs than observed with [11C]4F-MHPG, which is again an 
improvement on currently used radiotracers.16 Kinetic studies in isolated rat hearts and 
rhesus macaque monkeys showed a uniform uptake through the left ventricle with little 
background activity in the heart, lungs, and liver, and no uptake of free fluorine-18 was 
observed in the vertebral bones of the spine, indicating that the tracer did not undergo 
defluorination in non-human primates.10,18 Selectivity was analyzed by adding increasing 
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amounts of a potent inhibitor and the results showed that [18F]4F-MHPG was highly 
selective for presynaptic sympathetic nerve terminals.18  
Comparing the kinetic results for [18F]4F-MHPG and [18F]3F-PHPG showed similar 
uptake rates and long clearance times with T1/2 of >50 h for [18F]3F-PHPG and >24 h for 
[18F]4F-MHPG.10 The long neuronal retention times of these compounds are due to their 
efficient uptake and storage in norepinephrine storage vesicles.10 The metabolic pathway 
of [18F]3F-PHPG was analyzed and found to be different than [18F]4F-MHPG.10 Both 
tracers are currently undergoing first-in-human clinical trials (ClinicalTrials.gov, 
NCT02385877) and have minor differences, such as a more rapid clearance rate from 
the liver with [18F]4F-MHPG, improving the image interpretation and reducing spillover 
from the liver to the left ventricle.19 On the contrary, the prolonged accumulation of 
[18F]3F-PHPG in the sympathetic neurons may be advantageous in accurately measuring 
low nerve densities in areas of severe denervation.19 Because both tracers have 
advantages over the other, they continue to be compared head-to-head in heart failure 
patients staged for implantable cardioverter defibrillator placement to determine which is 
better for clinical assessments of regional denervation in diseased hearts.19  
 
5.2.1. Manual Results with [18F]4F-MHPG and [18F]3F-PHPGB 
As [18F]3F-PHPG and [18F]4F-MHPG progress through clinical trials, an improved 
and reliable synthesis is required. The current synthesis provides both tracers in relatively 
low quantities (ideally >50 mCi will be produced at the end of synthesis, non-decay 
corrected). We hypothesized that our recently developed methods could be used as an 
alternative synthesis to help produce these radiotracers as they progress through clinical 
trials. Initial optimization was performed with PHPG-SnMe3 (5). The initial conditions of 
the [18F]radiofluorination of arylstannanes20 provided the desired protected product in 
58% RCC in 30 min (Table 5.3, entry 1). Increasing the amount of Cu(OTf)2 or pyridine 
did not increase the amount of product formed (Table 5.3, entries 2-4). Decreasing the 
time from 30 min to 10 min and decreasing the scale to 5 µmol of 5 gave similar RCC of 
                                            
BThe work this section was done in collaboration with Dr. Allen Brooks. 
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product 6 (Table 5.3, entries 5-6). MHPG-SnMe3 under similar conditions gave a 
decreased RCC of 26% (Table 5.3, entries 7-8). 
 
Table 5.3. Preliminary Results with PHPG-SnMe3 
 
entry Cu(OTf)2 (equiv) pyridine (equiv) time (min) [18F]6 (% RCC) 
1 2 15 30 58 
2 4 15 30 42 
3 2 30 30 39 
4 4 30 30 24 
5 2 15 10 61 
6a 2 15 10 52 
7b 2 15 10 26 
8bc 2 15 10 26 
Conditions: PHPG-SnMe3 (5, 10 µmol), Cu(OTf)2, and pyridine were stirred in DMA (1.0 
mL, 10 mM). [18F]KF in DMA (0.1 mL) was added and the reaction was set to 100 ⁰C for 
the indicated time. RCC was determined by radio-TLC (n ≥ 2). aPHPG-SnMe3 (5, 5 µmol), 
DMA (1.0 mL, 5 mM). bMHPG-SnMe3 (7, 10 µmol), DMA (1.0 mL, 10 mM). cMHPG-SnMe3 
(7, 5 µmol), DMA (1.0 mL, 5 mM). 
 
As [18F]4F-MHPG offered more opportunities for improvement, a series of 
analogous were made to analyze our previously designed methodologies.3,20,21 MHPG-
Bpin and MHPG-SnMe3 were tested for fluorination in DMF (Table 5.4) and DMA (Table 
5.5) conditions.20,21 For every entry, MHPG-Bpin gave a higher RCC than MHPG-SnMe3.  
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Table 5.4. Aryl Boronic Acid Conditions to Generate [18F]4F-MHPG21 
 
entry [M] [M] (µmol) Cu(OTf)2 (equiv) pyridine (equiv) [18F]9 (% RCC) 
1 Bpin 4 5 125 8 
2 SnMe3 4 5 125 4 
3 Bpin 10 2 15 6 
4 SnMe3 10 2 15 5 
Conditions: MHPG-[M], Cu(OTf)2, and pyridine were stirred in DMF (1.0 mL, 10 mM). 
[18F]KF in DMF (0.1 mL) was added and the reaction was set to 110 ⁰C for 20 min. RCC 
was determined by radio-TLC (n ≥ 2). Radio-HPLC co-injection was performed to confirm 
product identity. 
 
Table 5.5. Arylstannane Conditions to Generate [18F]4F-MHPG20 
 
entry [M] [M] (µmol) Cu(OTf)2 (equiv) pyridine (equiv) [18F]9 (% RCC) 
1 Bpin 4 5 125 24 
2 SnMe3 4 5 125 2 
3 Bpin 10 2 15 27 
4 SnMe3 10 2 15 13 
Conditions: MHPG-[M], Cu(OTf)2, and pyridine were stirred in DMF (1.0 mL, 10 mM). 
[18F]KF in DMF (0.1 mL) was added and the reaction was set to 100 ⁰C for 10 min. RCC 
was determined by radio-TLC (n ≥ 2). Radio-HPLC co-injection was performed to confirm 
product identity. 
 
The iodonium salt of MHPG was synthesized with various counteranions. As 
observed before, using OTs as the counterion gave trace product (<5%). PF6 was better 
than BF4, but both were similar in yield (Table 5.6). Both yields were lower than was 
previously obtained.2 While using the (mesityl)iodonium salt could be a solution to the 
166 
 
current synthesis, the overall steps would be the same, substituting one diaryliodonium 
salt for another and adding Cu to the reaction. 
 
Table 5.6. (Mesityl)diaryliodonium Conditions to Generate [18F]4F-MHPG2,3 
 
entry [X] [18F]9 (% RCC) 
1 OTs trace 
2 PF6 23 
3 BF4 16 
Conditions: MHPG-IMes and Cu(OTf)2 were stirred in DMF (0.75 mL, 10 mM). [18F]KF•18-
crown-6 in DMF (0.1 mL, 5 mM) was added and the reaction was set to 85 ⁰C for 20 min. 
RCC was determined by radio-TLC (n ≥ 2). Radio-HPLC co-injection was performed to 
confirm product identity. 
 
5.2.2. Automation ResultsC 
After the promising manual reactions, the reaction was transitioned from a manual 
method to a semi-automated reaction. As shown in Scheme 5.10, there are several steps 
to consider for this automation process. First the reaction to get the crude protected 
product, then a deprotection and purification. All three stages have the chance of failure 
and need to be studied individually first. 
 
Scheme 5.10. Automation Considerations for [18F]4F-MHPG 
 
 
                                            
C The work this section was done in collaboration with Dr. Allen Brooks. 
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Taking into account the overall synthetic automation steps and the ease of 
implication, the arylstannane or aryl boronic acid would be the best precursors to pursue. 
The arylstannane is already an intermediate in the current route.10 Alternatively, the 
arylboronic acid could be easily synthesized from the current route. Investigating the first 
step in Scheme 5.10 produced [18F]9 in 24% RCC from MHPG-SnMe3 and 7% RCC form 
MHPG-Bpin (Table 5.7, entries 1–2). A recently improved automation method was 
published for the Ar-Bpin reactions with DOPA which uses a different preparation of 
[18F]KF.22 This preparation provided trace of the desired product (Table 5.7, entry 3). 
Although MHPG-Bpin gave higher RCC manual, the use of these precursors requires 
more optimization while MHPG-SnMe3 performed better than the manual conditions. 
 
Table 5.7. Semi-Automated Attempts to Generate Protected [18F]4F-MHPG 
entry precursor [18F]9 (% RCC) 
1a MHPG-SnMe3 24 
2b MHPG-Bpin 7 
3bc MHPG-Bpin trace 
Conditions: The reaction was performed in the hot cell module. [18F]KF, MHPG-[M], 
Cu(OTf)2, and pyridine were stirred in DMF. RCC was determined by radio-HPLC, with 
similar values obtained from radio-TLC. Radio-HPLC co-injection was performed to 
confirm product identity. a100 ⁰C for 10 min. b110 ⁰C for 20 min. cTBAOTf and Cs2CO3 
preparation of [18F]KF. 
 
 Now that step 1 of the full automation procedure worked, it was time to test the 
deprotection method. In original procedure, the reaction was performed in MeCN and the 
deprotection was heated to 120 ⁰C, well above the boiling point of MeCN (bp = 82 ⁰C).10 
These reactions are performed in DMA (bp = 165 ⁰C) and copper and pyridine are present 
in the mixture, making the deprotection step complicated. Ascorbic acid was added to the 
reaction to help keep the Cu soluble. Upon subjecting this mixture to reaction conditions, 
the desired product [18F]10 was obtained in 4% RCC, confirmed by HPLC co-injection 
with the authentic standard (Scheme 5.11). This proved that the deprotection step is 
highly inefficient as is and needs to be improved before new methodologies could be 
utilized for this reaction. 
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Scheme 5.11. Semi-Automated Deprotection of MHPG-SnMe3 
 
 
5.2.3. Outlook for [18F]4F-MHPG 
The improvement of the reaction not only depends on the improvement of the initial 
[18F]radiofluorination conditions, but also on the deprotection reaction. Preliminary results 
for alternative deprotection pathways seem promising. A deprotection method using 
concentrated HCl and formic acid at 80 °C for 45 min achieved a global deprotection of 
the fully protected standard of 4F-MHPG (Scheme 5.12, reaction A).23 A Pd/C method 
selectively cleaved the Ar-OBn group leaving the Boc groups intact (Scheme 5.12, 
reaction B).24 With the selective Ar-OBn group cleavage, a new easier deprotected group, 
could be installed on the PhOH so that HBr is not required for deprotection. Since the 
HCl/formic acid conditions were successful, it was attempted with in a solution with 
Cu(OTf)2, pyridine and DMA under the reported conditions, but no deprotection was 
observed.  
 
Scheme 5.12. Preliminary Deprotection Results 
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5.3. Experimental Details 
5.3.1. Instrumental Information 
NMR spectra were obtained on a Varian MR400 (400.52 MHz for 1H; 100.71 MHz for 13C; 
376.87 MHz for 19F), a Varian VNMRS 500 (500.10 MHz for 1H), or a Varian VNMRS 700 
(699.76 MHz for 1H; 175.95 MHz for 13C) spectrometer. 1H and 13C NMR chemical shifts 
are reported in ppm relative to TMS, with the residual solvent peak used as an internal 
reference. 19F NMR spectra are referenced based on an internal standard, 1,d-
difluorobenzene (–140.53 ppm). 1H and 19F multiplicities are reported as follows: singlet 
(s), doublet (d), triplet (t), quartet (q), and multiplet (m). Melting point data (mp) were 
collected on an OptiMelt Automated Melting Point System. HPLC was performed using a 
Shimadzu LC-2010A HT system equipped with a Bioscan B-FC-1000 radiation detector. 
Radio-TLC analysis was performed using a Bioscan AR 2000 Radio-TLC scanner with 
EMD Millipore TLC silica gel 60 plates (3.0 cm wide x 6.5 cm long). 
 
5.3.2. Materials and Methods 
All commercial products were used as received unless otherwise stated. Aryl iodide 
precursors were purchased from Frontier Scientific, Oakwood Products and Sigma 
Aldrich. Fluorine-19 reference standards were sourced commercially. HPLC grade 
acetonitrile, anhydrous N,N-dimethylformamide, potassium trifluoromethanesulfonate, 
silver trifluoromethanesulfonate, and potassium carbonate were purchased from Fisher 
Scientific. Sterile product vials were purchased from Hollister-Stier. QMA-light Sep-Paks 
were purchased from Waters Corporation. 
 
5.3.3. Synthesis of [18F] 
Generation of [18F]AgF. All loading operations were conducted under ambient 
atmosphere. Automated sample transfers utilized argon gas. Silver [18F]fluoride was 
prepared with a TRACERLab FXFN automated radiochemistry synthesis module (General 
Electronic, GE). [18F]Fluoride was produced via the proton beam bombardment of 18O-
target water (18O(p,n)18F) using a GE PETTrace cyclotron (40 µA beam for 5–10 min 
generated ca. 315–620 mCi of [18F]fluoride). The [18F]fluoride was delivered to the 
automated synthesis module in a 1.5 mL bolus of [18F]target water and trapped on the 
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preconditioned QMA-light Sep-Pak to remove [18O]target water and other aqueous 
impurities. [18F]Fluoride was eluted into the reaction vessel using silver 
trifluoromethanesulfonate in MQ water (11 mg, 1.0 mL, 0.04 M). MeCN (1.0 mL) was 
added and the mixture was azeotropically dried to produce anhydrous [18F]AgF.. The 
reaction vessel was cooled to room temperature via an argon stream, and anhydrous 
DMF or MeCN (4 mL) was added to dissolve the dried reagents. The resulting solution 
was cooled to room temperature and transferred to a sterile vial. 
 
Generation of [18F]KF•18-crown-6•K2CO3 Complex for (Mestyl)Iodonium Salts. All 
loading operations were conducted under ambient atmosphere. Argon was used as a 
pressurizing gas during automated sample transfers. Potassium [18F]fluoride was 
prepared using a TRACERLab FXFN automated radiochemistry synthesis module 
(General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction 
using a GE PETTrace cyclotron (40 μA beam for 2 min generated ca. 150 mCi of 
[18F]fluoride). The [18F]fluoride was delivered to the synthesis module in a 1.5 mL bolus 
of [18O]water and trapped on a QMA-light Sep-Pak to remove [18O]water. QMA-light Sep-
Paks were flushed with 10 mL of ethanol, followed by 10 mL of 900 mg/mL potassium 
trifluoromethanesulfonate solution, and finally 10 mL of sterile water prior to use. 
[18F]Fluoride was eluted into the reaction vessel using aqueous potassium carbonate (3.5 
mg in 0.5 mL of water). A solution of 18-crown-6 (15 mg in 1 mL of acetonitrile) was added 
to the reaction vessel, and the resulting solution was dried by azeotropic distillation to 
give dry [18F]KF•18-crown-6•K2CO3. Evaporation was achieved by heating the reaction 
vessel to 100 °C and drawing vacuum for 4 min. After this time, the reaction vessel was 
subjected to an argon stream and simultaneous vacuum draw for an additional 4 min. 
Finally, DMF (4 mL) was added to the dried reagent, and the resulting solution was 
transferred to a sterile vial for subsequent use in reactions. 
 
Generation of [18F]KF (KOTf Prep). All loading operations were conducted under an 
ambient atmosphere. Argon was used as a pressurizing gas during automated sample 
transfers. Potassium [18F]fluoride was prepared using a TRACERLab FXFN automated 
radiochemistry synthesis module (General Electric, GE). [18F]Fluoride was produced via 
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the 18O(p,n)18F nuclear reaction using a GE PETTrace cyclotron (40 μA beam for 2–5 min 
generated ca. 150–375 mCi of [18F]fluoride). The [18F]fluoride was delivered to the 
synthesis module in a 1.5 mL bolus of [18O]water and trapped on a QMA-light Sep-Pak to 
remove [18O]water and other impurities. QMA-light Sep-Paks were flushed with 10 mL of 
ethanol, followed by 10 mL of 900 mg/mL KOTf solution, and finally 10 mL of sterile water 
prior to use. [18F]Fluoride was eluted into the reaction vessel using 550 μL of aqueous 
solution containing 5 mg KOTf and 50 μg of K2CO3. Acetonitrile (1.0 mL) was added to 
the reaction vessel, and the resulting solution was dried by azeotropic distillation to 
provide anhydrous [18F]KF. Azeotropic drying/evaporation was achieved by heating the 
reaction vessel to 100 °C and drawing vacuum for 6 min. The reaction vessel was then 
subjected to an argon stream and simultaneous vacuum draw for an additional 6 min. 
Overall, 70% of activity remained after azeotropic drying (68%; calculated from 
TRACERLab FXFN reactor radiation detector by comparing activity before and after 
azeotropic drying). DMF or DMA (6 mL) was added to the dried reagent, and heated at 
120 °C with stirring for 5 min. The resulting solution was cooled to 40 °C and was 
transferred to a sterile vial for subsequent use in reactions. 
 
5.3.4. General Procedures for [18F]Radiofluorination Reactions (Manual Scale) 
Experimental Details for [18F]Fluorination Reactions Reported in Scheme 5.2 
In a drybox, 4-iodobiphenyl (10 µmol, 1 equiv) and (MeCN)4Cu(OTf) (1.5 equiv) were 
weighed into a 4 mL vial equipped with a micro stir-bar. tBuCN (0.3 mL, 0.03 M) was 
added and the reaction vial was sealed with a septa lined cap, removed from the drybox, 
and stirred overnight at room temperature. [18F]AgF in MeCN (0.1 mL) was added and 
the reaction was set to 140 °C for 1 h. The reaction was cooled to room temperature and 
analyzed by radio-TLC to determine RCC and radio-HPLC to confirm product identity. 
 
Experimental Details for [18F]Fluorination Reactions Reported in Scheme 5.3 
In a drybox, 4-iodobiphenyl (50 µmol, 1 equiv), (MeCN)4Cu(OTf) (3 equiv), and AgF (2 
equiv) were weighed into a 4 mL vial equipped with a micro stir-bar. DMF (0.3 mL, 0.17 
M) was added and the reaction vial was sealed with a septa lined cap, removed from the 
drybox, and stirred overnight at room temperature. [18F]AgF in DMF (0.1 mL) was added 
172 
 
and the reaction was set to 140 °C for 1 h. The reaction was cooled to room temperature 
and analyzed by radio-TLC to determine RCC and radio-HPLC to confirm product identity. 
 
(Mesityl)(4-biphenyl)iodonium tetrafluoroborate (6 µmol, 1 equiv) was weighed into a 4 
mL vial equipped with a micro stir-bar and dissolved in DMF (0.35 mL, 0.17 M). A stock 
solution of (MeCN)4Cu(OTf) in DMF (0.15 mL, 38 µmol in 1.0 mL, 38 mM) was added and 
the reaction vial was sealed with a septa lined cap. [18F]KF•18-crown-6•K2CO3 in DMF 
(0.1 mL) was added and the reaction was set to 85 °C for 20 min. The reaction was cooled 
to room temperature and analyzed by radio-TLC to determine RCC and radio-HPLC to 
confirm product identity. 
 
Experimental Details for [18F]Fluorination Reactions Reported in Table 5.3  
Stock solutions were made of PHPG-SnMe3 (5, 0.1 M), MHPG-SnMe3 (7, 0.1 M), 
Cu(OTf)2 (0.2 M), and pyridine (1.0 M). Solutions of Cu(OTf)2 (0.1 mL, 2 equiv) and 
pyridine (0.15 mL, 15 equiv) were diluted in DMA (0.55 mL) and Ar-SnMe3 solution (0.1 
mL, 1 equiv) was added. [18F]KF in DMA (0.1 mL) was added to the reaction via a septa 
cap and the reaction was heated to 100 °C, for 10–30 min. Note: no stir-bars were used. 
 
Experimental Details for [18F]Fluorination Reactions Reported in Table 5.4 and Table 5.5, 
entries 1–2. Stock solutions were made of MHPG-SnMe3 (7, 40 mM), MHPG-Bpin (8, 40 
mM), Cu(OTf)2 (0.1 M), and pyridine (1.0 M). A vial was charged with solutions of Cu(OTf)2 
(0.2 mL, 5 equiv), pyridine (0.5 mL, 125 equiv) and Ar-[M] (0.1 mL, 1 equiv). [18F]KF in 
DMF/DMA (0.2 mL) was added to the reaction via a septa cap and the reaction was 
heated to 110 °C for 20 min (Table 5.4) or 100 °C, for 10 min (Table 5.5). Note: no stir-
bars were used. 
 
Experimental Details for [18F]Fluorination Reactions Reported in Table 5.4 and Table 5.5, 
entries 3–4. Stock solutions were made of MHPG-SnMe3 (7, 40 mM), MHPG-Bpin (8, 40 
mM), Cu(OTf)2 (0.1 M), and pyridine (0.5 M). A vial was charged with solutions Cu(OTf)2 
(0.2 mL, 2 equiv), pyridine (0.3 mL, 15 equiv), DMF/DMA (0.05 mL) and Ar-[M] (0.25 mL, 
1 equiv). [18F]KF in DMF/DMA (0.2 mL) was added to the reaction via a septa cap and 
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the reaction was heated to 110 °C for 20 min (Table 5.4) or 100 °C, for 10 min (Table 
5.5). Note: no stir-bars were used. 
 
Experimental Details for [18F]Fluorination Reactions Reported in Table 5.6  
MHPG-IMes were weighed into 4 mL vial and dissolved in DMF (0.3 mL, 0.75 mL total 
volume, 5 mM). [18F]KF•18-crown-6 in DMF (0.25 mL) was added to the reaction via a 
septa cap and the reaction was heated to 85 °C for 20 min. 
 
5.3.5. General Procedures for Fluorination Reactions 
Experimental Details for Fluorination Reactions Reported in Table 5.1 
In a drybox, substrate 1 (0.1 mmol, 1.0 equiv), Cu source [(tBuCN)2Cu(OTf) (3 equiv), 
CuI (0.25 equiv), Cu(OAc)2 (0.25 equiv)], NMO (4.5 equiv), and AgF (added in the dark) 
were weighed into a 4 mL vial equipped with a micro stirbar. DMF (0.5 mL) was added, 
and the reaction vial was sealed with a Teflon-lined cap, removed from the drybox, and 
stirred at the 140 ⁰C for 24 h. The reaction was then cooled to room temperature, diluted 
with EtOAc (2 mL), filtered through celite and an internal standard (1, 2-difluorobenzene, 
200 μL of a 0.25 M solution in EtOAc) was added. An aliquot was removed for analysis 
by 19F NMR spectroscopy. For the 0.05 mmol scale reactions, 100 μL of a 0.25 M solution 
of internal standard was added. 
 
Experimental Details for Fluorination Reactions Reported in Table 5.2 
In a drybox, substrate 1 (0.05 mmol, 1.0 equiv), Cu(OAc)2 (0.25 equiv), NMO (4.5 equiv), 
and [F] source (3.5 equiv) were weighed into a 4 mL vial equipped with a micro stirbar. 
DMF (0.5 mL) was added, and the reaction vial was sealed with a Teflon-lined cap, 
removed from the drybox, and stirred at the 140 ⁰C for 2 h. The reaction was then cooled 
to room temperature, diluted with EtOAc (2 mL), filtered through celite and an internal 
standard (1, 2-difluorobenzene, 100 μL of a 0.25 M solution in EtOAc) was added. An 
aliquot was removed for analysis by 19F NMR spectroscopy.  
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5.3.6. Semi-Automated Synthesis of Protected [18F]4F-MHPG 
All loading operations were conducted under an ambient atmosphere. Argon was used 
as a pressurizing gas during automated sample transfers. Potassium [18F]fluoride was 
prepared using a TRACERLab FXFN automated radiochemistry synthesis module 
(General Electric, GE). [18F]Fluoride was produced via the 18O(p,n)18F nuclear reaction 
using a GE PETTrace cyclotron. [18F]KF was produced as indicated above. A 10 min 
beam was used for the semi-automated reaction, generally providing ~900–1000 mCi of 
activity for each reaction.  
 
Experimental Details Reported in Table 5.7 
A solution containing MHPG-SnMe3 or MHPG-Bpin (0.01 mmol, 1 equiv, 0.1 M stock) in 
0.4 mL of anhydrous DMA in vial 3 and Cu(OTf)2 (0.02 mmol, 2 equiv, 0.2 M stock), 
pyridine (0.015 mmol, 15 equiv, 1 M stock), in 0.25 mL of DMA from vial 4 (prepared from 
separate stock solutions of the three reagents) were added to a reactor containing dry 
[18F]KF (KOTf prep) by applying Ar gas through the valve containing the reagent solution 
for a final reaction volume of 1 mL of DMA. Open valves leading out of the reactor were 
closed, and the mixture was stirred for 10 min at 100 ºC (for entry 1) or 20 min at 110 ºC 
(for entry 2). The mixture was then cooled, extra DMA (2 mL from vial 6) was added to 
aid in the removal and the crude reaction was analyzed manually.  
 
Experimental Details Reported in Scheme 5.11 
A solution containing MHPG-SnMe3 (0.01 mmol, 1 equiv, 0.1 M stock) in 0.4 mL of 
anhydrous DMA in vial 3 and Cu(OTf)2 (0.02 mmol, 2 equiv, 0.2 M stock), pyridine (0.015 
mmol, 15 equiv, 1 M stock), in 0.25 mL of DMA from vial 4 (prepared from separate stock 
solutions of the three reagents) were added to a reactor containing dry [18F]KF (KOTf 
prep) by applying Ar gas through the valve containing the reagent solution for a final 
reaction volume of 1 mL of DMA. Open valves leading out of the reactor were closed, and 
the mixture was stirred for 10 min at 100 ºC. The mixture was then cooled to 50 °C. A 
mixture of ascorbic acid (0.2 mL, 0.25 M), HBr (48%, 0.5 mL), and DMA (0.5 mL) in vial 
5 were added to the reactor and the mixture was stirred for 15 min at 120 ºC. The mixture 
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was cooled, extra DMA (2 mL from vial 6) was added to aid in the removal and the crude 
reaction was analyzed manually.  
 
5.4. Synthesis and Characterization 
5.4.1. Substrates 
 
2-fluoro,6-iodo-N-(quinolin-8-yl)benzamide (1) was prepared according to the 
literature procedure.25 To an oven-dried vial, 2-fluoro-6-iodobenzoic acid (523.3 mg, 2.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (4.4 mL, 0.45 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 mmol, 1.2 equiv) 
was added dropwise at 0 °C, resulting in vigorous bubbling. The mixture was allowed to 
warm to room temperature under N2 and stirred for 2 h. The solvent was removed in 
vacuo and the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (323.1 mg, 2.2 mmol, 1.1 equiv) and NEt3 
(0.35 mL, 2.5 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.75 M). A 
solution of acid chloride in CH2Cl2 (3.0 mL, 6.0 mL total, 0.37 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (100% dichloromethane), affording the product 
(1) as a yellow solid (602.9 mg, 78% yield, Rf = 0.82 in hexanes, mp = 209–210 °C).  
 
1H NMR (CDCl3): δ 10.07 (s, 1H), 8.94 (d, J = 7.0 Hz, 1H), 8.76 (d, J = 0.9 Hz, 1H), 8.16 
(d, J = 2.1 Hz, 1H), 7.70 (d, J = 2.1 Hz, 1H), 7.56–7.61 (multiple peaks, 2H), 7.44 (m, 1H), 
7.11–7.18 (multiple peaks, 2H) 
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13C NMR (CDCl3): δ 163.04, 158.76 (d, J = 251.7 Hz), 148.37, 138.41, 136.35, 135.31 (d, 
J = 3.5 Hz), 133.97, 132.14 (d, J = 8.8 Hz), 131.44 (d, J = 21.1 Hz), 127.96, 127.35, 
122.45, 121.74, 117.14, 115.99 (d, J = 21.1 Hz), 93.65 (d, J = 3.5 Hz) 
19F NMR (CDCl3): δ –110.77 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C16H11FIN2O: 392.9822; Found 392.9892 
 
 
2-bromo,6-fluoro-N-(quinolin-8-yl)benzamide (3) was prepared according to the 
literature procedure.25 To an oven-dried vial, 2-bromo-6-fluorobenzoic acid (431.1 mg, 2.0 
mmol, 1 equiv) was placed under N2. DMF (5 drops) and CH2Cl2 (4.4 mL, 0.45 M) were 
added, and the solution was cooled to 0 °C. Oxalyl chloride (0.2 mL, 2.4 mmol, 1.2 equiv) 
was added dropwise at 0 °C, resulting in vigorous bubbling. The mixture was allowed to 
warm to room temperature under N2 and stirred for 6 h. The solvent was removed in 
vacuo and the resulting acid chloride was used immediately without further purification. 
 
To another oven-dried vial, 8-aminoquinoline (323.0 mg, 2.2 mmol, 1.1 equiv) and NEt3 
(0.35 mL, 2.5 mmol, 1.3 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.75 M). A 
solution of acid chloride in CH2Cl2 (2.0 mL, 5.0 mL total, 0.45 M) was added dropwise at 
room temperature. The resulting mixture was stirred at room temperature overnight. The 
mixture was washed with 1 N HCl, saturated aqueous NaHCO3, and brine. The organic 
layers were combined, dried over MgSO4, and concentrated in vacuo. The crude residue 
was purified by column chromatography (100% dichloromethane), affording the product 
(3) as an off-white solid (573.6 mg, 84% yield, Rf = 0.29 (20% ethyl acetate in hexanes, 
mp = 194–196 °C).  
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1H NMR (CDCl3): δ 10.10 (s, 1H), 8.94 (d, J = 6.3 Hz, 1H), 8.76 (d, J = 1.1 Hz, 1H), 8.15 
(d, J = 2.1 Hz, 1H), 7.56–7.60 (multiple peaks, 2H), 7.42–7.46 (multiple peaks, 2H), 7.30 
(m, 1H), 7.15 (m, 1H) 
13C NMR (CDCl3): δ 161.39, 159.53 (d, J = 251.7 Hz), 148.36, 138.38, 136.35, 133.96, 
131.69 (d, J = 8.8 Hz), 128.85 (d, J = 3.5 Hz), 127.94, 127.70 (d, J = 22.9 Hz), 127.34, 
122.45, 121.74, 120.83 (d, J = 3.5 Hz), 117.10, 115.19 (d, J = 22.9 Hz) 
19F NMR (CDCl3): δ –111.61 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C16H11BrFN2O: 345.0033; Found 345.0037 
 
4I-MHPG (S8) was prepared by the following 6-step procedure. 
 
 
 
 
Step 1: 
Intermediate S3 was prepared according to a literature procedure.18 The product was 
purified by flash column chromatography on silica gel (30% ethyl acetate in hexanes), 
which afforded S3 as a white solid (5.76 g, 85% yield, Rf = 0.48 in 50% ethyl acetate in 
hexanes, mp = 62–63 °C). The 1H and 13C NMR spectra matched that reported previously 
in the literature.18 HRMS [M+Na]+ Calculated for C14H13INaO2: 362.9852; Found 
362.9848. 
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Step 2: 
Intermediate S4 was prepared according to a literature procedure.18 The product was 
purified by flash column chromatography on silica gel (20% ethyl acetate in hexanes), 
which afforded S4 as a white solid (0.76 g, 72% yield, Rf = 0.77 in 100% hexanes, mp = 
89–90 °C). The 1H and 13C NMR spectra matched that reported previously in the 
literature.18 HRMS [M]+ Calculated for C14H12BrIO: 401.9116; Found 401.9126. 
 
 
Step 3: 
Intermediate S5 was prepared according to a literature procedure.18 The product was 
purified by flash column chromatography on silica gel (20% ethyl acetate in hexanes), 
which afforded S5 as a yellow solid (1.57 g, 72% yield, Rf = 0.26 in 20% ethyl acetate in 
hexanes, mp = 49–51 °C). The 1H and 13C NMR spectra matched that reported previously 
in the literature.18 HRMS [M]+ Calculated for C15H12INO: 348.9964; Found 348.9965. 
 
 
Step 4: 
Intermediate S6 was prepared according to a literature procedure.18 After the crude 
reaction was quenched with methanol and concentrated to remove solvent, HCl (4.0 M 
HCl in dioxane, 1 mL) and excess diethyl ether was added. The precipitate was filtered 
and washed with diethyl ether to afford S6 as a white solid (1.21 g, 53% yield, mp = 155–
156 °C). The 1H and 13C NMR spectra matched that reported previously in the literature.18 
HRMS [M–HCl] Calculated for C15H16INO: 354.0349; Found 354.0354. 
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Step 5: 
Intermediate S7 was prepared according to a literature procedure.18 The product was 
purified by flash column chromatography on silica gel (10% ethyl acetate in hexanes), 
which afforded S7 as a white solid (1.92 g, 87% yield, Rf = 0.38 in 20% ethyl acetate in 
hexanes, mp = 99–100 °C). The 1H and 13C NMR spectra matched that reported 
previously in the literature.18 HRMS [M+H]+ Calculated for C26H34IN3O5: 596.1616; Found 
596.1613. 
 
 
Step 6: 
Intermediate S8 was prepared according to a literature procedure.10 The product was 
purified by flash column chromatography on silica gel (15% ethyl acetate in hexanes), 
which afforded S8 as a clear oil (1.55 g, 65% yield, Rf = 0.68 in 20% ethyl acetate in 
hexanes). The 1H and 13C NMR spectra matched that reported previously in the 
literature.10 HRMS [M+H]+ Calculated for C36H50IN3O9: 796.2664; Found 796.2657. 
 
  
MHPG-SnMe3 (7) was prepared according to a literature procedure.10 The product was 
purified by flash column chromatography on silica gel (15% diethyl ether in pentanes), 
which afforded 7 as a colorless oil (576.3 mg, 72% yield, Rf = 0.52 in 20% ethyl acetate 
in hexanes). The 1H and 13C NMR spectra matched that reported previously in the 
literature.10 HRMS [M+H]+ Calculated for C39H59N3O9Sn: 834.3346; Found 834.3349. 
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MHPG-Bpin (8) was prepared according to a modified literature procedure.26 In a 
glovebox, a 20 mL vial was charged with intermediate S8 (845.9 mg, 1.1 mmol), 
pinacoldiboron ester (297.7 mg, 1.2 mmol, 1.1 equiv), potassium acetate (311.9 mg, 3.2 
mmol, 3.0 equiv), and Pd(dppf)Cl2 dichloromethane complex (86.4 mg, 0.11 mmol, 0.1 
equiv), and DMSO (5.8 mL, 0.18 M). The vial was sealed and set to 80 °C. After 3 h, the 
reaction was cooled to room temperature, filtered through a silica plug with Et2O. The 
Et2O later was washed with H2O (150 mL x 3). The organic layers were combined, dried 
over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (20% ethyl acetate in hexane) affording the product 8 as a white solid 
(435.3 mg, 52% yield, Rf = 0.57 in 25% ethyl acetate in hexanes, mp = 54–55 °C).  
 
1H NMR (CDCl3): δ 7.63 (m, 3H), 7.37 (t, J = 7.7 Hz, 2H), 7.28 (t, J = 7.7 Hz, 1H), 6.88 
(d, J = 7.0 Hz, 1H), 6.86 (s, 1H), 5.13 (s, 2H), 3.97 (t, J = 8.4 Hz, 2H), 2.95 (t, J = 8.4 
Hz, 2H), 1.52 (s, 9H), 1.51 (s, 9H), 1.49 (s, 18H), 1.36 (s, 12H) 
13C NMR (CDCl3): δ 163.63, 157.78, 151.19, 147.34, 143.84, 143.57, 137.66, 136.92, 
128.06, 127.22, 126.78, 121.20, 112.75, 83.60, 83.53, 83.31, 81.99, 69.94, 48.56, 33.63, 
28.02, 27.96, 27.89, 25.00, 24.90 
HRMS (ESI+) [M+H]+ Calculated for C42H63BN3O11: 796.4550; Found 796.4558 
 
 
MHPG-IMes OTs (10-OTs) was prepared according to a modified thesis procedure.2 In 
an oven-dried flask, iodomesitylene diacetate (200.4 mg, 0.55 mmol, 1.6 equiv) was 
added with CH3CN (2.0 mL, 0.28 M) and cooled to 0 °C using an ice bath under N2. To 
the cooled solution, p-TsOH•H2O (78.5 mg, 0.41 mmol, 1.2 equiv) was added in one 
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portion, and the solution immediately turned yellow and was allowed to stir for 10 min. 
MHPG-SnMe3 dissolved in DCM (2 mL, 0.17M) was added dropwise. An additional 15 
mL of DCM was added. The reaction was warmed up to room temperature and stir for 2 
days. The product was purified by flash column chromatography on silica gel (5% 
methanol in DCM), which afforded 10-OTs as a white solid (172.1 g, 54% yield, mp = 95–
96 °C).  
 
1H NMR (CD3OD): δ 7.92 (d, J = 7.7 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.37–7.38 (multiple 
peaks, 3H), 7.26–7.28 (multiple peaks, 2H), 7.25 (s, 1H), 7.21 (d, J = 8.4 Hz, 2H), 7.11 
(s, 2H), 7.00 (d, J = 7.7 Hz, 1H), 5.25 (s, 2H), 3.96 (t, J = 7.4 Hz, 2H), 3.01 (t, J = 7.4 Hz, 
2H), 2.46 (s, 6H), 2.36 (s, 3H), 2.34 (s, 3H), 1.49 (s, 9H), 1.46 (s, 18H), 1.37 (s, 9H) 
13C NMR (CD3OD): δ 159.34, 157.86, 152.44, 149.26, 148.35, 145.34, 145.25, 143.88, 
143.62, 141.56, 138.21, 136.47, 131.16, 129.90, 129.85, 129.76, 126.95, 125.55, 120.82, 
116.25, 100.73, 85.58, 85.28, 83.58, 73.01, 34.38, 28.31, 28.25, 28.19, 26.74, 21.32, 
20.96 
HRMS (ESI+) [M–OTs]+ Calculated for C45H61IN3O9: 914.3452; Found: 914.3452 
 
  
MHPG-IMes OTs (10-OTs, 97.5 mg) was dissolved in DCM (5 mL) and saturated KPF6 
(aq, 5 mL) was added and vigorously stirred for 1.5 h. The organic layer was separated, 
and the aqueous layer was extracted with DCM twice and concentrated. The product was 
purified by flash column chromatography on silica gel (100% DCM), which afforded 10-
PF6 as a white solid (88.8 mg, 93% yield, Rf = 0.28 in 4% methanol in DCM, mp = 92–93 
°C).  
 
1H NMR (CD3OD): δ 7.95 (d, J = 8.4 Hz, 1H), 7.40–7.42 (multiple peaks, 3H), 7.30–7.31 
(multiple peaks, 2H), 7.28 (s, 1H), 7.15 (s, 2H), 7.04 (d, J = 8.4 Hz, 1H), 5.28 (s, 2H), 4.00 
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(t, J = 7.7 Hz, 2H), 3.05 (t, J = 7.7 Hz, 2H), 2.49 (s, 6H), 2.37 (s, 3H), 1.53 (s, 9H), 1.49 
(s, 18H), 1.41 (s, 9H) 
13C NMR (CD3OD): δ 159.36, 157.87, 152.45, 149.28, 148.42, 145.36, 145.32, 143.88, 
138.16, 136.47, 131.19, 129.91, 129.85, 129.78, 125.59, 120.75, 116.28, 100.65, 85.59, 
85.30, 83.59, 73.04, 34.38, 28.31, 28.28, 28.24, 28.18, 26.73, 20.95 
19F NMR (CD3OD): δ –74.00 (m, 1F), –75.88 (m, 1F) 
HRMS (ESI+) [M–PF6]+ Calculated for C45H61IN3O9: 914.3452; Found: 914.3442 
 
 
MHPG-IMes OTs (10-OTs, 107.0 mg) was dissolved in DCM (5 mL) and saturated NaBF4 
(aq, 5 mL) was added and vigorously stirred for 1.5 h. The organic layer was separated, 
and the aqueous layer was extracted with DCM twice and concentrated. The product was 
purified by flash column chromatography on silica gel (7% methanol in DCM), which 
afforded 10-BF4 as a white solid (92.4 mg, 94% yield, Rf = 0.19 in 4% methanol in DCM, 
mp = 96–97 °C).  
 
1H NMR (CD3OD): δ 7.96 (d, J = 8.4 Hz, 1H), 7.40–7.42 (multiple peaks, 3H), 7.29–7.31 
(multiple peaks, 2H), 7.28 (s, 1H), 7.15 (s, 2H), 7.04 (d, J = 8.4 Hz, 1H), 5.28 (s, 2H), 3.99 
(t, J = 7.7 Hz, 2H), 3.04 (t, J = 7.7 Hz, 2H), 2.49 (s, 6H), 2.37 (s, 3H), 1.52 (s, 9H), 1.49 
(s, 18H), 1.40 (s, 9H) 
13C NMR (CD3OD): δ 159.35, 157.87, 152.45, 149.28, 148.42, 145.35, 145.31, 143.88, 
138.18, 136.47, 131.18, 129.91, 129.86, 129.78, 125.58, 120.77, 116.28, 100.68, 85.59, 
85.30, 83.59, 73.04, 34.38, 28.31, 28.25, 28.19, 26.73, 20.95 
19F NMR (CD3OD): δ –155.21 (m, 4F) 
HRMS (ESI+) [M–BF4]+ Calculated for C45H61IN3O9: 914.3452; Found: 914.3447 
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5.4.2. Standards 
 
2,6-difluoro-N-(quinolin-8-yl)benzamide (2) was prepared according to the literature 
procedure.27 8-Aminoquinoline (141.7 mg, 1.0 mmol, 1 equiv) and NEt3 (0.20 mL, 1.4 
mmol, 1.5 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.33 M) followed by a slow 
dropwise addition of 2,6-difluorobenzoyl chloride (0.15 mL, 1.2 mmol, 1.2 equiv). The 
resulting mixture was stirred at room temperature exposed to air overnight. The mixture 
was washed with 1 N HCl, sat. NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (10% ethyl acetate in hexane) affording the product (2) as a white solid 
(175.6 mg, 62% yield, Rf = 0.31 in 20% ethyl acetate in hexanes, mp = 173–174 °C). 
 
1H NMR (CDCl3): δ 10.32 (s, 1H), 8.92 (d, J = 7.0 Hz, 1H), 8.76 (d, J = 0.5 Hz, 1H), 8.14 
(d, J = 2.1 Hz, 1H), 7.53–7.57 (multiple peaks, 2H), 7.34–7.43 (multiple peaks, 2H), 7.00 
(m, 2H) 
13C NMR (CDCl3): δ 160.16 (d, J = 253.4 Hz), 160.12 (d, J = 253.4 Hz), 158.47, 148.34, 
138.32, 136.28, 134.06, 131.96 (t, J = 9.7 Hz), 127.87, 127.27, 122.33, 121.69, 116.99, 
114.78 (t, J = 19.4 Hz), 112.22 (d, J = 3.5 Hz), 112.10 (d, J = 5.3 Hz) 
19F NMR (CDCl3): δ –111.76 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C16H11F2N2O: 285.0834; Found 285.0837 
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2-Fluoro-N-(quinolin-8-yl)benzamide (4) was prepared according to the literature 
procedure.27 8-Aminoquinoline (147.6 mg, 1.0 mmol, 1 equiv) and NEt3 (0.20 mL, 1.4 
mmol, 1.4 equiv) were dissolved in anhydrous CH2Cl2 (3.0 mL, 0.34 M) followed by a slow 
dropwise addition of 2-fluorobenzoyl chloride (0.15 mL, 1.3 mmol, 1.2 equiv). The 
resulting mixture was stirred at room temperature exposed to air overnight. The mixture 
was washed with 1 N HCl, sat. NaHCO3, and brine. The organic layers were combined, 
dried over MgSO4, and concentrated in vacuo. The crude residue was purified by column 
chromatography (5% ethyl acetate in hexane) affording the product (4) as a white solid 
(243.8 mg, 92% yield, Rf = 0.42 in 20% ethyl acetate in hexanes, mp = 126–127 °C). The 
1H and 13C NMR spectra matched those reported in the literature.28 19F NMR (377 MHz, 
CDCl3, ppm): δ –112.10 (m, 1F). HRMS (ESI+) [M+H]+ Calculated for C16H12FN2O: 
267.0928; Found 267.0922. 
 
4F-MHPG (S8-F) was prepared by the following 6-step procedure. 
 
 
 
 
Step 1: 
Intermediate S3-F was prepared according to the modified literature procedure.18 2-
fluoro-5-(hydroxymethyl)phenol S2-F (2.45 g, 17.2 mmol) was dissolved in DMF (30.0 
mL, 0.58 M) at room temperature open to air. K2CO3 (3.58 g, 25.9 mmol) and benzyl 
chloride (2.2 mL, 19.1 mmol) was added and the reaction was heated to 130 °C. After 2 
h the reaction was cooled to room temperature and washed with a saturated NH4Cl 
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solution (200 mL) and extracted with ethyl acetate (100 mL x 3). The combined organic 
layers were washed with brine (100 mL), dried over Mg2SO4, and concentrated. The crude 
residue was purified by column chromatography (15% ethyl acetate in hexane) affording 
the product (S3-F) as a white solid (3.57 g, 89% yield, Rf = 0.48 in 40% ethyl acetate in 
hexanes, mp = 36–37 °C).  
 
1H NMR (CDCl3): δ 7.43 (d, J = 7 Hz, 2H), 7.37 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 
1H), 7.04 (multiple peaks, 2H), 6.85 (m, 1H), 5.12 (s, 2H), 4.57 (s, 2H), 1.83 (br s, 1H) 
13C NMR (CDCl3): δ 152.21 (d, J = 246.4 Hz), 146.69 (d, J = 10.9 Hz), 137.09, 136.37, 
128.57, 128.09, 127.43, 119.66 (d, J = 7.0 Hz), 116.07 (d, J = 18.7 Hz), 114.20, 71.21, 
64.73 
19F NMR (CDCl3): δ –135.28 (m, 1F) 
HRMS (ESI+) [M+NH4]+ Calculated for C14H17FNO2: 250.1238; Found 25.1236 
 
 
Step 2: 
Intermediate S4-F was prepared according to the modified literature procedure.18 A 
solution of PBr3 (2.6 mL, 28.6 mL total, 0.1 M in CH2Cl2) was added a solution of alcohol 
SF-3 (3.14 g, 13.5 mmol) in CH2Cl2 (100 mL, 0.14 M) dropwise over 1.5 h at room 
temperature open to air. After 4 h, TLC showed no starting material remaining. The 
reaction was quenched slowly with saturated NaHCO3 solution (100 mL) and extracted 
with CH2Cl2 (100 mL x 3). The combined organic layers were washed with brine (100 mL), 
dried over Mg2SO4, and concentrated. The crude residue was used without further 
purification to afford the product (S4-F) as a white solid (3.71 g, 93% yield, Rf = 0.70 in 
20% ethyl acetate in hexanes, mp = 72–73 °C).  
 
1H NMR (CDCl3): δ 7.44 (d, J = 7.0 Hz, 2H), 7.39 (t, J = 7.0 Hz, 2H), 7.33 (t, J = 7.0 Hz, 
1H), 7.03 (multiple peaks, 2H), 6.92 (m, 1H), 5.13 (s, 2H), 4.41 (s, 2H) 
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13C NMR (CDCl3): δ 152.72 (d, J = 248.2 Hz), 146.80 (d, J = 10.6 Hz), 136.14, 134.01 (d, 
J = 5.3 Hz), 128.61, 128.19, 127.50, 122.00 (d, J = 7.0 Hz), 116.39 (d, J = 8.8 Hz), 116.32 
(d, J = 7.0 Hz), 71.36, 33.03 
19F NMR (CDCl3): δ –133.20 (m, 1F) 
HRMS (EI) [M]+ Calculated for C14H12BrFO: 294.0056; Found 294.0065 
 
 
Step 3: 
Intermediate S5-F was prepared according to the modified literature procedure.18 Sodium 
cyanide (337.6 mg, 6.9 mmol, 1.2 equiv) was added portion-wise over 15 min to a solution 
of the bromide S4-F (1.71 g, 5.8 mmol, 1 equiv) in DMSO (21.5 mL, 0.27 M) at room 
temperature open to air. After 45 min TLC showed no starting material remaining. The 
reaction was poured over ice water (250 mL). The aqueous solution was extracted with 
EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), 
dried over Mg2SO4, and concentrated. The crude residue was purified by column 
chromatography (8% ethyl acetate in hexane) affording the product (S5-F) as a white 
solid (1.14 g, 82% yield, Rf = 0.30 in 20% ethyl acetate in hexanes, mp = 37–38 °C).  
 
1H NMR (CDCl3): δ 7.44 (d, J = 7.0 Hz, 2H), 7.38 (t, J = 7.0 Hz, 2H), 7.33 (t, J = 7.0 Hz, 
1H), 7.06 (dd, J = 14.0, 7.0 Hz, 1H), 6.96 (dd, J = 7.0, 7.0 Hz, 1H), 6.84 (m, 1H), 5.13 (s, 
2H), 3.65 (s, 2H) 
13C NMR (CDCl3): δ 152.44 (d, J = 248.2 Hz), 147.05 (d, J = 12.3 Hz), 135.94, 128.62, 
128.23, 127.45, 125.95 (d, J = 3.5 Hz), 120.77 (d, J = 7.0 Hz), 117.58, 116.72 (d, J = 19.4 
Hz), 115.22 (d, J = 1.8 Hz), 71.39, 23.14 
19F NMR (CDCl3): δ –134.19 (m, 1F) 
HRMS (EI) [M]+ Calculated for C15H12FNO : 241.0903; Found 241.0909 
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Step 4: 
Intermediate S6-F was prepared according to a modified literature procedure.18 BH3-THF 
(17 mL, 1.0 M solution in tetrahydrofuran, 17 mmol, 2.8 equiv) was added dropwise to a 
solution of the cyanide S5-F (1.4434 g, 6.0 mmol, 1 equiv) in anhydrous tetrahydrofuran 
(45 mL, 0.13 M) at room temperature under a nitrogen atmosphere. The reaction was 
heated to 70 °C for 4.5 h and excess BH3 was quenched with the cautious addition of 
methanol until effervescence ceased. The solvent was removed under reduced pressured 
and the residue was taken up in HCl solution (4.0 M HCl in dioxane, 3 mL) with excess 
diethyl ether (200 mL). The precipitate was filtered, washed with excess diethyl ether, and 
dried in vacuo to give the desired product S6-F as a white solid (1.4482 g, 86% yield, mp 
= 194–196 °C).  
 
1H NMR (CD3OD with 1 drop of d6-DMSO): δ 7.45 (d, J = 7.7 Hz, 2H), 7.37 (t, J = 7.4 Hz, 
2H), 7.31 (t, J = 7.4 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.07 (m, 1H), 6.85 (m, 1H), 5.16 (s, 
2H), 3.14 (t, J = 7.4 Hz, 2H), 2.92 (t, J = 7.4 Hz, 2H) 
13C NMR (CD3OD with 1 drop of d6-DMSO): δ 153.46 (d, J = 246.0 Hz), 148.31 (d, J = 
12.3 Hz), 138.26, 134.62 (d, J = 3.5 Hz), 129.70, 129.27, 128.88, 122.81 (d, J = 7.0 Hz), 
117.57, 117.43 (d, J = 17.6 Hz), 72.37, 42.03, 34.19 
19F NMR (CD3OD with 1 drop of d6-DMSO): δ –138.32 (m, 1F) 
HRMS (ESI+) [M]+ Calculated for C15H17FNO : 246.1289; Found 2461292 
 
 
Step 5: 
Intermediate S7-F was prepared according to a modified literature procedure.18 To a 
cooled (0 °C) solution of S6-F (1.32 g, 4.7 mmol, 1 equiv) and triethylamine (2.6 mL, 18.7 
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mmol, 4 equiv) in anhydrous DMF (13 mL, 0.36 M) was added in portion 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (1.442 g, 5.0 mmol, 1.1 equiv). The resulting 
mixture was stirred at 0 °C for 1 h, warmed to room temperature and stirred overnight. 
The mixture was diluted with ethyl acetate (50 mL), washed with saturated NH4Cl solution 
(200 mL), and extracted with ethyl acetate (2 × 250 mL). The combined extracts were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
product was purified by flash column chromatography on silica gel (5% ethyl acetate in 
hexanes), which afforded S7-F as a colorless oil (1.986 g, 87% yield, Rf = 0.40 in 20% 
ethyl acetate in hexanes). 
 
1H NMR (CDCl3): δ 11.47 (bs, 1H), 8.34 (bs, 1H), 7.43 (d, J = 7.0 Hz, 2H), 7.35 (t, J = 7.4 
Hz, 2H), 7.29 (t, J = 7.4 Hz, 1H), 6.99 (t, J = 9.4 Hz, 1H), 6.88 (d, J = 7.7 Hz, 1H), 6.72 
(m, 1H), 5.11 (s, 2H), 3.61 (m, 2H), 2.77 (m, 2H), 1.48 (s, 9H), 1.44 (s, 9H) 
13C NMR (CDCl3): δ 163.49, 156.03, 153.12, 151.56 (d, J = 227.0 Hz), 146.56 (d, J = 8.8 
Hz), 136.46, 134.73 (d, J = 3.5 Hz), 128.48, 127.99, 127.43, 121.42 (d, J = 7.0 Hz), 116.12 
(d, J = 17.6 Hz), 115.98, 83.02, 79.21, 71.21, 42.09, 34.79, 28.22, 27.95 
19F NMR (CDCl3): δ –137.12 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C26H35FN3O5: 488.2555; Found 488.2555 
 
 
Step 6: 
Intermediate S8-F was prepared according to a modified literature procedure.10 A solution 
of (Boc)2O (3.9 mmol, 0.9 mL of 1.0 M solution in THF, 6.3 equiv) was added to a solution 
of S7-F (305.2 mg, 0.63 mmol, 1 equiv), DMAP (46.9 mg, 0.38 mmol, 0.6 equiv) and 
triethylamine (0.55 mL, 3.9 mmol, 6.3 equiv) in anhydrous THF (7.5 mL, 84 mM) at room 
temperature. The mixture was stirred for 48 h and then poured over water (75 mL). The 
mixture was diluted with ethyl acetate (50 mL) and extracted with ethyl acetate (50 mL x 
2). The combined extracts were washed with brine, dried over Na2SO4 and concentrated 
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under reduced pressure. The product was purified by flash column chromatography on 
silica gel (10% ethyl acetate in hexanes), which afforded S8-F as a white solid (391.4 mg, 
91% yield, Rf = 0.73 in hexanes, mp = 113–114 °C). 
 
1H NMR (CDCl3): δ 7.43 (d, J = 7.7 Hz, 2H), 7.36 (t, J = 7.7 Hz, 2H), 7.30 (t, J = 7.7 Hz, 
1H), 6.94–6.99 (multiple peaks, 2H), 6.77 (m, 1H), 5.11 (s, 2H), 3.91 (m, 2H), 2.87 (m, 
2H), 1.50 (s, 9H), 1.47 (s, 27H) 
13C NMR (CDCl3): δ 159.69, 151.66 (d, J = 244.6 Hz), 151.14, 147.36, 146.47 (d, J = 10.6 
Hz), 143.60, 136.50, 135.06 (d, J = 3.5 Hz), 128.50, 128.02, 127.60, 121.61, (d, J = 7.0 
Hz), 116.43, 115.98 (d, J = 17.6 Hz), 83.61, 83.55, 81.97, 71.35, 48.73, 32.81, 27.95 (d, 
J = 12.3 Hz), 27.85 
19F NMR (CDCl3): δ –137.27 (m, 1F) 
HRMS (ESI+) [M+H]+ Calculated for C36H51FN3O9: 688.3604; Found 688.3601 
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5.5. NMR Spectra 
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5.6. Radio-HPLC Data 
5.6.1. General HPLC Conditions  
To confirm the identity of the radiolabeled substrate, a HPLC co-injection of the crude 
reaction mixture with an aliquot of the authentic product was performed. The two HPLC 
traces show the RAD and UV trace (254 nm or 280 nm) from the crude reaction mixture 
spiked with an authentic standard of the product. The wavelength shown is the 
wavelength where the analyte compound exhibited greatest absorptivity. Because of the 
physical separation of the two detectors, the two traces are offset by 0.2 min.  
 
HPLC Conditions A 
Condition: 70% MeCN/H2O, 10 mM NH4OAc, pH 7 
Flow Rate: 2 mL/min 
Column: Luna C-18 Column 150 x 4.6 mm; 5 μm 
 
HPLC Conditions B 
Condition: 75% MeCN/H2O, 10 mM NH4OAc, pH 7 
Flow Rate: 2 mL/min 
Column: Luna C-18 Column 150 x 4.6 mm; 5 μm 
 
HPLC Conditions C 
Condition: 95% MeCN/H2O, 10 mM NH4OAc, pH 7 
Flow Rate: 2 mL/min 
Column: Luna NH2 Column 150 x 4.6 mm; 5 μm 
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5.6.2. Radio-HPLC Co-Injections with Authentic Standards 
Table 5.4, entry 1 
HPLC Conditions A 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.4, entry 4 
HPLC Conditions A 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.5, entry 3 
HPLC Conditions A 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.5, entry 4 
HPLC Conditions A 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.6, entry 2 
HPLC Conditions B 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.6, entry 3 
HPLC Conditions B 
HPLC – UV 
 
HPLC – Gamma 
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Table 5.7, entry 1 
HPLC Conditions B 
HPLC – UV 
 
HPLC – Gamma 
 
(peak at 10 and 11 min are background activity from production) 
 
 
  
235 
 
Table 5.7, entry 2 
HPLC Conditions B 
HPLC – UV 
 
HPLC – Gamma 
 
(peak at 10 min is background activity from production) 
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